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ABSTRACT 
Each year, cancer and tuberculosis cause approximately 10 million deaths. The only 
approved tuberculosis vaccine, BCG, has highly variable efficacy. For the majority of 
cancers, no efficacious vaccines currently exist. The difficulty of designing vaccines for 
cancer lies in the fact that most of the biomolecules produced by cancer cells are the same 
as those produced by healthy cells. Thus, tumour-associated antigens are typically poorly 
immunogenic. There is an urgent need for new vaccine candidates with improved safety 
and efficacy for both cancer and tuberculosis. To improve the immunogenicity of such 
antigens, we and others have investigated self-adjuvanting vaccine candidates, in which 
an antigen is covalently attached to a lipopeptide adjuvant. Such vaccines have an 
advantage over traditional subunit vaccines in that they have improved uptake by 
antigen-presenting cells (APCs), while ensuring that the APCs are activated by the 
adjuvant are the same cells exposed to antigen. To date, however, there has been a dearth 
of synthetic techniques for the rapid, efficient synthesis of self-adjuvanting vaccines. 
This thesis details the design, synthesis and immunological evaluation of novel 
self-adjuvanting vaccine candidates for cancer and tuberculosis. Chapter 2 describes the 
immunological evaluation of a series of glycolipopeptide self-adjuvanting cancer vaccine 
candidates. When injected into mice, these candidates induced high titres of 
tumour-specific antibodies, but not cytotoxic T cell responses. In order to accelerate the 
synthesis of rationally designed self-adjuvanting vaccine candidates, a new synthetic 
method to access them needed to be developed. Chapter 3 describes the development of 
a novel strategy for the synthesis of long lipopeptide vaccine candidates through native 
chemical ligation. This strategy was successfully applied to the synthesis of a 
self-adjuvanting TB vaccine candidate, which demonstrated protective efficacy in a 
mouse model of M. tuberculosis infection. In Chapter 4, this synthetic strategy was 
applied to the synthesis of a self-adjuvanting cancer vaccine candidate that had been 
re-designed with the goal of inducing cytotoxic T cell responses while maintaining strong 
humoral responses. Chapter 5 describes the synthesis and immunological evaluation of 
the signal peptide of the cancer antigen mucin 1 (MUC1) and a more soluble analogue, 
K4-MUC1SP. Through the investigation of K4-MUC1SP as a potential antigen for cancer 
vaccines, we uncovered a novel role for the MUC1 signal peptide as a potent 
immunosuppressant. 
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 INTRODUCTION 
 Vaccines 
In his “History of the Peloponnesian War”, on the topic of the plague of Athens in 
~430 B.C., the Greek philosopher Thucydides wrote: 
“… the same man was never attacked twice - never at least fatally.” 
This was the earliest written acknowledgement that prior exposure to a disease can 
provide protection from the disease upon re-exposure. This concept of acquired immunity 
underpins the modern practice of vaccination - the most successful public health 
intervention in human history. Since the first report of vaccination against smallpox by 
Edward Jenner in 1798, vaccines have led to the eradication of smallpox (World Health 
Organization 1980) and the control of a range of previously fatal diseases such as 
poliomyelitis (Howard 2005). Indeed, it is estimated that vaccination programs saved the 
lives of 732,000 children in the USA alone between 1994-2013 (Whitney, et al. 2014).  
Vaccines offer protection by establishing long-lived adaptive immune responses by B 
and T lymphocytes. The adaptive immune system is made up of two arms: cell-mediated 
immune responses and humoral responses. Cell-mediated responses are carried out by 
T cells, which recognise short peptide epitopes (7-11 amino acids) presented on major 
histocompatibility complex (MHC) molecules. Humoral responses, in contrast, are 
performed by antibody-producing B cells, which recognise conformational epitopes in 
situ. Several excellent text books detail the modes of activation and action of these 
lymphocytes (Abbas, et al. 2016; Murphy and Weaver 2016). 
Although the majority of vaccines in use in humans are prophylactic (administered in 
order to prevent disease occurrence), the term ‘vaccine’ covers all treatments that give 
rise to long-lived adaptive immune responses. Indeed, vaccines can be used 
therapeutically for pre-existing diseases, including the anti-cancer vaccines discussed 
below. Here, a brief overview of two types of vaccine in use today (whole-agent and 
subunit vaccines) is provided. Thorough review of the wide range of vaccination 
strategies developed over recent years, including viral vectors, DNA vaccines, virus-like 
particles, and cell-based therapies, has been the topic of two recent books (Wen, et al. 
2015; Modjarrad and Koff, 2017). 
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1.1.1 Whole-agent vaccines 
Live-attenuated 
The earliest vaccines were obtained by passaging pathogenic microbes in sub-optimal 
hosts or in cell culture until they lost virulence. Patients could then be inoculated with 
these “attenuated” microbes, which would stimulate an immune response without 
inducing severe disease. Successful live-attenuated vaccines induced long-lived immune 
responses capable of protecting the subject from future exposure to the wild-type 
pathogen. This approach has been applied to the generation of vaccines for smallpox, 
poliomyelitis, yellow fever, and measles, among many others (Minor 2015). More 
recently, live-attenuated vaccines have been developed by knocking out virulence factors 
from pathogenic microbes (Lauring, et al. 2010). Indeed, a rationally-attenuated vaccine 
strain of Mycobacterium tuberculosis known as MTBVAC, in which two genes 
associated with virulence were knocked out through site-specific recombination, is 
currently in Phase II clinical trials (Spertini, et al. 2015). MTBVAC was attenuated by 
the stable deletion of phoP and fadD26 from mycobacteria using site-specific 
recombination in order to conform to the Second Geneva Consensus for progressing new 
live mycobacterial vaccines to advanced clinical development (Arbues, et. al. 2013; 
Aguilo, et. al. 2016). The transcription factor PhoP regulates a range of proteins including 
the virulence factor ESAT6, while the fadD26 gene controls the synthesis of phthiocerol 
dimycoesterases, which are responsible for many of the pathogen effects of mycobacteria. 
Live-attenuated vaccines can confer protective immunity for decades, and have been 
administered to billions of people. However, there is a risk that the attenuated microbe 
will revert to a virulent phenotype (Hanley 2011). Furthermore, attenuated vaccines 
cannot be given to immunosuppressed patients, who could be susceptible to infection 
with the attenuated microbe. This is particularly important in the context of 
immunosuppressive HIV infection, which has a high rate of co-morbidity with a range of 
diseases including tuberculosis. 
Inactivated 
In order to circumvent the risk of disease associated with live-attenuated vaccines, 
alternative vaccines have been generated from pathogens which have been killed or 
inactivated. This approach has led to the development of vaccines towards a wide range 
of pathogens, including the seasonal influenza vaccine, which is comprised of four 
different strains of heat-inactivated virus (Regan, et al. 2015). However, inactivated 
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pathogens often lack potent immunogenicity in the absence of active replication (Hoft, et 
al. 2011). 
1.1.2 Subunit vaccines 
Over the past 50 years, the development of molecular immunology has led to a clearer 
understanding of the antigens and epitopes responsible for protective immunity. This has 
led to vaccination strategies in which only the antigen(s) of interest are included in the 
vaccination, rather than the whole pathogen. However, the efficient induction of 
protective immunity by whole agent vaccines relies on the activation of innate immunity. 
This occurs through the activation of pattern-recognition receptors (PRRs), which are 
activated by molecules that are pathogen-derived (Takeuchi and Akira 2010). In isolation, 
antigens are typically poorly immunogenic because they lack such patterns and do not 
stimulate inflammatory responses. As such, subunit vaccines are typically delivered in 
conjunction with a compound or preparation that can induce activation of innate 
immunity via pattern-recognition receptors (PRRs). These compounds/preparations are 
known as adjuvants. 
Toxoid vaccines 
In certain bacterial infections, the major cause of disease pathology is the presence of 
toxic proteins, known as toxins. In such cases, vaccines have been developed that consist 
of toxin proteins that have been rendered harmless. Such vaccines do not induce 
sterilising immunity, but rather induce the production of neutralising antibodies towards 
the toxin. Examples include the tetanus, diphtheria, and pertussis toxoid vaccines in use 
today (Kretsinger, et al. 2006). The toxins are isolated from bacterial culture, then 
inactivated by treatment with formaldehyde.  
Self-adjuvanting vaccines 
Adjuvants are thought to be a vital feature to make cancer vaccines immunogenic enough 
to break through immunological self-tolerance to tumour antigens (Mesa and Fernandez 
2004). While traditional antigenic peptide/protein vaccines are formulated into mixtures 
of an antigen admixed with an adjuvant, vaccines in which the two moieties are contained 
within a single molecule are dubbed self-adjuvanting vaccines. Such vaccines have an 
advantage over traditional vaccines in that they are taken up by APCs faster (Zhu, et al. 
2004), while ensuring that the APCs activated by the adjuvant are the same APCs exposed 
to the antigen (Blander and Medzhitov, 2006). Indeed, there are examples in which the 
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administration of adjuvant and antigen which are not co-localised led to tolerance rather 
than immunity (Toes et. al. 1996). Another major advantage is that self-adjuvanting 
vaccines avoid the use of highly toxic adjuvants such as complete Freund’s adjuvant 
(CFA), that cannot be used in humans, while still eliciting potent immune responses 
(Chua, et al. 2014). In experimental models, these approaches have proved beneficial in 
vaccines against cancer (Le Gal, et al. 2002; Liu, et al. 2013), infectious diseases 
(Batzloff, et al. 2006; Bettahi, et al. 2006), and allergy (Anderson, et al. 2014), and have 
been reviewed previously (BenMohamed, et al. 2002; Brown and Jackson 2005; Moyle 
and Toth 2008; Chentoufi, et al. 2009). The synthesis of self-adjuvanting vaccines relies 
heavily on the chemical tools of peptide synthesis and peptide ligation, which are 
introduced below. 
Introduction 
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 Solid-phase peptide synthesis 
Modern peptide synthesis is carried out through solid-phase peptide synthesis (SPPS), 
first developed in 1963 by Robert Bruce Merrifield (Merrifield 1963). By tethering the 
C-terminal amino acid residue to an insoluble support (polystyrene resin), soluble 
by-products and excess reagents can be filtered off at the completion of the reactions. 
This technology enabled much more rapid and high-yielding synthesis of peptides as it 
removed the need for intermediary purification steps. The utility of SPPS was 
demonstrated in the remarkable total synthesis of a 124 amino acid protein with activity 
consistent with ribonuclease A (Gutte and Merrifield 1969; 1971). Today, SPPS is carried 
out using one of two strategies, employing either tert-butyloxycarbonyl (Boc) or 
fluorenylmethyloxycarbonyl (Fmoc) protecting groups on the α-amine functionality. 
Although each strategy has advantages and disadvantages, Fmoc-strategy SPPS will be 
used throughout this thesis because it is amenable to the synthesis of peptides bearing 
acid-sensitive modifications such as glycosylation. 
SPPS relies on insoluble resins as solid supports on which peptides can be elongated from 
their C- to N-terminus using amino acid building blocks bearing orthogonal protecting 
groups on the N-terminal amine and side-chain functional groups. A wide variety of 
functionalised resins are commercially available, tailored towards different applications 
and C-terminal modifications. Here, a brief overview of standard methods for SPPS on 
polystyrene resin functionalised with a 2-chlorotrityl chloride (2-CTC) linker is provided 
(Scheme 1.1). Briefly, the suitably protected C-terminal amino acid is loaded onto the 
resin as a 2-chlorotrityl ester in the presence of a hindered base such as iPr2NEt. 
Subsequently, the N-Fmoc group is removed by treatment with piperidine to provide a 
free α-amine. From here, the next amino acid building block is converted to an active 
ester by treatment with a coupling reagent, and added to the nascent peptide to form the 
desired peptide bond. The chemistry and evolution of coupling reagents has been widely 
researched since Merrifield’s initial report. SPPS coupling reagents have been 
extensively reviewed previously, and will not be discussed in any more detail here (El-
Faham and Albericio 2011). Iterative Fmoc-deprotection and coupling reactions can then 
furnish the desired resin-bound and side chain protected peptide. Concomitant 
deprotection of the acid-sensitive side-chain protecting groups and cleavage of the crude 
peptide from the acid labile linker on the resin is achieved through treatment with a 
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cocktail containing an acid, such as trifluoroacetic acid (TFA), water, and a cation 
scavenger such as triisopropylsilane (iPr3SiH). 
 
Scheme 1.1: Schematic of Fmoc-strategy SPPS. Benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) and N-methylmorpholine (NMM) are shown as the coupling conditions. 
1.2.1 Limitations of SPPS 
Over the past 40 years, SPPS has been continually improved through optimisation of 
conditions and the development of novel coupling reagents, resins and linkers. Today, 
automated, microwave-assisted peptide synthesisers are available to accelerate the 
peptide synthesis protocols and have become reasonably affordable. These synthesisers 
are capable of synthesising most soluble peptide targets, but suffer from a few key 
limitations. Even when each step in the synthesis of a peptide is exceptionally high 
yielding, small (<1%) impurities combine over each of the iterative 
coupling/deprotection cycles, and peptides much longer than 50 residues in length are 
therefore likely to have low overall yields and purity (Table 1.1). It is important to note 
that even if a single coupling proceeds in low yield, this can dramatically decrease the 
overall yield of a full-length peptide. In addition, significant optimisation of individual 
couplings is often required when non-standard building blocks are used, such as 
N-methylated residues or glycosylamino acids.  
It is now well established that standard SPPS conditions are incapable of providing high-
purity peptides for so-called “difficult peptide” sequences, which aggregate on-resin 
(Tickler and Wade 2007). Such aggregation, caused by hydrophobic sequences or the 
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formation of secondary structures by the nascent, protected peptide, causes reduced 
solvation of the N-terminal amine and reduced yield for the deprotection/coupling steps.  
Table 1.1: Influence of peptide length on overall yield  
Length # Steps 
Stepwise 
Yield 
Overall 
Yield 
20 40 
99% 66.90% 
98% 44.60% 
95% 12.90% 
90% 1.50% 
50 100 
99% 36.60% 
98% 13.30% 
95% 0.60% 
90% 0.00% 
Many strategies have been developed to suppress aggregation and effect the synthesis of 
difficult sequences, including the use of microwave irradiation to carry out reactions at 
higher temperatures (Murray and Gellman 2005). Another common method to improve 
yields is to incorporate pseudoproline dipeptides (Figure 1.1). These residues are 
dipeptide mimics of proline by virtue of an isopropylidene O,N-acetal between the 
backbone nitrogen and side-chain oxygen of a serine or threonine residue, forming a 
five-membered ring. This oxazolidine causes a “kink” in the peptide backbone similar to 
that caused by proline, and is believed to improve the yield of aggregation-prone peptides 
by restricting the available conformations of the growing peptide chain (Wohr and Mutter 
1995; Wohr, et al. 1996). Despite these advances, synthesis of difficult peptide sequences 
often requires case-by-case optimisation. 
 
Figure 1.1: Structure of pseudoproline dipeptides derived from Ser (R2 = H) or Thr (R2 = Me). R1 = amino 
acid side-chain 
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 Peptide ligation 
In order to overcome the length limitations of SPPS, the number of linear steps required 
to synthesis a large polypeptide or protein can be reduced through a convergent synthetic 
strategy. Specifically, shorter peptide fragments can be assembled through SPPS and then 
“ligated” together to furnish the full-length target. 
Many methods exist to ligate/modify peptide fragments produced by SPPS. A range of 
these methodologies make use of bio-orthogonal “click reactions” (Kolb, et al. 2001), 
and involve incorporation of non-natural linkages through reactions that are 
chemoselective in the presence of peptide side-chain functional groups. Such methods 
include the formation of oximes via reaction of an aldehyde and an aminooxy group (Rose 
1994; reviewed by Ulrich, et al. 2014), or triazoles via cycloaddition of an alkyne and an 
azide (Rostovtsev, et al. 2002; reviewed by Sletten and Bertozzi 2009). These approaches 
have the benefits of being chemoselective and proceed under mild, 
biologically-compatible conditions, but cannot be used to prepare native amide bonds. 
Below, two methods for ligating peptide fragments to form amide bonds are discussed: 
condensation of protected peptide fragments, and native chemical ligation. 
1.3.1 Fragment condensation 
Analogous to the logic of SPPS, peptide fragments can be ligated by ensuring that all 
functional groups that might interfere with the desired amide bond-forming reaction are 
protected. Nascent peptides synthesised on 2-chlorotrityl chloride resins can be cleaved 
under mild acidic conditions that leave the side-chain and N-terminal protecting groups 
intact. This protected peptide can then be ligated to another side-chain protected peptide 
with a free N-terminal amine through activation of the C-terminus and coupling, 
analogous to the SPPS coupling reactions (Scheme 1.2). The condensation of protected 
peptide fragments has proved useful in the total synthesis of many proteins, including 
human epidermal growth factor (Shin, et al. 1992). 
Fragment condensation enables the fusion of peptide fragments through the formation of 
native peptide bonds. As a general method for the synthesis of protein targets, however, 
this methodology has a number of important limitations. Epimerisation of the α-centre of 
the C-terminal active ester is common (Knorr, et al. 1989). Furthermore, 
side-chain-protected peptides are difficult to purify, and so fragment condensation is 
untenable for the synthesis of very large peptides and proteins. Additionally, because the 
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reaction is not chemoselective in the presence of free side-chain acid and amine 
functional groups, it cannot be used for the modification of expressed proteins. 
 
Scheme 1.2: On-resin fragment condensation of protected peptide fragments. 
1.3.2 Native chemical ligation 
In 1994, Kent and colleagues reported a chemoselective method for ligating purified, 
unprotected peptide fragments to generate native amide bonds, termed “Native Chemical 
Ligation” (NCL) (Dawson, et al. 1994). The method, inspired by earlier work of Wieland 
and colleagues (Wieland, et al. 1953), involves a chemoselective reaction between a 
peptide in which the C-terminal carboxylate has been derivatised as a thioester and a 
peptide bearing an N-terminal cysteine at neutral pH. The reaction proceeds via 
transthioesterification to produce a branched intermediate, in which the two fragments 
are stitched together through a side-chain thioester (Scheme 1.3). A spontaneous, rapid 
S→N acyl shift then furnishes the desired ligated peptide.  
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Scheme 1.3: Mechanism of native chemical ligation (NCL) 
NCL has greatly expanded the scope of protein synthesis by enabling the ligation of 
unprotected peptide fragments. Indeed, in combination with SPPS, NCL is the most 
powerful tool developed to date for the synthesis of proteins, and has paved the way to 
the successful total chemical synthesis of a wide variety of peptide and protein targets 
that were previously beyond the scope of synthetic chemistry (Bondalapati, et al. 2016). 
NCL is not without limitations, however: the ligation junction needs to possess a cysteine 
residue, which has a low abundance in naturally-occurring proteins. This limitation was 
addressed by the development of desulfurisation chemistry, through which unprotected 
cysteine residues could be converted to alanine after the ligation reaction. Dawson and 
colleagues reported the desulfurisation of Cys to Ala by treatment with Pd on Al2O3 under 
an atmosphere of hydrogen gas (Yan and Dawson 2001). This approach was later 
improved upon by Danishefsky and colleagues, who reported a metal-free desulfurisation 
method in which NCL products could be treated with the water-soluble radical initiator 
VA-044 in the presence of tris(2-carboxyethyl)phosphine (TCEP) as a reductant and 
tert-butyl thiol as a hydrogen atom source (Scheme 1.4) (Wan and Danishefsky 2007).  
Importantly, these desulfurisation technologies effectively enabled ligation at Ala 
junctions in addition to Cys. In their initial report, Dawson and colleagues proposed that 
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the logic underpinning this methodology could be further extended to ligation at other 
amino acids. Indeed, a large range of amino acid building blocks bearing pendant thiols 
at the β- or γ-position have since been reported by our laboratory and others, which can 
be incorporated into peptides via SPPS, mediate NCL reactions and subsequently be 
desulfurised to provide other proteinogenic amino acids at the ligation junction (Malins 
and Payne 2014). 
 
 
Scheme 1.4: Radical desulfurisation of Cys to Ala. 
1.3.3 One-pot ligation-desulfurisation 
For NCL, thioesters are usually prepared as unreactive alkyl thioesters. Aryl thiols such 
as thiophenol are then included as additives in the ligation mixture, which undergo 
transthioesterification to form reactive aryl thioesters that are competent in the ligation 
reaction. Unfortunately, the radical desulfurisation reaction discussed above is hindered 
by the presence of aryl thiol additives, which necessitates purification of ligation products 
prior to desulfurisation (Wan and Danishefsky 2007). This occurs because aryl thiyl 
radicals, which are heavily stabilised by delocalisation of the radical throughout the aryl 
ring (Lim et. Al. 2007), prevent the propagation of radical desulfurisation. Clearly, 
methods to carry out the ligation and subsequent desulfurisation reactions without 
intermediate HPLC purification would lead to faster syntheses and improved yields due 
to the reduction in loss of material through handling and purification. 
One approach to one-pot ligation-desulfurisation is the removal of aryl thiol additives 
from the ligation mixture prior to desulfurisation. Brik and colleagues employed an aryl 
thiol derivatised with a hydrazide functional group, which could be captured by an 
aldehyde-functionalised resin and removed from solution (Moyal, et al. 2013). 
Alternatively, Payne and colleagues took advantage of the hydrophobicity of thiophenol, 
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and removed it from the aqueous ligation mixture by extraction with diethyl ether 
(Cergol, et al. 2014). These two methods allowed, for the first time, the synthesis of large 
polypeptides by one-pot ligation-desulfurisation chemistry. However, it should be noted 
that trace amounts of aryl thiol remained in both cases, which reduced the speed and 
selectivity of the desulfurisation reaction and gave rise to small amounts of by-products. 
Previously, Kent and colleagues demonstrated that thiol additives that gave rise to the 
most efficient ligations all had a pKa in the range of 6-8, much lower than the alkyl thiols 
tested (Johnson and Kent 2006). Payne and colleagues rationalised that an alkyl thiol with 
appropriate electron withdrawing groups would lie in this pKa range, and thus mediate 
efficient ligation reactions, without a detrimental impact on desulfurisation, as alkyl thiols 
are much less efficient radical traps than aryl thiols (Thompson, et al. 2014). Indeed, 
ligation reactions carried out in the presence of 2,2,2-trifluoroethanethiol (TFET, 
pKa = 7.3) proceeded at a similar rate to those reactions catalysed by the gold-standard 
aryl thiol 4-mercaptophenylacetic acid (MPAA, pKa = 6.6). Furthermore, desulfurisation 
reactions proceeded at a similar rate and selectivity in the presence or absence of TFET. 
It should be noted that, although TFET does not interfere with the desulfurisation 
reaction, it is volatile, and is typically removed from the reaction mixture during 
degassing prior to desulfurisation. Following the TFET report, Li and colleagues 
achieved similar results with methyl thioglycolate (pKa = 7.9) as an alkyl thiol additive 
for one-pot ligation-desulfurisation (Huang, et al. 2016). 
1.3.4  Selenoester-selenocystine ligation 
Ligation-desulfurisation technologies at cysteine and synthetic thiolated amino acids 
have revolutionised the chemical synthesis of proteins and long peptides. It has 
limitations, however: ligation reactions tend to be very slow (>48 h) when the C-terminal 
thioester is a sterically hindered residue, such as valine (Hackeng, et al. 1999). 
Furthermore, the desulfurisation reaction discussed above is not selective for the 
desulfurisation of thiolated amino acids at the ligation junction over native cysteine 
residues present elsewhere in the sequence. To address this, the logic of NCL has been 
extended to ligation at selenocysteine (Sec). Peptides containing an N-terminal Sec 
residue are competent in ligations with peptides bearing a C-terminal thioester through a 
similar mechanism to NCL (Gieselman, et al. 2001; Hondal, et al. 2001; Quaderer, et al. 
2001). However, the weak C-Se bond undergoes homolysis in the presence of phosphine 
reductants such as TCEP, and thus Sec can be deselenised to alanine chemoselectively in 
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the presence of unprotected cysteine residues by treatment with TCEP and dithiothreitol 
(DTT) as a hydrogen atom source (Metanis, et al. 2010).  
Sec has a low reduction potential (-488 mV) compared to Cys (-233 mV), and so 
Sec-containing peptides, when exposed to air, are rapidly oxidised to the corresponding 
peptide diselenides (Keire, et al. 1992; Muttenthaler and Alewood 2008), which do not 
participate in ligation reactions with C-terminal thioesters. Weak reductants, such as aryl 
thiols, are therefore required to reduce these diselenides to selenols that are competent in 
ligation reactions. 
In 2015, Payne and colleagues reported an extremely rapid (<1 min), additive-free 
ligation between a peptide bearing a C-terminal phenyl selenoester and a peptide bearing 
the diselenide form of selenocysteine (selenocystine) at the N-terminus (Mitchell, et al. 
2015). Excitingly, such ligations proceeded swiftly (<10 min) even at sterically hindered 
C-terminal selenoesters such as valine and isoleucine. The fact that the ligations 
proceeded in the absence of an external reductant, such as an aryl thiol, suggests a novel 
reaction mechanism, which is still under investigation. However, following extraction of 
the insoluble diphenyl diselenide (DPDS) ligation by-product with hexane, the diselenide 
ligation products were readily deselenised to provide the desired Ala residue at the 
ligation junction (Scheme 1.5). Recently, this work has been extended to ligation at Asp 
and Glu using β-selenated Asp and γ-selenated Glu (Mitchell, et al. 2017). 
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Scheme 1.5: Selenoester-selenocystine ligation-deselenisation.  
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 MUC1 
Mucin 1 (MUC1) is a large, transmembrane glycoprotein normally expressed on the 
apical surface of mucosal epithelial cells. Also known as CD227, cancer antigen 15-3 
(CA15-3), Episialin, and Peanut-reactive urinary mucin (PUM), MUC1 is strongly 
expressed in the epithelium of the lung, gastrointestinal tract, mammary gland, pancreas, 
and genital tract, but not in the skin (Zotter, et al. 1988). Furthermore, it is expressed at 
lower levels on many hematopoietic cells, including T cells and DCs (Dent, et al. 1999; 
Chang, et al. 2000; Wykes, et al. 2002). MUC1 has attracted attention because it is highly 
over-expressed and aberrantly glycosylated in a wide range of cancers. Here, we provide 
an overview of the current state of the literature on MUC1, including its structure and 
function in both healthy and transformed cells.  Furthermore, we provide a brief overview 
of the MUC1-based vaccines that have entered clinical trials, and an in-depth review of 
the factors contributing to the efficacy of pre-clinical self-adjuvanting glycopeptide 
cancer vaccines. 
1.4.1 Structure and processing 
MUC1 is encoded by the MUC1 gene at chromosome 1q21. The MUC1 gene is 
polymorphic, varying in the number of tandem repeats (vide infra). 
After ribosomal synthesis, the nascent MUC1 protein undergoes autoproteolysis in the 
sea urchin sperm protein, enterokinase, and agrin (SEA) domain (Levitin, et al. 2005). 
Cleavage of the SEA domain release two subunits, which remain associated through 
non-covalent interactions (Ligtenberg, et al. 1992). The N-terminal α subunit (MUC1-N) 
is mostly comprised of the variable number tandem repeat (VNTR), while the C-terminal 
β subunit (MUC1-C) contains a short extracellular domain, the single-pass 
transmembrane domain, and the 72 residue cytoplasmic tail (MUC1-CT). 
The extracellular domains of MUC1 are N- and O-glycosylated in the endoplasmic 
reticulum (ER) and Golgi, respectively, and carbohydrates typically account for 50-90% 
of the mass of mature MUC1 proteins on healthy cells. Indeed, mucins are defined as 
proteins containing at least 50% (w/w) carbohydrate (Gendler 2001). During transport 
through the Golgi to the cell surface, the 21 residue signal peptide is cleaved by signal 
peptide peptidase. The current literature regarding the MUC1 Signal peptide is discussed 
in the introduction to Chapter 4. 
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Figure 1.2: MUC1 is a heavily glycosylated single-pass transmembrane protein. 
Further modification of the MUC1 protein occurs after it is expressed at the cell surface. 
S-Palmitoylation of cysteine residues in the MUC1-CT extends the half-life of the protein 
by enabling recycling of MUC1 proteins from endosomes back to the cell surface 
(Kinlough, et al. 2006). Furthermore, phosphorylation of tyrosine, serine, and threonine 
residues in the MUC1-CT is thought to be involved in cell signalling. 
The range of post-translational modifications on MUC1 gives rise to a heterogeneous 
mixture of MUC1 glycoproteins in vivo. This heterogeneity makes the study of the 
relationship between structure and function of particular PTMs difficult, because it is not 
possible to purify particular isoforms of modified proteins. As such, chemical synthesis 
of homogeneously modified proteins is required for thorough investigation of the impact 
of glycosylation on the structure and function of MUC1. 
MUC1VNTR 
MUC1-N is mostly comprised of the VNTR: a series of repeating units of the 20 amino 
acids GVTSAPDTRPAPGSTAPPAH (glycosylation sites in bold font). The high content 
of proline, serine, and threonine residues is common to the VNTRs of all known mucins. 
The number of repeats in the VNTR is germline-encoded, and varies between 20-120 
repeats in different individuals, with a very high (<80%) heterozygosity (Gendler, et al. 
1990). The VNTR is densely O-glycosylated, typically bearing glycans on 50-100% of 
the Ser and Thr residues (Lamblin, et al. 1984). Native, heavily glycosylated MUC1 
VNTRs adopt rod-like structures extending from the cell-surface, while unglycosylated 
mucins from more globular structures and asialo MUC1 adopts an intermediate structure 
(Shogren, et al. 1989). It should be noted, however, that these studies were limited by the 
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heterogeneity of glycosylation of native mucins. In 1998, Kunz and colleagues 
synthesised glycosylated and unglycosylated MUC1 decapeptides and, using NMR, 
demonstrated that the glycosylated peptides adopted elongated β-turn conformations 
while the unglycosylated peptides were unstructured in solution (Braun, et al. 1998). 
Combined, these studies suggest that the steric and electrostatic effects of O-linked 
glycans are essential for the elongated β-barrel structure of the MUC1VNTR in vivo.  
Soluble MUC1 
Although MUC1 is typically membrane-anchored, soluble MUC1 was identified in the 
tissues of both healthy and cancer patients, and in the supernatant of cultured MUC1+ 
tumour cells. Papadimitriou and colleagues confirmed that this soluble MUC1 isoform 
(dubbed sMUC1) lacked MUC1-C, the MUC1 subunit containing the cytoplasmic and 
transmembrane domains (Boshell, et al. 1992). They hypothesised that sMUC1 may arise 
due to alternative splicing or proteolysis of the mature MUC1 protein. Almost a decade 
later, Carson and colleagues confirmed that, in response to inflammatory stimuli, sMUC1 
could be shed from intact MUC1-N/MUC1-C complexes by TNF-α converting enzyme 
(TACE, also known as ADAM17) or membrane-type 1 matrix metalloproteinase 
(MT1-MMP) (Thathiah, et al. 2003; Thathiah and Carson 2004). These matrix 
metalloproteinases digest the extracellular domain of MUC1-C, releasing MUC1-N as 
sMUC1, revealing a truncated MUC1-C domain known as MUC1*. Interestingly, this 
proteolysis is reliant on the prior autoproteolysis of MUC1 into MUC1-N and MUC1-C, 
and mutation of the Gly-Ser cleavage site in the SEA domain prevents release of sMUC1 
into the extracellular milieu (Lillehoj, et al. 2003). 
1.4.2 Function in healthy cells 
The glycocalyx of healthy epithelial tissues is comprised of densely glycosylated proteins 
which serve as a physical barrier between the contents of the airways/GI tract and the 
epithelial cell layer. The glycosylation of these proteins is controlled by the relative 
concentrations and activities of glycosyltransferases, and mucinous proteins are typically 
decorated with elongated, branched carbohydrate chains (Shimizu and Yamauchi 1982). 
The rod-like structure of the MUC1VNTR extends 100-400 nm from the cell surface. 
This is much further than most surface-bound proteins, and it has been hypothesised that 
the dense packing of heavily glycosylated mucins on the microvilli and cilia of epithelial 
cells forms a gel through which particles cannot easily pass (Kesimer, et al. 2013). 
Furthermore, this heavy glycosylation gives rise to a very hydrophilic environment, 
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important for the hydration and lubrication of mucosal surfaces. 
The importance of MUC1 as a component of the mucosal barrier is supported by evidence 
from studies on MUC1-/- mice. Knockout mice housed in pathogen-free conditions 
display no obvious phenotype, while mice housed in pathogen-containing environments 
are highly susceptible to infection by otherwise commensal reproductive-tract microbes 
and display chronic inflammation of the uterus (DeSouza, et al. 1999). However, MUC1 
is involved in the immune response beyond its role as a physical barrier. It has been 
shown that MUC1 is involved in anti-inflammatory processes during infection with 
airway pathogens such as Pseudomonas aeruginosa (Umehara, et al. 2012) and, more 
recently, influenza A (McAuley, et al. 2017). 
1.4.3 Tumour-associated changes in expression, glycosylation and function 
MUC1 is overexpressed in cancer 
Worldwide research interest in MUC1 originated from the discovery that MUC1 was 
over-expressed in a wide range of adenocarcinomas (Burchell, et al. 1984).  Indeed, 
MUC1 is highly overexpressed in solid tumours of the breast, colon, kidney, pancreas, 
and lung, among others (Hollingsworth and Swanson 2004). MUC1 is also overexpressed 
on a variety of non-solid tumours, including those arising from MUC1- cell populations, 
such as cutaneous T cell lymphoma, acute myelogenous leukemia, and multiple myeloma 
(Stroopinsky, et al. 2016). In many of these cancers, increased MUC1 expression is 
correlated with poor prognosis (Hinoda, et al. 2003). Furthermore, MUC1 expression is 
correlated with enhanced metastatic ability in ovarian, prostate, and breast cancers (Horm 
and Schroeder 2013). In addition to its role as a cancer biomarker, MUC1 is oncogenic. 
Human MUC1-transgenic mice develop spontaneous pancreatic tumours (Rowse, et al. 
1998; Tinder, et al. 2008b), and MUC1 has been implicated in the oncogenesis of human 
breast cancer (Hattrup and Gendler 2006). 
Tumour-associated MUC1 is aberrantly glycosylated 
During cancer, changes in the expression of key glycosyltransferases can lead to 
expression of heavily truncated O-linked glycans known as tumour-associated 
carbohydrate antigens (TACAs) appended to the peptide backbones of these mucin-type 
glycoproteins (Meezan, et al. 1969; Dennis, et al. 1999). Such TACAs include the 
monosaccharidyl TN and disaccharidyl T antigens and their sialylated derivatives 
(Sialyl-TN, 2,3-Sialyl-T and 2,6-Sialyl-T), which arise from over-expression of 
sialyltransferases (Figure 1.3). 
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1.4.1 MUC1 as a vaccine antigen 
As discussed above (Section 1.1.2), vaccines that induce cancer-specific immune 
responses are difficult to design due to their typically poor immunogenicity. Ideal cancer 
antigens would be highly expressed by cancer cells, and not expressed on healthy cells. 
Although MUC1 is highly expressed on epithelial cells, the VNTRs of MUC1 on healthy 
cells are glycosylated with long, branched carbohydrate chains. In contrast, the TACAs 
mentioned above are found only on tumour cells, and are thus not subject to central 
tolerance (Ryan, et al. 2009). Therefore, MUC1 glycosylated with TACAs constitutes a 
cancer-specific antigen. In 2012, MUC1 was ranked 2nd out of 75 cancer antigens for 
vaccine development for these reasons (Cheever, et al. 2009). The development of a 
cancer vaccine targeting MUC1 has been the focus of a large amount of research effort, 
with over 50 clinical trials incorporating more than 1200 patients run over the past 20 
years (www.clinicaltrials.gov). The vaccines utilised in these trials include 
virally-encoded MUC1 (Madan, et al. 2007), MUC1 glycopeptide-carrier protein 
conjugates (Wurz, et al. 2014), and ex vivo vaccination of autologous dendritic cells 
(Lepisto, et al. 2008), among others. However, despite these studies, no such vaccine has 
advanced beyond clinical trials. The failure of these vaccine trials is attributed to the poor 
immunogenicity of MUC1 and the enrolment of patients with late-stage cancer. These 
trials have been extensively reviewed and will not be discussed in any further detail in 
this thesis (Singh and Bandyopadhyay 2007; Tang, et al. 2008; Kimura and Finn 2013; 
Rivalland, et al. 2015). 
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Figure 1.3: A) Structures of common tumour-associated carbohydrate antigens (TACAs). B) Illustration 
of the tumour-associated changes in MUC1 O-glycosylation. 
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 Self-adjuvanting glycopeptide cancer vaccines 
The lacklustre performance of MUC1-based vaccines in clinical trials has prompted the 
investigation of MUC1-based self-adjuvanting glycopeptide cancer vaccines as a strategy 
to improve immunogenicity. Here, an overview of the current literature regarding 
self-adjuvanting glycopeptide cancer vaccines, including discussion of their key design 
features and subsequent immunological outcomes, is provided. This overview has been 
published as a mini-review (McDonald, et al. 2015). 
1.5.1 Antigens 
The studies reviewed here focus on the induction of immunological responses to TACAs 
and glycopeptides bearing these glycan structures by self-adjuvanting vaccines (Figure 
1.4). Early self-adjuvanting glycopeptide cancer vaccines consisted of clustered TACAs 
linked via spacers to tri-palmitoylated cysteine (Pam3Cys) (Toyokuni, et al. 1994; Kuduk, 
et al. 1998). These vaccines induced TACA-specific antibodies, predominantly of the 
IgM isotype. Inclusion of a Th epitope led to the induction of high titres of class-switched 
IgG antibodies, but did not induce any cellular anti-cancer immunity because no CD8+ T 
cell epitopes were included (Buskas, et al. 2005; Abdel-Aal, et al. 2012). 
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Figure 1.4: Examples of self-adjuvanting TACA and glycopeptide cancer vaccines discussed here. 
Boons and colleagues have reported the use of the immunodominant epitope 
SAPDT*RPAP (Where T* indicates a threonine residue glycosylated with TACAs) 
conjugated to a polio Th epitope and Pam3Cys (Ingale, et al. 2007). This 9-mer binds 
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H-2Kb in mice (Apostolopoulos, et al. 1997a) and contains the human leukocyte antigen 
(HLA)-A2-binding epitope APDTRPA (Apostolopoulos, et al. 1997b). Additionally, the 
peptide contains the immunodominant MUC1 B cell epitope PDT*RP. When formulated 
into liposomes and injected into mice, these vaccines gave rise to high titres of 
MUC1-specific antibodies, as well as up-regulation of tumour necrosis factor (TNF), 
CD83, and the co-stimulatory molecules CD80 and CD86. Importantly, the authors have 
recently demonstrated induction of CTL responses and inhibition of mouse mammary 
tumour growth in response to these vaccines (Lakshminarayanan, et al. 2012). 
Many groups (including the Payne laboratory) have used full 20-amino acid residue 
MUC1VNTR peptides in self-adjuvanting vaccines. Kunz and colleagues reported the 
induction of MUC1-specific antibodies in response to vaccination with CFA and a 
Pam3Cys-MUC1VNTR conjugate containing a full copy of the VNTR 
(PAHGVT*SAPDTRPAPGSTAP) glycosylated with TN, T or 2,6-ST at a single Thr 
residue within the VNTR (indicated by asterisk) (Kaiser, et al. 2010). Payne and 
colleagues incorporated a per-glycosylated MUC1 epitope 
(GVT*S*APDT*RPAPGS*T*APPAH), whereby all possible glycosylation sites were 
occupied with TACAs (indicated by asterisks), in order to maximise the potential 
recognition of glycopeptide tumour-associated epitopes (Wilkinson, et al. 2011). 
Vaccines containing per-glycosylated MUC1 antigens, when injected in PBS without 
external adjuvant or formulation into liposomes, induced high titres of MUC1 antibodies 
capable of recognizing MCF-7 breast cancer cells. CD8+ T cell responses were not 
observed, possibly due to over-glycosylation of the VNTR backbone leading to reduced 
presentation of CD8+ T cell epitopes. Li and colleagues used vaccines containing 
full-length MUC1VNTR epitopes glycosylated variably at a Ser and/or Thr residue 
within the VNTR (HGVTSAPDT*RPAPGS*TAPPA) to induce IgG antibodies capable 
of recognizing tumour cells (Cai, et al. 2014). However, while these were capable of 
inducing antibody-dependent cell-mediated cytotoxicity (ADCC), no CD8+ T cell 
responses were reported for these vaccines. It is worth noting that different MUC1VNTR 
sequences were used in each of these studies, and each vaccine consequently contained 
different possible T and B cell antigens. In the future, we envisage that the use of longer 
VNTR peptides containing overlapping repeats will be important to cover the full range 
of epitopes in the VNTR sequence. 
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1.5.2 Multi-antigenic vaccines 
A necessary feature of self-adjuvanting vaccines is that they target the immune system to 
particular, well-defined molecular epitopes such as tumour-associated glycoforms of the 
MUC1VNTR. This can be problematic, since mutation or down-regulation of tumour 
antigens can lead to tumour escape and growth even in the presence of a robust 
antigen-specific anti-tumour immune response (Kim, et al. 1975; Stackpole, et al. 1980). 
One solution is to utilize long peptides containing multiple short TAA epitopes (Slingluff 
2011), although such an approach has yet to be widely adopted for self-adjuvanting 
glycopeptide cancer vaccines. BenMohamed and colleagues showed reduced tumour 
burden and increased survival in response to self-adjuvanting vaccines containing four 
copies of the TN antigen in concert with a CD8 epitope from the breast cancer antigen 
human epidermal growth factor receptor 2 (Her2) and the pan HLA DR-binding Epitope 
or “PADRE” (Renaudet, et al. 2010). PADRE is a synthetic epitope designed to give rise 
to CD4+ T cell responses in humans by binding promiscuously to a wide range HLA 
haplotypes. Protection from murine breast cancer was associated with both generation of 
TACA-specific antibodies and Her2-specific, Interferon (IFN)-γ-secreting CD8+ T cells. 
1.5.3 Adjuvants  
Most self-adjuvanting cancer vaccines have utilised lipopeptide-derived toll-like receptor 
(TLR)-2 agonists as the adjuvant. Tri- and di-palmitoylated cysteine (Pam3Cys and 
Pam2Cys) agonise TLR1/2 heterodimers and TLR2/6 heterodimers, respectively, leading 
to signaling via the NF-κB pathway and APC activation. Monopalmitoylated peptides 
(Bettahi, et al. 2009) and lipoamino acids (Abdel-Aal, et al. 2012) have also been 
investigated, which both signal via TLR2.  
Boons and colleagues compared MUC1 conjugate vaccines containing unmethylated 
CpG nucleotides, a TLR9 agonist, to Pam3CysSKKK (Abdel-Aal, et al. 2014). They 
found that, although vaccines containing CpG could induce MUC1-specific antibodies, 
those antibodies were less efficient at inducing ADCC against cancer cell lines than 
antibodies raised against Pam3Cys-containing vaccines. Furthermore, vaccines 
containing Pam3Cys led to a reduction of mouse mammary tumour burden and induced 
CTLs capable of killing MUC1-overexpressing cell lines, neither of which was observed 
after treatment with CpG-containing vaccines. The authors hypothesised that the 
increased efficacy of Pam3Cys-containing vaccines over CpG-containing vaccines might 
be due to the ability of TLR2 agonists to reduce the function of regulatory T cells. 
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Monophosphoryl lipid A (MPLA) is a TLR4 agonist derived from bacterial 
lipopolysaccharide. Guo and colleagues reported the synthesis and evaluation of 
self-adjuvanting vaccines consisting of MPLA conjugated to the 2,3-ST (Wang, et al. 
2012) and STN (Zhou, et al. 2014) TACAs.  The MPLA conjugates induced 
TACA-specific IgG antibodies capable of recognizing cancer cells. 
A few studies have investigated the interaction between self-adjuvanting vaccines and 
traditional experimental vaccines. The adjuvant QS-21 in combination with a 
Pam3Cys-containing vaccine was shown to lead to Th2 polarization compared to the 
vaccine alone, but induced similar levels of MUC1-specific IgG antibodies 
(Lakshminarayanan, et al. 2012).  Surprisingly, in some instances the inclusion of 
complete Freund’s adjuvant (CFA) actually led to inhibition of self-adjuvanting vaccine 
immunogenicity (Huang, et al. 2012; Cai, et al. 2013), while in others CFA inclusion led 
to increased antibody production (Abdel-Aal, et al. 2012). Similarly, co-injection of 
MPLA conjugates with Titermax gold completely abrogated anti-TACA immunity 
(Wang, et al. 2012; Zhou, et al. 2014). 
1.5.4 Synthesis 
Generally, chemical approaches for the synthesis of tumour antigens containing TACAs 
have involved incorporation of suitably protected glycosylserine/threonine residues into 
nascent peptides via Fmoc-strategy solid phase peptide synthesis (SPPS), with 
deprotection of the carbohydrates after cleavage of the crude glycopeptide from resin. 
Various syntheses of TN, STN, T, and ST TACA-derived amino acids for incorporation 
into SPPS have been reported to date (Brocke and Kunz 2002; Dziadek and Kunz 2004; 
Wilkinson, et al. 2010; Corcilius and Payne 2013; Wilson and Danishefsky 2013). It 
should be noted that incorporation of TACAs has also been achieved through 
chemoenzymatic means (Bezay, et al. 2001; Sorensen, et al. 2006; Bello, et al. 2014). 
The most challenging step in the development of self-adjuvanting vaccines is often the 
conjugation of (glyco)peptide antigens to lipopeptide adjuvants. The direct incorporation 
of lipidated adjuvants such as Pam2Cys and Pam3Cys into short peptides via SPPS works 
well (Metzger, et al. 1991), including through the use of microwave-assisted SPPS 
(Thompson, et al. 2015). However, longer self-adjuvanting vaccine constructs often 
produce complex mixtures which are difficult to purify. We have reported the efficient 
synthesis of such vaccines via the fragment condensation of suitably protected 
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(glyco)peptide fragments activated at the C-termini as pentafluorophenyl esters 
(Wilkinson, et al. 2010). This approach generated the desired self-adjuvanting vaccine 
candidates in good to excellent yields, but is incompatible with unprotected lysine 
side-chains (which could undergo unwanted fragment condensation reactions), 
necessitating the purification of protected lipopeptide fragments using normal-phase 
HPLC. Li and colleagues utilised a side-chain deprotected, iodoacetylated 
Pam3Cys-Ser-(Lys)5 to conjugate unprotected Pam3Cys to MUC1 glycopeptide 20-mers 
via a thioether linkage in moderate to good yields (Cai, et al. 2013). 
Boons and colleagues have reported the synthesis of vaccine constructs containing 
Pam3Cys via liposome-mediated native chemical ligation (NCL) (Ingale, et al. 2006). 
The use of dodecylphosphocholine liposomes was necessary owing to the insolubility of 
Pam3Cys-containing peptides in ligation buffer. While this approach has the benefit of 
chemoselectivity, it requires formulation of each ligation fragment into liposomes, 
followed by HPLC after each ligation to separate the ligation products from the liposomal 
components.  
1.5.5 Higher-order structures 
Another major factor that underlies the choice of adjuvant is the higher-order structure of 
the vaccine constructs. Peptide amphiphiles have long been known to form ordered 
structures in solution, and it has been demonstrated that MUC1 glycolipopeptide-based 
self-adjuvanting vaccines can form stable, ordered nanoparticles in solution (Wilkinson, 
et al. 2012b). The long lipid chains of TLR2 agonists support the formation of such 
structures through hydrophobic interactions. Moreover, the multivalent presentation of 
adjuvant and antigen moieties that results from such structures is likely to be important 
for the activation of APCs (Bachmann and Jennings 2010; Oyewumi, et al. 2010) and 
possibly underpins the differences in vaccine efficacy between various classes of 
adjuvant.  
The location of the lipid-containing adjuvant within self-adjuvanting vaccines has 
ramifications for the resultant immune response. BenMohamed and colleagues found that 
a linear glycolipopeptide led to increased IFN-γ production by CD8+ T cells and 
inhibition of tumour growth compared to a branched analogue (Renaudet, et al. 2010). 
The authors demonstrated in vitro that this was associated with a difference in uptake by 
DCs. Furthermore, the authors showed that the two vaccines were subject to different 
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cross-presentation pathways, which may explain the difference in DC and T cell 
activation observed. Similarly, Toth and colleagues found significantly higher 
TN-specific antibodies in response to a linear vaccine construct than a branched construct 
(Abdel-Aal, et al. 2012). In a more recent study (Eskandari, et al. 2015), the same group 
found that the location of the TLR-2 agonist in the middle or at the terminus of similar 
constructs containing ovalbumin model antigens controlled the physical properties of the 
self-assembled particles observed in solution.  
Li and colleagues synthesised a range of vaccine constructs containing full-length 
MUC1VNTR glycopeptides conjugated to the Q11 peptide aggregation sequence 
(Huang, et al. 2012). The resulting constructs formed well-defined fibrils over 200 nm in 
length, irrespective of glycosylation pattern. These constructs were able to induce 
MUC1-specific, class-switched antibodies in the absence of a canonical adjuvant, and 
were capable of inducing complement-dependent lysis of MCF-7 breast cancer cells, 
while T cell responses to the vaccines were not reported. IgG antibody titres induced by 
these constructs were 1-2 orders of magnitude lower than those typically seen for 
vaccines containing a TLR2 agonist (Ingale, et al. 2007; Wilkinson, et al. 2011; Cai, et 
al. 2013). Nonetheless, it remains an excellent example of the importance of higher-order 
structure and multivalent antigen presentation to the immune response elicited by 
conjugate vaccines. 
It is clear from these studies that the formation of higher-order structures by 
self-adjuvanting vaccines plays and important role in their immunogenicity. To date, 
however, the relationships between vaccine primary structure, higher-order organization 
in solution, and resulting immunological response are poorly understood, and should 
serve as an important subject for study in the future to better understand immune 
stimulation by self-adjuvanting constructs. 
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 Tuberculosis 
Mycobacterium tuberculosis (M. tuberculosis) is the aetiological agent of tuberculosis 
(TB), which causes an estimated 1.8 million deaths per year worldwide, making it the 
leading cause of death due to a single infectious disease (World Health Organization 
2016). Treatment options for M. tuberculosis are dwindling due to the emergence of 
bacteria resistant to most or all of the frontline anti-tubercular chemotherapies (Dheda, et 
al. 2017). As such, there is a clear need for the development of new therapeutic or 
prophylactic anti-tubercular agents. In our laboratory and globally, research efforts are 
being made to develop novel anti-tubercular drugs (Giltrap, et al. 2016; Tran, et al. 2017). 
However, the development of an efficacious vaccine remains the major goal of the global 
End TB Strategy (World Health Organization 2015; Fletcher and Schrager 2016). 
1.6.1 Vaccines for tuberculosis 
The only TB vaccine approved for human use is the Bacillus Calmette-Guérin (BCG) 
vaccine, a live-attenuated strain derived from Mycobacterium bovis which was first 
introduced in 1921. Reports of the efficacy of BCG vaccination in preventing tuberculosis 
vary. A systematic review and meta-analysis of studies between 1950 and 2013 found 
that BCG vaccination prevented 19-27% of infections in children under the age of 16 
(Roy, et al. 2014). Furthermore, among the infected population, BCG vaccination 
afforded approximately 58% protection from progression to disease. However, BCG 
protection from pulmonary disease, particularly among adults, varies dramatically 
geographically, down to 0% in sub-Saharan Africa (Pitt, et al. 2013), and all forms of 
protection wane in adults. Furthermore, BCG is subject to all the risks of a live-attenuated 
vaccine; in particular, it cannot be used in immunocompromised patients due to the risk 
of disseminated BCG disease. This has become an issue in sub-Saharan Africa, where 
high rates of infant HIV infection often prevent BCG vaccination even amongst 
populations at high risk of tuberculosis exposure (Mak, et al. 2008). 
For these reasons, there is an urgent need for novel TB vaccines with improved efficacy 
and safety compared to the BCG vaccine. As of August 2016, 13 TB vaccine clinical 
trials were underway (Fletcher and Schrager 2016; Ginsberg, et al. 2016).  Of these, 5 
utilise whole-cell vaccines such as modified BCG, Mycobacterium vaccae, or 
live-attenuated strains of M. tuberculosis. The majority of ongoing trials, however, are 
assessing subunit vaccines as a means of boosting the protection garnered by the BCG 
vaccine. These subunit vaccines contain mycobacterial peptide/protein antigens, and four 
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trials each are assessing delivery of the antigen admixed with adjuvant or delivered via 
viral vectors. Three of the M. tuberculosis antigens currently under investigation are 
discussed below. 
1.6.2 Antigens for TB subunit vaccines 
Antigen 85 
The most abundant proteins secreted by M. tuberculosis are the three components of the 
Antigen 85 (Ag85) complex, dubbed Ag85A (31 kDa), Ag85B (30 kDa), and Ag85C 
(31.5 kDa) (Fukui and Yoneda 1961; Wiker, et al. 1990). Each of these proteins has 
acyltransferase activity, and has been implicated in the biosynthesis of 
mycolylarabinogalactan, and trehalose mono- and dimycolate, which are components of 
the mycobacterial cell wall (Belisle, et al. 1997; Kremer, et al. 2002). 
It has been hypothesised that the immunogenicity of secreted antigens, including Ag85, 
is responsible for the increased efficacy of live vaccines compared to killed/inactivated 
whole agent vaccines (Wiker and Harboe 1992). The majority of the TB subunit vaccines 
currently in clinical trials contain Ag85A or Ag85B (Fletcher and Schrager 2016; 
Ginsberg, et al. 2016). In experimental animal models, protective immunity was induced 
by vaccination with P25, a CD4+ T cell epitope from Ag85B (Florido, et al. 2015). 
ESAT6 and TB10.4 
Much of the reduced virulence of BCG, compared to M. tuberculosis or M. bovis, is 
attributed to the inability of BCG to mediate phagosomal rupture and reach the cytosol 
of phagocytes (Hsu, et al. 2003). This is owing to the absence of a protein dubbed 6 kDa 
early secretory antigenic target (ESAT6) in BCG that is responsible for this rupture (de 
Jonge, et al. 2007). Furthermore, ESAT6 has been shown to interfere with host immune 
responses through the direct inhibition of TLR2 (Pathak, et al. 2007), inhibition of 
LPS-induced reactive oxygen species (Ganguly, et al. 2008), and sequestration of 
β2-microglobulin in the ER (Sreejit, et al. 2014). ESAT6 was originally discovered due 
to its role as a potent CD8+ T cell antigen (Sorensen, et al. 1995), and vaccination with 
ESAT6 has been shown to confer protection in animal models (Kamath, et al. 1999). 
Over the following 20 years, much research effort has been targeted towards the 
development of a subunit vaccine containing ESAT6.  
The mapping of the M. tuberculosis genome led to the discovery of a family of genes 
with sequence homology to ESAT6 (Alderson, et al. 2000). One such esat6 gene family 
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member, Rv0288, encodes the protein TB10.4, a known mycobacterial virulence factor 
(Rindi, et al. 1999). In humans and mice, exposure to BCG or M. tuberculosis induces 
strong CD4+ and CD8+ T cell responses towards TB10.4, which correlate with protection 
(Skjot, et al. 2002; Hervas-Stubbs, et al. 2006).  
The Serum Statens Institute is currently carrying out a number of clinical trials involving 
vaccination with these antigens, including phases II trials of an Ag85B-TB10.4 fusion 
protein, and an Ag85B-ESAT6 fusion protein (Fletcher and Schrager 2016; Ginsberg, et 
al. 2016). To the best of our knowledge, however, none of these antigens have been 
incorporated into self-adjuvanting vaccine candidates. 
Introduction 
 30 
 Overview of this thesis 
The overarching goal of the research described in this thesis was to design and synthesise 
novel self-adjuvanting vaccine candidates for cancer and tuberculosis. This goal 
necessitated the development of new synthetic methods for the preparation of the target 
vaccine compounds.  
Chapter 2 describes the immunological evaluation of a series of self-adjuvanting cancer 
vaccine candidates comprised of the adjuvant macrophage-activating lipopeptide 2 
(MALP2) covalently attached to MUC1 (glycopeptides) via a triethyleneglycolate spacer. 
When injected into mice, these vaccine candidates induced high titres of class-switched, 
MUC1-specific antibodies, but not MUC1-specific T cell responses. 
Chapter 3 describes the development of a novel strategy for the synthesis of 
self-adjuvanting lipopeptide vaccine candidates through NCL, in order to accelerate the 
iterative process of design, synthesis and immunological evaluation. This strategy was 
successfully applied to the synthesis of a self-adjuvanting TB vaccine candidate, which 
demonstrated protective efficacy in a murine model of M. tuberculosis infection. 
Chapter 4 describes the re-design of the MUC1VNTR glycopeptide epitope included in 
our self-adjuvanting cancer vaccines, with the goal of inducing MUC1-specific CTL 
responses while maintaining strong humoral responses. The synthetic strategy developed 
in Chapter 3 was adapted to the synthesis of a novel self-adjuvanting vaccine candidate 
via selenoester-selenocystine ligation-deselenisation.  
Chapter 5 describes the synthesis and immunological evaluation of the MUC1SP and a 
more soluble analog, K4-MUC1SP. Through the investigation of K4-MUC1SP as a 
potential antigen for cancer vaccines, we uncovered a novel role for MUC1SP as a potent 
immunosuppressant.  
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 MALP2-MUC1 
SELF-ADJUVANTING VACCINES 
 Introduction 
2.1.1 Macrophage-activating lipopeptide 2 
Macrophage-activating lipopeptide 2 (MALP2) is a 14 amino acid lipopeptide originally 
isolated from Mycoplasma fermentans (Muhlradt, et al. 1997). Native MALP2 contains 
an N-terminal S-glyceryl cysteine residue bearing a mixture of palmitate and stearate 
esters, while synthetic MALP2 is di-palmitoylated. MALP2 is a potent activator of 
macrophages, B cells (Borsutzky, et al. 2005), and DCs (Weigt, et al. 2003; Link, et al. 
2004). This activation is attributed to the agonism of TLR2/6 heterodimers by the 
lipopeptide ligand (Takeuchi, et al. 2000; Takeuchi, et al. 2001). Stimulation via TLR2/6 
leads to the downstream production of a variety of pro-inflammatory cytokines including 
IL-1α, IL-6, TNF, and IL-12 (Link, et al. 2004).  
 
Figure 2.1: Structure of Macrophage Activating Lipopeptide 2 (MALP2). 
MALP2 showed early promise as an adjuvant therapy for the treatment of tumours in 
mice (Schneider, et al. 2004) and was considered safe in a Phase I/II trial in human 
pancreatic carcinoma patients (Schmidt, et al. 2007). It has attracted interest as an 
adjuvant for vaccines against infectious diseases (Rharbaoui, et al. 2004), but to our 
knowledge has not been investigated in the context of tumour vaccination, nor in any 
self-adjuvanting vaccines. We hypothesised that MALP2 would be a potent adjuvant for 
the activation of MUC1-specific immune responses, which could be readily incorporated 
into self-adjuvanting vaccines. 
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2.1.2 Synthesis of MALP2-MUC1 self-adjuvanting vaccines 
Synthesis of MALP2-MUC1 vaccine constructs was carried out by Dr Brendan 
Wilkinson in our laboratory. Three vaccines were designed, comprised of MALP2 
conjugated via a triethyleneglycolate spacer to a single copy of the MUC1 VNTR either 
unglycosylated (201) or per-glycosylated with the TN (202) or T (203) antigens at each 
of the five serine and threonine residues in the VNTR (Figure 2.2).  
 
Figure 2.2: Structure of MALP2-MUC1 vaccine candidates 201-203. 
The target compounds 201-203 were assembled using an iterative fragment condensation 
strategy from three building blocks, each synthesised through SPPS as described in the 
general methods (Section 6.1.1). These were an N-Fmoc and side-chain protected peptide 
fragment of MALP2 bearing a triethyleneglycolate at the C-terminus, activated as a 
pentafluorophenol (Pfp) ester (204), an N-Fmoc protected Pam2CysGly, also activated as 
a Pfp ester (205), and fully deprotected MUC1VNTR (glyco)peptides 206-208.  
First, N-Fmoc protected aminotriethyleneglycolic acid (Fmoc-[PEG]-OH) was coupled 
onto 2-chlorotrityl chloride (2-CTC) polystyrene resin, and elaborated with the 12 
C-terminal residues of MALP2 (Scheme 2.1). Initially, the peptide portion of MALP2 
synthesised poorly due to on-resin aggregation. To overcome this, an Ile-Ser 
pseudoproline residue (Fmoc-L-Ile-L-Ser[ψMe,MePro]-OH) was incorporated at the IS 
junction. Treatment with the mild acid 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) effected 
cleavage from resin with the side-chain protecting groups intact. The crude, protected 
peptide was then coupled with pentafluorophenol trifluoroacetate (Pfp-TFA) in the 
presence of pyridine to furnish the crude N-Fmoc and sidechain-protected Pfp active ester 
204. Normal-phase HPLC purification afforded 204 in 12% yield calculated from initial 
resin loading.  
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The N-terminal lipopeptide portion of MALP2 was prepared as a Pfp active ester in 
similar fashion (Scheme 2.2). Briefly, Fmoc-Pam2CysGly-OH was synthesised by SPPS 
on 2-CTC resin, and removed from resin by treatment with HFIP. Coupling with Pfp-TFA 
in the presence of pyridine and purification via normal-phase HPLC afforded pure 
Fmoc-Pam2CysGly-Pfp 205 in 63% yield calculated from initial resin loading.  
 
Scheme 2.1: Synthesis of N-Fmoc and side-chain protected MALP2 peptidyl Pfp ester 204. Underlined IS 
refers to the incorporation of a pseudoproline dipeptide (Fmoc-Ile-Ser(ψMe,MePro)-OH) at this position 
 
Scheme 2.2: Synthesis of Fmoc-Pam2CysGly-OPfp 205. 
The MUC1VNTR 20mers 206-209 were synthesised via SPPS as described previously 
(Wilkinson, et al. 2010). Briefly, TACAs were incorporated into standard Fmoc SPPS as 
N-Fmoc and per-O-acetyl protected glycosylamino acids (Figure 2.3). Following final 
Fmoc deprotection, removal of the side-chain protecting groups and cleavage from resin 
was achieved by treatment with an acidic cocktail, and carbohydrates were deacetylated 
by treatment with aqueous hydrazine. (Glyco)peptides were purified by reverse-phase 
HPLC in 14-45% yield calculated from initial resin loading. 
These three fragments were then assembled by Pfp ester-mediated fragment condensation 
(Scheme 2.3). Briefly, pure unprotected (glyco)peptides 206-208 were coupled with the 
protected MALP2 peptide-Pfp ester in the presence of 1-hydroxybenzotriazole (HOBt) 
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and N,N-diisopropylethylamine (DIEA).  Following in situ Fmoc deprotection with 
piperidine, partially protected (glyco)peptides 209-211 were purified by C4 HPLC  in 
40-64% yield. Similarly, Fmoc-Pam2CysGly-OPfp 205 was coupled to 209-211 in the 
presence of HOBt and DIEA, followed by Fmoc deprotection. Finally, treatment with an 
acidic cocktail effected removal of the remaining side-chain protecting groups, and 
vaccine constructs 201-203 were purified by C4 HPLC in 82-87% yield. 
 
Figure 2.3: Protected glycosylamino acids for incorporation of TACAs into Fmoc-strategy SPPS 
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Scheme 2.3: Synthesis of MALP2-MUC1 vaccine candidates 201-203 via fragment condensation of 
(glyco)peptides 206-208 and Pfp esters 204 and 205. 
 Experimental design 
In order to immunologically evaluate MALP2-MUC1 self-adjuvanting vaccine 
candidates 201-203, C57BL/6 mice were vaccinated with 3.5 nmol (15-21 μg) of a given 
vaccine candidate in PBS (Figure 2.4). It has been demonstrated that MUC1VNTR 
peptides alone do not give rise to immunological responses (Lakshminarayanan, et al. 
2012), and therefore PBS was used a negative control. Mice received vaccinations four 
times at weekly intervals; a dose schedule previously shown to induce high titres of 
αMUC1 antibodies (Ingale, et al. 2009). Serum was collected by sub-mandibular bleed 
24 h prior to each vaccination. For determination of in vivo MUC1-specific CTL activity, 
a mixed cohort of MUC1-labelled target cells and control cells was injected intravenously 
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16 h prior to euthanasia, as described in section 6.2.6. Spleens and inguinal lymph nodes 
were collected for flow cytometric analysis on day 28. 
 
Figure 2.4: Vaccination schedule and experimental design for immunological evaluation of 
MALP2-MUC1 self-adjuvanting vaccine candidates 201-203. 
 Induction of MUC1-specific antibodies 
2.3.1 IgM and IgG 
Sera from vaccinated mice were evaluated for MUC1-specific antibodies by indirect 
enzyme-linked immunosorbent assay (ELISA) as described in section 6.2.7. Briefly, 
blood was collected via sub-mandibular bleed and stored at -20 °C until analysed. ELISA 
plates were coated with MUC1VNTR (glyco)peptides 201-203, and then incubated with 
serial dilutions of thawed sera. In each case, sera were evaluated against the MUC1VNTR 
(glyco)peptide epitopes against which they were raised, and sera from PBS-treated mice 
were evaluated against unglycosylated MUC1 VNTR epitopes. MUC1-specific 
antibodies were detected with Horseradish peroxidase (HRP)-conjugated secondary 
antibodies specific for murine immunoglobulin. 
Harvest spleen, LN 
For T Cell studies 
Day 28 
Vaccine candidate 
3.5 nmol (~20 μg)  
(sub-cutaneous)  
Days 0, 7, 14, 21 
Harvest serum 
Days -1, 6, 13, 20, 27 
C57BL/6 
1 day 
ivCTL target cells 
(intravenous)  
Day 27 
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As expected, mice treated with PBS displayed no induction of MUC1-specific antibodies, 
while mice treated with MALP2-MUC1 self-adjuvanting vaccine candidates 201-203 
exhibited high titres of MUC1-specific IgM just 1 week after the first vaccination, which 
persisted until the end of the experiment (Figure 2.5). Each vaccine induced isotype class 
switching, evidenced by the rising titres of MUC1-specific IgG throughout the 
experiment. In all cases, the unglycosylated vaccine 201 induced the highest titres of 
MUC1-specific antibodies, followed by the TN-containing 202 and then the T-containing 
203. This is consistent with previous findings (Wilkinson, et al. 2011; Wilkinson, et al. 
2012a).  
 
Figure 2.5: Total MUC1-specific titres of IgM and IgG over time in sera collected from mice treated with 
PBS or vaccines 201-203. Plotted points represent median (± IQR) endpoint titres of n = 6 mice from two 
independent experiments. 
Given the strong IgG class switching observed, we next interrogated which IgG sub-types 
were induced. The MUC1-specific IgG antibodies generated by the MALP2-MUC1 
conjugate vaccines were predominantly of the IgG3 and IgG2b subtype, with some IgG1 
and IgG2c present in the sera of mice vaccinated with the unglycosylated 201 (Figure 
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2.6). No MUC1-specific IgA was detected in the sera of vaccinated mice. We were 
particularly encouraged to observe the class-switched humoral responses for the MALP2 
conjugate vaccines. Specifically, these antibodies are important for the clearance of 
metastases, particularly through antibody-dependent cell-mediated cytotoxicity (Bindon, 
et al. 1988; Von Mensdorff-Pouilly, et al. 2011). 
 
Figure 2.6: MUC1-specific titres of IgG subtypes or IgA in sera collected from mice treated with PBS or 
vaccines 201-203 on day 27 of the immunisation schedule. Plotted points represent median (± IQR) 
endpoint titres of n = 6 mice from two independent experiments.  
2.3.2 Antibody cross-reactivity 
Having determined that the MALP2-MUC1 conjugate vaccines 201-203 induced a 
class-switched IgG response, we next investigated the specificity of the antibodies for the 
(glyco)peptide epitopes 206-208. Antibodies from mice vaccinated with the 
unglycosylated vaccine candidate 201 were specific for unglycosylated MUC1VNTR 
epitope 206, and had low titres against the glycosylated MUC1VNTR epitopes 207 and 
208 (Figure 2.7). In contrast, sera from mice vaccinated with glycosylated vaccine 
candidates 202 and 203 had high IgG titres to unglycosylated MUC1VNTR peptide 206. 
Indeed, antisera from mice vaccinated with TN-containing vaccine 202 had high titres to 
all three peptides 206-208. The recognition of unglycosylated MUC1 epitopes by antisera 
from mice vaccinated with glycosylated MUC1VNTR peptides could arise through two 
mechanisms: 1) vaccines containing glycosylated MUC1VNTR epitopes could induce 
antibodies capable of cross-reacting to unglycosylated MUC1VNTR epitopes, or 2) the 
polyclonal antibody response induced by vaccines containing glycosylated MUC1VNTR 
epitopes could contain antibodies specific for the TACA-bearing regions of the VNTR as 
well as antibodies specific for unglycosylated regions of the peptide. If 2) were 
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responsible for the broader specificity of the antisera from mice vaccinated with 
glycosylated MUC1VNTR peptides, we would expect a similar level of cross-reactivity 
from antisera induced by the unglycosylated vaccine 201 towards the unglycosylated 
regions of glycosylated peptides 207-208, which was not observed. As such, we 
hypothesise that antibodies induced by vaccines containing the TN antigen were able to 
cross-react to both unglycosylated MUC1VNTR peptides and those bearing the T 
antigen. To test this hypothesis thoroughly, monoclonal antibodies would need to be 
developed from animals vaccinated with 202. Irrespective of the mechanism, 
cross-reactivity of anti-MUC1 responses to multiple tumour-associated glycoforms is 
desirable, because MUC1VNTR epitopes on tumour cells are heterogeneous, bearing a 
variety of TACAs as well as unglycosylated epitopes. 
 
Figure 2.7: Antibody cross-reactivity studies: Titres of Total IgG specific for unglycosylated MUC1 (206), 
or MUC1 bearing TN (207) or T (208) antigens in sera collected from mice treated with PBS or vaccines 
201-203 on day 27 of the immunisation schedule. Plotted points represent median (± IQR) endpoint titres 
of n = 6 mice from two independent experiments. 
 MUC1-specific cytotoxicity in vivo 
To date, most reports of MUC1-based self-adjuvanting vaccines have used the production 
of MUC1-specific antibodies as their primary outcome (discussed in introduction section 
1.5.1). In order for cancer vaccines to be efficacious, however, they must activate both 
the humoral and cell-mediated arms of the adaptive immune system. As such, we sought 
to determine whether MALP2-MUC1 vaccine candidates 201-203 were able to induce 
MUC1-specific T cell responses.  
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2.4.1 CD8+T cell epitopes 
McKenzie and colleagues determined that the MUC1VNTR peptides SAPDTRPAP and 
APGSTAPPA bound to H-2Kb and H-2Db, respectively, in C57BL/6 mice 
(Apostolopoulos, et al. 1997a). The same laboratory subsequently showed that the 
affinity of SAPDTRPAP for H-2Kb was increased when bearing the TN antigen at Thr-5 
(SAPDT(TN)RPAP) (Apostolopoulos, et al. 2003). The authors rationalised this 
increased peptide-MHC binding affinity by comparing the crystal structure of 
H-2Kb:SAPDTRPAP with molecular models of H-2Kb:SAPDT(TN)RPAP, 
demonstrating that Thr-TN likely occupies the central C pocket, anchoring the peptide to 
the MHC. 
It is well-documented that N-linked glycans do not survive proteasomal degradation, and 
so are not generally cross-presented to CD8+ T cells on MHC-I (Werdelin, et al. 2002). 
Conversely, O-linked glycopeptides from the MUC1VNTR have been shown to survive 
proteolysis by isolated DC proteasomes in vitro (Ninkovic and Hanisch 2007). 
Furthermore, Finn and colleagues demonstrated that long MUC1 peptides glycosylated 
with the TN antigen could be cross-presented by DCs in vitro and induce activation and 
expansion of glycopeptide-specific CTLs (Ryan, et al. 2009). Together, these 
observations indicate that O-glycosylated MUC1 peptides can be taken up, processed, 
and presented on MHC by DCs, and that they can induce MUC1 glycopeptide-specific 
CTL activity. As SAPDT(TN)RPAP is the only MUC1 glycopeptide epitope that has been 
demonstrated to bind murine MHC, we envisaged (glyco)nonapeptides SAPDT*RPAP, 
either unglycosylated (212), or bearing the TN (213) or T (214) antigens at Thr5 (Figure 
2.8). 
 
Figure 2.8: Structure of MUC1VNTR nonapeptide CD8+ T cell epitopes 212-214. 
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(Glyco)peptides 212-214 were synthesised divergently by Fmoc-strategy SPPS as 
described in the general methods (section 6.1.1). Fmoc-Pro-OH was loaded onto 2-CTC 
resin (300 μmol) in the presence of iPr2NEt in DMF:CH2Cl2 (1:1 v/v), and the unreacted  
2-CTC was capped by treatment with methanol and iPr2NEt in CH2Cl2. Deprotection of 
the N-Fmoc group was effected by treatment with piperidine (10% in DMF). 
Fmoc-Ala-OH was then coupled in the presence of the coupling reagent 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and the 
base N-methylmorpholine (NMM), followed by capping of unreacted amines with 
Ac2O:pyridine (1:9 v/v). The peptide was elongated to Arg5 through iterative cycles of 
deprotection, coupling and capping (Scheme 2.4), and then the resin was split into 3 
batches. Further elongation by standard manual SPPS furnished crude, resin-bound 
peptide 212. Cleavage from resin and concomitant removal of the acid-labile side-chain 
protecting groups was effected by treatment with an acidic cocktail of TFA:iPr3SiH:H2O 
(90:5:5 v/v/v). Following HPLC purification and lyophilisation, 212 was afforded in 71% 
yield calculated from initial resin loading (98% yield per linear step). 
 
Scheme 2.4: SPPS of (glyco)peptides 212-214. 
The remaining batches of resin-bound H-RPAP were elongated with glycosylthreonine. 
Fmoc-Thr(Ac3TN)-OH or Fmoc-Thr(Ac6T)-OH (Figure 2.3) were coupled to the nascent 
peptide in the presence of the coupling reagents 1-[bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) and 1-hydroxy-7-
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azabenzotriazole (HOAt), with iPr2NEt as a base. Due to the precious nature of the 
glycosylamino acid building blocks, only a small excess (1.5 eq.) was used, and the 
coupling reaction proceeded to completion over 16 h. The glycopeptides were further 
elongated by Fmoc-strategy SPPS, and cleaved from resin as described above. The crude 
O-acetyl protecting groups on the carbohydrates of the crude glycopeptides were 
removed by treatment with aqueous hydrazine (10% v/v) for 30 min. Following HPLC 
purification and lyophilisation, 213 was afforded in 53% yield (96% yield per linear step), 
and 214 was afforded in 61% yield (97% yield per linear step). 
2.4.2 MUC1-specific ivCTL 
An in vivo CTL assay was conducted in order to test whether vaccine candidates 201-203 
induced cytotoxicity towards MUC1VNTR CD8+ T cell epitopes 212-214. Because it 
was not clear from the literature which glycoforms of the MUC1VNTR epitopes might 
survive processing by APCs (vide supra), CTL activity towards each glycoform was 
tested simultaneously. To do this, four cohorts of splenocytes from untreated C57BL/6 
mice were stained with a high (10 μM) or low (1 μM) concentration of the fluorescent 
cell stains Cell Tracker Orange (CTO) or carboxyfluorescein succinimidyl ester (CFSE). 
These stained cells were then incubated with (glyco)peptides 212-214, or a scrambled, 
unglycosylated peptide sequence (PSAPRPDTA, 215) as a negative control. Equal 
numbers of these cells were mixed and then adoptively transferred into mice vaccinated 
with MALP2-MUC1 self-adjuvanting vaccines 201-203 on day 27 post-vaccination 
(Figure 2.4). Vaccinated mice were euthanised 16 h later, and the splenocytes were 
analysed by flow cytometry to determine the relative number of target and control cells 
recovered (Figure 2.9). Percentage specific CTL activity was defined as: 
�1 − 𝑟𝑟𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛
𝑟𝑟𝑠𝑠𝑛𝑛𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛
� ∗ 100, where 𝑟𝑟 =  # 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑟𝑟𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠# 𝑐𝑐𝑡𝑡𝑟𝑟𝑡𝑡𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠  
In all cases, the specific lysis of splenocytes labelled with MUC1 epitopes 212-214 was 
similar in those mice vaccinated with MALP2-MUC1 vaccine candidates to PBS-treated 
mice (Figure 2.10).  
This lack of MUC1-specific lysis could be due to a range of factors. Firstly, it is plausible 
that a MUC1-specific CTL response occurred, but was not detected in these assays. As 
discussed above, the nonapeptide epitopes chosen for the in vivo CTL assay represent 
only a small fraction of the potential CD8+ T cell epitopes that could be generated through 
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proteolysis of the MALP2-MUC1 vaccine candidates. As such, it was possible that the 
vaccine candidates induced T cell activation towards epitopes other than the three 
glycopeptides tested here. To overcome this, splenocytes obtained from vaccinated mice 
were exposed to full-length MUC1VNTR (glyco)peptides in vitro and stained for the 
presence of activation markers and inflammatory cytokines (Section 2.5 below). It must 
be noted, however, that mice vaccinated with the unglycosylated vaccine candidate 201 
did not generate cytotoxicity towards the bona fide CD8+ T cell epitope SAPDTRPAP 
212, suggesting that choice of epitope was not solely responsible for the lack of observed 
CTL activity.  
 
 
 
 
 
Figure 2.9: Representative gating strategy for the identification of CFSE- and CTO-labelled splenocytes 
by flow cytometry.  
 
Label:     CTOHi CTOLo  CFSELo CFSEHi 
Epitope:  T  Tn  Control Ungly 
       214  213  215  212 
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Figure 2.10: In vivo CTL function of mice immunised with PBS or vaccine candidates 201-203. 
Splenocytes were harvested on day 28 of the immunisation schedule. CTL activity was measured against 
unglycosylated, TN and T antigen-containing MUC1 (glyco)peptide epitopes 212-214. Bars represent 
median (± IQR) of n = 6 mice from two independent experiments. 
It is also plausible that the MALP2-MUC1 vaccine candidates induced a transient 
MUC1-specific T cell response, which was no longer detectable at day 27 of the 
vaccination schedule. Indeed, antigen persistence can cause functional exhaustion of 
antigen-specific CTLs within three weeks (Ramsdell and Fowlkes 1992; Tay, et al. 2014). 
For this reason, it is suggested that at least two weeks is required between priming and 
boosting vaccinations for optimal T cell activation while avoiding exhaustion (Woodland 
2004; Butler, et al. 2011). To determine whether a longer interval between priming and 
boosting could induce MUC1-specific CTL activity, mice were vaccinated with vaccine 
candidate 202, bearing the TN antigen, on days 0 and 14 of the vaccination schedule, 
omitting the vaccinations on days 7 and 21 (Figure 2.4). The in vivo CTL activity in mice 
that received two vaccinations of 202 was similar to mice that received four vaccinations 
(Figure 2.11), suggesting that the lack of observed CTL activity was not solely due to 
the high frequency of vaccination. 
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Figure 2.11: In vivo CTL function of mice immunised with PBS or vaccine candidate 202 two or four 
times. Splenocytes were harvested on day 28 of the immunisation schedule. CTL activity was measured 
against unglycosylated, TN and T antigen-containing MUC1 (glyco)peptide epitopes 212-214. Bars 
represent median (± IQR) of n = 6 mice from two independent experiments. 
The simplest explanation for the lack of an observed CTL response, however, is that no 
such response occurred. To determine factors that might have contributed to a lack of 
CTL priming, we compared the design of vaccine candidates 201-203 to vaccines in the 
literature that generated MUC1-specific CTLs. CTL induction has been reported against 
unglycosylated MUC1VNTR peptides (Apostolopoulos, et al. 1997a; Hiltbold, et al. 
1999), but there is only one report of in vivo CTL induction towards a MUC1VNTR 
glycopeptide by a vaccine. Boons and colleagues reported induction of CTL responses 
towards SAPDT(TN)RPAP by a self-adjuvanting vaccine consisting of 
Pam3CysSKKKK, a helper T cell epitope from poliovirus, and the MUC1VNTR epitope 
SAPDT(TN)RPAP, each separated by a PEG spacer (Lakshminarayanan, et al. 2012). As 
discussed above, SAPDT(TN)RPAP is the only MUC1VNTR glycopeptide that has been 
proven to bind murine MHC (Apostolopoulos, et al. 2003). Additionally, the decapeptide 
SAPDT(TN)RPAPG is the only MUC1VNTR glycopeptide that has been shown to bind 
human MHC, specifically HLA-A*0201 (Ninkovic, et al. 2009). As discussed above, it 
is unclear whether SAPDTRPAP epitopes glycosylated at Ser can bind MHC, let alone 
induce CTLs. Furthermore, it has been demonstrated that O-glycosylation of the SAP 
region can inhibit proteolysis by the immunoproteasome (Ninkovic and Hanisch 2007).  
Taken together, these observations indicate that perglycosylation of the MUC1VNTR, 
and in particular glycosylation of the SAP region, may have hindered the capacity of 
vaccine candidates 202-203 to induce MUC1-specific CTLs. 
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 T cell activation 
MALP2-MUC1 self-adjuvanting vaccine candidates 201-203 induced very high levels of 
MUC1-specific IgM and IgG antibodies (Figure 2.5). For peptide antigens, isotype class 
switching from IgM to IgG is usually dependent on help from CD4+ helper T cells. 
However, no CD4+ T cell epitopes were included in the vaccine preparations. 
Additionally, the lack of MUC1-specific CTL activity observed in vivo (Figure 2.10) did 
not preclude the presence of activated, MUC1-specific CD8+ T cells that were incapable 
of mediating antigen-specific lysis. 
To determine whether vaccine candidates 201-203 led to the activation of CD4+ and/or 
CD8+ T cells, splenocytes and inguinal lymph node cells harvested from mice on day 28 
of the immunisation schedule (Figure 2.4) were restimulated overnight in vitro. Cells 
were stimulated with either 1) 20mer MUC1VNTR (glyco)peptides 206-208, or 2) 
phorbol 12-myristate 13-acetate (PMA) and ionomycin as a non-specific stimulation. As 
a positive control, cells from PBS-treated mice were activated with concanavalin A. 
Restimulated cells were treated with brefeldin A for 4 h to block protein transport, and 
then fixed and stained for intracellular flow cytometry as described in the general 
methods (section 6.2.4). Cells were stained for CD4 and CD8, the activation markers 
CD44 and CD25, and the cytokines IFN-γ, IL-4 and IL-6, as well as the degranulation 
marker CD107a. With both specific (MUC1VNTR glycopeptides) and non-specific 
(PMA/ionomycin) stimulation, no significant difference was seen between treatment 
groups in any of the activation markers or inflammatory cytokines tested in either lymph 
node cells or splenocytes. Representative data are presented for the restimulation of 
splenocytes with MUC1VNTR (glyco)peptides (Figures 2.12, 2.13). Cytokine+ gates 
were set manually from unstimulated controls. As above, these data do not conclusively 
rule out a T cell response induced by vaccine candidates 201-203. It is evident, however, 
that if any T cell responses were induced, they were either very weak or absent at day 28 
of the immunisation schedule.  
The lack of helper T cell activation in these experiments may partially explain the absence 
of MUC1-specific CTL activity. It has been demonstrated that, while high-affinity CD8+ 
T cells can expand and acquire effector function without help from CD4+ T cells (in the 
form of cytokine secretion, particularly IL-2), low-affinity CD8+ T cells may require help 
to be efficiently activated (Curtsinger, et al. 1999; Denton, et al. 2011). Due to negative 
selection against self-antigens in the thymus, most cancer-specific T cells have a lower 
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affinity than, for example, virus-specific T cells (Aleksic, et al. 2012). As such, the lack 
of a helper T cell response may have contributed to the absence of CTL induction 
observed.    
 
Figure 2.12: Representative gating strategy for the identification of CD25+, IFN-γ+ and IL-4+ populations 
of CD8+ and CD4+ T cells by intracellular flow cytometry. 
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Figure 2.13: IFN-γ+ (A), CD25+ (B), and IL-4+ (C) CD4+ and CD8+ T cells as a percentage of live T cells 
isolated from the spleens of mice immunised with PBS or vaccine candidates 201-203 on day 28 of the 
immunisation schedule activated with MUC1VNTR (glyco)peptides 206-208. Bars represent the median 
(± IQR) of n = 6 C57BL/6 mice from two independent experiments. 
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 Antibody class-switching in the absence of a helper T cell response 
The apparent absence of a helper T cell response in these experiments was perhaps 
unsurprising, given that no CD4+ T cell epitopes were included in the vaccine preparation. 
The question remains, however, as to how isotype class switching occurred in the absence 
of a helper T cell response.  
Two types of T cell-independent class switching have been described previously: type 1 
T-independent (TI-1) antigens contain molecular patters such as TLR agonists capable of 
directly activating B cells in a polyclonal fashion (Mosier, et al. 1977). Type 2 
T-independent (TI-2) antigens are repetitive, containing multiple copies of the BCR 
binding site, such that BCR cross-linking occurs on the surface of the B cell (Mond, et 
al. 1995). In each case, B cell activation (by TLR stimulation or BCR cross-linking) can 
induce class-switch recombination in the absence of helper T cell cytokines. Archetypal 
TI-2 antigens are polysaccharides with high molecular weight and many repeating units, 
but pre-organisation of either polysaccharide (Anish, et al. 2014) or peptide antigens 
(Temchura, et al. 2014) on polymeric supports increased their capacity to induce IgG 
antibodies as antigen density increased. As discussed above (Introduction section 1.5.5), 
lipoglycopeptide self-adjuvanting vaccines can form stable nanoparticles in solution, 
driven by the hydrophobic interactions of their lipid domains (Wilkinson, et al. 2012a). 
Furthermore, it has been shown that MALP2 can directly activate B cells via TLR2/6 
without the need for accessory cells such a DCs (Borsutzky, et al. 2005). As such, vaccine 
candidates 201-203 contain the characteristics of both TI-1 and TI-2 antigens, and we 
propose that they mediated T cell-independent humoral responses to generate 
MUC1-specific IgG in these experiments. 
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 Conclusions and Future Directions 
In summary, a range of MALP2-MUC1VNTR self-adjuvanting lipo(glyco)peptide 
cancer vaccine candidates were synthesised. When injected into C57BL/6 mice without 
a helper T cell epitope or a conventional adjuvant, these vaccines gave rise to high titres 
of MUC1-specific IgM and several isotypes of IgG antibodies, indicative of a 
polyfunctional humoral immune response.  
Importantly, the generation of class-switched IgG antibodies in these experiments 
occurred in the absence of a detected helper T cell response. We propose that this was 
due to the T cell-independent class-switching of MUC1-specific B cells. In order to rule 
out an undetected T cell response, however, these experiments will be repeated in mice 
deficient for CD4+ T cells. This could be achieved with the use of CD4-knockout mice, 
CD4-depleting antibodies, or in thymectomised mice. 
The cross-reactivity observed in the antibodies generated by vaccination with 
TN-containing vaccine 202 could be due to glycan remodelling, in which the glycopeptide 
epitopes presented on MHC are different from those phagocytosed by the APC. MUC1 
(glyco)peptide epitopes and self-adjuvanting vaccine candidates will be incubated with 
DCs and macrophages in vitro, and then analysed by mass spectrometry at different 
timepoints in order to determine whether glycan remodelling occurs during 
cross-presentation. 
Finally, although the results presented here demonstrate that MALP2-MUC1 vaccines 
are capable of generating strong MUC1-specific humoral responses, ideal cancer 
vaccines will give rise to both humoral and cell-mediated immune responses. These 
studies have highlighted features of the glycopeptides included in vaccine candidates 
201-203 which may have hindered CTL formation, and led us to redesign the MUC1 
glycopeptide antigens used in our vaccine candidates with the aim of maintaining a strong 
humoral immune response while also generating tumour-specific CTLs (Chapter 4).
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SELF-ADJUVANTING VACCINE 
CANDIDATES FOR TUBERCULOSIS 
 Introduction 
3.1.1 Pam2Cys-P25-TB10.4 self-adjuvanting tuberculosis vaccine candidate 
Initial synthesis of the Pam2Cys-P25-TB10.4 vaccine construct 301 was carried out by 
Dr Santosh Rudrawar in our laboratory. It consisted of Pam2CysSKKKK on the 
N-terminus (See Introduction section 1.5.3), separated by a triethyleneglycolate spacer 
from the CD4+ T cell epitope Ag85B280-294 (FQDAYNAAGGHNAVF, known as the P25 
epitope) and the CD8+ T cell epitope TB10.43-11 (QIMYNYPAM) (Figure 3.1, 
Introduction section 1.6.2).  
 
Figure 3.1: Structure of Pam2Cys-P25-TB10.4 vaccine candidate 301. 
The target compound 301 was prepared by on-resin peptide coupling of crude 
resin-bound peptide 302 and pure protected lipopeptide 303, each prepared through 
standard Fmoc-strategy SPPS (Scheme 3.1). The side-chain and N-Fmoc protected 
lipopeptide 303 was removed from resin using HFIP in CH2Cl2, and purified by 
normal-phase HPLC. The coupling of 302 and 303 was achieved using HATU, HOAt 
and iPr2NEt. Subsequent treatment with an acidic cocktail to remove the side-chain 
protecting groups furnished the crude lipopeptide vaccine candidate.  
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Scheme 3.1: Synthesis of Pam2Cys-P25-TB10.4 vaccine candidate 301 via on-resin fragment 
condensation. 
Purification of 301 by preparative and semi-preparative reverse-phase C4 HPLC proved 
extremely challenging. Indeed, only 300 μg of the desired product was obtained from the 
combined pure fractions of 20 repetitive purifications on an analytical scale (Waters 
Symmetry® C18; 5μ, 300Å, 2.1 x 150 mm).  
Clearly, this synthetic strategy and purification protocol was not amenable to preparation 
of the quantities of 301 required for biological evaluation and, as such, a new synthetic 
approach and purification strategy were sought. 
3.1.2 Native chemical ligation at aspartic acid 
As discussed previously (section 1.3.2), the utility of native chemical ligation (NCL) has 
been greatly expanded by the introduction of novel amino acid reagents bearing a thiol 
functionality at the β- or γ-positions. Widespread incorporation of these reagents for the 
synthesis of peptides and proteins has been slow, however, due to the long synthetic 
routes required to generate them. Recently, our laboratory reported the synthesis of 
β-mercaptoaspartic acid 304 (Thompson, et al. 2013), that was protected with Boc- and 
tert-butyl ester groups on the α-amine and side-chain carboxylate, respectively, while the 
key thiol functionality was protected as a 2,4,6-trimethoxybenzyl (Tmob) thioether 
(Figure 3.2). This building block was prepared in excellent yield in three steps from the 
widely available Boc-Asp(OtBu)-OH, and could be readily incorporated into 
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Fmoc-strategy SPPS to generate peptides bearing an N-terminal β-mercaptoaspartic acid. 
Such peptides were competent in peptide ligation reactions under a native chemical 
ligation manifold, and could be chemoselectively desulfurised to form a native Asp 
residue, even in the presence of free cysteine residues (Scheme 3.2). 
 
Figure 3.2: Suitably protected β-mercaptoaspartic acid building block 
 
Scheme 3.2: Chemoselective ligation-desulfurisation at Asp. 
 Aims 
The generation of useful quantities of self-adjuvanting vaccine candidates was hindered 
by a dearth of methods for the efficient synthesis and purification of the long lipopeptide 
target molecules. It was envisaged that such vaccines could be assembled from smaller 
(lipo)peptide fragments. Thus, the primary aims of this chapter were to optimise a 
purification procedure for short, fully unprotected lipopeptides obtained via SPPS, and to 
develop a strategy for the assembly of those fragments via NCL. It was envisaged that 
these synthetic aims could be accomplished en route to the synthesis of the first synthetic 
self-adjuvanting vaccine candidates for TB. 
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 Synthesis of Pam2Cys-P25-TB10.4 
3.3.1 Retrosynthesis 
The on-resin fragment condensation approach for the synthesis of vaccine candidate 301 
(section 3.1.1) involved coupling of pure, sidechain-protected lipopeptide 302 and crude, 
resin-bound protected peptide 303. The lack of purification of peptide intermediates was 
likely a contributing factor to the difficulty of purification of the final vaccine. We 
rationalised that a NCL approach to the synthesis of 301 would circumvent this issue by 
allowing for the purification of both lipopeptide and peptide intermediates prior to 
assembly by ligation. This approach would also simplify the purification of the 
lipopeptide intermediate without sidechain protecting groups. It was envisaged that 301 
could be disconnected between Gln2-Asp3, and that the key peptide bond could be 
generated via native chemical ligation/desulfurisation between N-Fmoc protected 
lipopeptide thioester 305 and peptide 306, bearing an N-terminal β-mercaptoaspartic acid 
residue (Scheme 3.3). Finally, 301 could be accessed by Fmoc deprotection of the 
ligation-desulfurisation product. 
 
Scheme 3.3: Retrosynthesis of Pam2Cys-P25-TB10.4 vaccine candidate 301. 
3.3.2 Synthesis and purification of Pam2Cys-P25-TB10.4 via native chemical 
ligation 
Synthesis of lipopeptide thioester 305 was achieved via Fmoc-strategy SPPS on 
2-chlorotrityl chloride (2-CTC) resin as described in the general methods. The N-terminal 
Fmoc protecting group was maintained in order to provide a UV handle for purification 
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and reaction monitoring. The nascent lipopeptide was cleaved from resin with sidechain 
and N-Fmoc protecting groups intact by treatment with the mildly acidic HFIP in CH2Cl2. 
The crude, protected peptide was dried under a stream of N2, then thioesterified with ethyl 
3-mercaptopropionate in the presence of PyBOP and iPr2NEt in DMF at -20 °C for 2 h 
(Scheme 3.4). The low temperature was employed to prevent epimerisation of the 
C-terminal glutamine residue. The solvent was subsequently removed under a stream of 
N2 overnight, and then global sidechain protecting group removal was effected by 
treatment with an acidic cocktail (TFA:H2O:iPr3SiH, 90:5:5, v/v/v) for 3 h. Crude 
lipopeptide 305 thioester was obtained by precipitation from ice-cold ether. 
 
Scheme 3.4: Synthesis of lipopeptide thioester 305. 
As expected, HPLC purification of 305 required optimisation (Table 3.1). Firstly, the 
crude lipopeptide was insoluble the in H2O:MeCN + 0.1% TFA mixtures normally used 
as sample diluents for HPLC. The crude mixture could be analysed by HPLC using a 
diluent of H2O:DMF (2:1 v/v), but the inclusion of DMF caused severe broadening of 
peaks by semi-preparative or preparative HPLC. We reasoned that the four free ε amines 
in 305 could be solubilised at lower pH through protonation and, pleasingly, the crude 
peptide proved to be soluble in H2O:MeCN (1:1 v/v, 1% TFA). Previously, our laboratory 
has purified unprotected lipopeptides using Grace Vydac® Protein C4 columns and a 
solvent system containing 10% iPrOH in both eluent A and B. Although C4 columns were 
able to resolve 305 on an analytical scale, up-scaling to preparative HPLC led to a loss 
of resolution. After screening a number of reverse-phase columns, we found that a 
Phenomenex Luna® C18 column provided the best peak shape and resolution. The 
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temperature of purification was also altered using a semi-preparative HPLC column oven 
in order to obtain the optimal resolution. At room temperature, 305 eluted after the end 
of the gradient (Rt = 63.4 min) in isocratic MeCN:iPrOH (9:1 v/v, 0.1% TFA), and was 
poorly resolved from impurities such as the hydrolysed thioester. Increasing the 
temperature to 40 °C using the column oven resulted in 305 eluting within the gradient 
(Rt = 37.0 min) with improved resolution. Using this optimised purification method 
followed by lyophilisation, lipopeptide thioester 305 was obtained as a white solid in 5% 
yield calculated from initial resin loading (85% yield per step over 18 linear steps). 
Table 3.1: Optimised conditions for reverse-phase HPLC purification of lipopeptide thioester 305 
Column Phenomenex Luna® C18(2) (5 μm, 100Å, 10 x 250 mm) 
Diluent H2O:MeCN (1:1 1% TFA) 
Solvent 
System 
A: H2O:MeCN:iPrOH (8:1:1 v/v/v, 0.1% TFA) 
B: MeCN:iPrOH (9:1 v/v, 0.1% TFA) 
Temperature 40 °C 
 
Figure 3.3: Preparative HPLC traces of crude lipopeptide thioester 305 (indicated by *) at RT and 40 °C 
(50 to 100% B over 40 min, λ = 230 nm). 
Synthesis of C-terminal peptide fragment 306 proceeded smoothly via Fmoc-strategy 
SPPS, starting from 2-CTC resin (Scheme 3.5). Suitably protected β-mercaptoaspartic 
acid was provided by Dr Robert Thompson from our laboratory and incorporated into 
SPPS using HATU/HOAt/iPr2NEt as described previously (Thompson, et al. 2013). The 
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crude peptide was cleaved from resin with an acidic cocktail, then purified by HPLC in 
13% yield with respect to the initial resin loading (95% yield per step over 42 steps). 
. 
Scheme 3.5: Synthesis of peptide 306 bearing an N-terminal β-mercaptoaspartic acid residue. 
With lipopeptide thioester 305 and peptide 306 in hand, we turned our attention to the 
key ligation step. To this end, 305 and 306 were dissolved in a mixed solvent system 
(Payne, et al. 2008; Santhakumar and Payne 2015) of N-methyl-2-pyrrolidone (NMP) 
and aqueous HEPES buffer containing 6 M guanidine hydrochloride (4:1 v/v) at neutral 
pH. To ensure reduction of any disulfides, tris(2-carboxyethyl)phosphine (TCEP) was 
added, and finally 2,2,2-trifluoroethanethiol (TFET) was added in order to exchange with 
the unreactive ethyl 3-mercaptopropionate thioester to afford the more reactive TFET 
thioester  (Scheme 3.6). Formation of the ligation product was observed via LCMS after 
16 h, but unfortunately could not be resolved in the chromatogram from unknown by-
products (Figure 3.4, Rt = 16.2 min). Furthermore, the peak corresponding to the ligation 
product diminished as the reaction proceeded, indicating decomposition. Unfortunately, 
even when the ligation was stopped at earlier time points, pure 301 could not be obtained 
by HPLC.  
 Degradation of P25-TB10.4 fusion peptide 
To explore the decomposition observed during ligation of 305 and 306, the peptide 
component of the target vaccine (P25-TB10.4 fusion peptide 307) was synthesised via 
Fmoc-strategy SPPS. To test its stability, 307 was dissolved in aqueous HEPES buffer 
(1 M, pH 7) containing guanidine hydrochloride (6 M) and incubated at 37 °C. After three 
days, substantial degradation had occurred, evidenced by the appearance of new LCMS 
peaks. Similar degradation was observed in the absence of guanidine and/or TCEP. The 
major by-product peak at 3.7 min corresponded to a mass of cleavage of the peptide 
between Asn12 and Ala13. We propose that this could occur through formation of an 
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Scheme 3.6: Attempted ligation between lipopeptide thioester 305 and peptide 306.  
 
Figure 3.4: HPLC-MS monitoring of ligation between lipopeptide thioester 305 and peptide 306.  
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aspartimide (succinimide) by nucleophilic attack of the sidechain primary amide onto the 
backbone amide carbonyl (Figure 3.5). Formation of aspartimide moieties at Asn-Ala 
junctions, as well as the many by-products that can form from nucleophilic ring-opening 
of the resultant aspartimide, is well-described in the literature (Mergler, et al. 2003; 
Zahariev, et al. 2006), but is most commonly associated with cleavage of the primary 
amide bond after attack by the backbone amide nitrogen. However, cleavage of the 
backbone amide following nucleophilic attack by the sidechain primary amide has been 
proposed as the mechanism through which protein splicing occurs in intein sequences 
(Clarke 1994; Shah and Muir 2014). Interestingly, degradation has not been reported for 
the individual P25 and TB10.4 epitopes in the past and, indeed, both peptides displayed 
minimal decomposition in ligation buffer over 50 h (Figure 3.6). 
 
 
 
 
Figure 3.5: UPLC traces and proposed mechanism for cleavage of P25-TB10.4 fusion peptide 307 via 
aspartimide formation (0-50% B over 8 min, λ=214 nm). 
3 4
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Figure 3.6: Analytical UPLC traces of P25 (red, Rt = 3.17 min) and TB10.4 (blue, Rt = 3.50 min) peptide 
epitopes (0-50% B over 8 min, λ=214 nm). Peptides were dissolved in aqueous HEPES buffer (1 M, pH~7) 
containing guanidine hydrochloride (6 M) and incubated for 50 h. Broad peaks at Rt = 2.0-2.5 min are 
injection artefacts.  
 Synthesis of Pam2Cys-ESAT6-TB10.4 via native chemical ligation 
Design 
Because the P25-TB10.4 fusion peptide was unstable in aqueous buffer, the synthesis of 
vaccine candidate 301 was abandoned. Instead, we designed an alternative vaccine 
candidate 308 (Figure 3.7), in which the P25 epitope from 301 was replaced with 
ESAT61-20 (MTEQQWNFAGIEAAASAIQG), containing the dominant ESAT6 CD4+ T 
cell epitope (Aagaard, et al. 2009). ESAT6 is currently being investigated as an antigen 
for TB vaccination in a number of clinical trials (see introduction section 1.6.2). 
 
Figure 3.7: Structure of Pam2Cys-ESAT6-TB10.4 vaccine candidate 308. 
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3.5.2 Retrosynthesis 
Retrosynthetically, 308 was disconnected at Phe8-Ala9 in the ESAT6 peptide moiety, and 
it was envisaged that the key peptide bond could be formed via ligation-desulfurisation 
between lipopeptide thioester 309, containing Pam2CysSKKKK and ESAT61-8 linked via 
a triethyleneglycolate spacer, and C-terminal peptide fragment 310, bearing a cysteine 
residue at the N-terminus. 
 
Scheme 3.7: Retrosynthesis of Pam2Cys-ESAT6-TB10.4 vaccine candidate 308. 
3.5.3 Fragment Synthesis 
Lipopeptide thioester 309 and peptide 310 were synthesised as described above for 305 
and 306. The Trp residue in 309 provided strong UV absorption, and so the N-terminal 
Fmoc protecting group was not required for HPLC monitoring. Furthermore, we 
rationalised that the free amine would aid solubility, and so 309 was prepared without a 
protecting group on the N-terminal amine. In order to avoid undesired coupling reactions 
during thioesterification, the free amine was protected as the tert-butyl carbamate 
on-resin by treatment with 20 equivalents of di-tert-butyl dicarbonate and pyridine in 
DMF. Mild acidic cleavage from resin and thioesterification proceeded as described 
above, and the Boc group was removed during global cleavage with TFA. Following 
HPLC purification and lyophilisation, 309 was obtained in 9% yield over 30 steps (93% 
yield per linear step). Peptide 310 was obtained in 13% yield over 40 steps (95% yield 
per linear step). 
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Figure 3.8: Synthesis of lipopeptide thioester 309 and peptide 310 via Fmoc-strategy SPPS. 
3.5.4 Ligation-desulfurisation 
With the requisite lipopeptide thioester 309 and peptide 310 in hand, the fragments could 
next be assembled by NCL. The key ligation step was carried out in aqueous phosphate 
buffer (0.1 M, pH 7.0-7.5) containing guanidine hydrochloride (6 M), TCEP (50 mM) 
and TFET (2% v/v) (Scheme 3.8). The ligation was attempted in the mixed solvent 
system described above, but the reactants precipitated from solution over ~1 h and the 
ligation product could not be observed. Toth and colleagues observed similar behaviour 
during ligation of lipopeptides in mixed solvent systems and instead solubilised the 
lipopeptides using the surfactant sodium dodecyl sulphate (SDS) (Moyle, et al. 2006). 
However, SDS is incompatible with the guanidine included in NCL reactions as a 
chaotropic agent, because guanidinium dodecylsulfate precipitates from solution. 
Ligation of 310 and 311 did not proceed in ligation buffer containing SDS that lacked 
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guanidine, likely due to the formation of secondary structures or aggregates which 
suppressed the availability of functional groups required for ligation. We rationalised that 
a non-ionic surfactant might solubilise the lipopeptide thioester while still being 
compatible with 6 M guanidine. All ligation components dissolved when the non-ionic 
Tween®-20 was added to the ligation buffer (0.5% v/v) (Figure 3.9). To avoid formation 
of branched thioesters, 2 equivalents of C-terminal peptide 310 were included. The 
reaction was monitored by LCMS (Figure 3.10) and, within 2 h, the thioester was mostly 
converted to ligation product 311. Although there was a small amount of residual 
thioester remaining at 24 h, by-products had begun to appear and the reaction had stalled. 
As such, the reaction mixture was subjected to desulfurisation conditions by addition of 
ligation buffer containing TCEP (500 mM) as a reductant, glutathione (80 mM) as a 
hydrogen atom source, and the radical iniator VA-044 (40 mM). Ligation product 311 
was completely consumed after 8 h, affording the desired self-adjuvanting vaccine 
candidate 308 (Figure 3.11). A small amount of by-product was observed with a mass 
16 a.m.u. greater than the desired product, visible as a right-hand tail in the peak in the 
UPLC chromatogram. It is likely that this by-product arose via 1) oxidation of methionine 
to methionine sulfoxide, or 2) oxidative desulfurisation of Cys to Ser rather than Ala 
during the radical desulfurisation reaction (Malins, et al. 2015). In either case, the 
aberrant oxidation could be avoided by ensuring thorough degassing of the 
ligation-desulfurisation reactions to remove oxygen. Finally, Pam2Cys-ESAT6-TB10.4 
self-adjuvanting vaccine candidate 308 was separated from the oxidised by-product by 
preparative HPLC and was obtained as a white solid on multi-milligram scale in 34% 
yield over two steps following lyophilisation (Figure 3.12). 
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Scheme 3.8: Synthesis of Pam2Cys-ESAT6-TB10.4 vaccine candidate 308 via ligation-desulfurisation of 
309 and 310. 
 
Figure 3.9: Structure of Tween®-20. w + x + y + z = 20 
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Figure 3.10: Analytical HPLC-MS traces of lipopeptide thioester 309 and peptide 310, and ligation 
monitoring at 2 h and 24 h (10 to 100% B over 30 min, λ = 230 nm).  
309 (ESI+) calcd: [M+2H]2+ = 1299.74, [M+3H]3+ = 866.82, [M+4H]4+ = 650.49; found 1300.10, 867.00, 
650.50.  
310 (ESI+) calcd: [M+2H]2+ = 1102.00, [M+3H]3+ = 735.00; found 1102.25, 735.05.  
311 (ESI+) calcd: [M+3H]3+ = 1556.13, [M+4H]4+ = 1167.35, [M+5H]5+ = 934.08, [M+6H]6+ = 778.57; 
found 1556.6, 1167.75, 934.3, 621.3. 
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Figure 3.11: Analytical UPLC-MS traces of desulfurisation of ligation product 311 (Rt = 4.63 min) to 
vaccine candidate 308 (Rt = 4.54 min) (10 to 100% B over 8 min, λ = 280 nm).  
311 (ESI+) calcd: [M+3H]3+ = 1556.13, [M+4H]4+ = 1167.35, [M+5H]5+ = 934.08, [M+6H]6+ = 778.57; 
found 1556.55, 1167.70, 934.25, 621.35.  
308 (ESI+) calcd: [M+3H]3+ = 1545.48, [M+4H]4+ = 1159.36, [M+5H]5+ = 927.69; found 1545.95, 1159.65, 
927.85. 
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Figure 3.12: Analytical HPLC-MS trace of TB vaccine candidate 308. Rt 15.1 min (25-100% B over 
30 min, λ = 214 nm). LRMS calcd: [M+3H]3+ = 1545.48, [M+4H]4+ = 1159.36, [M+5H]5+ = 927.69; found 
(ESI+): 1545.95, 1159.65, 927.85. 
 Immunological evaluation of Pam2Cys-ESAT6-TB10.4 
self-adjuvanting TB peptide vaccine candidate 
The immunological evaluation of Pam2Cys-ESAT6-TB10.4 vaccine candidate 308 was 
carried out by Mrs Anneliese Ashhurst in Prof. Warwick Britton’s mycobacteria research 
laboratory at the Centenary Institute, NSW.  
3.6.1 T cell activation 
Firstly, to evaluate the capacity of 308 to induce activation of CD4+ and CD8+ T cells, 
C57BL/6 mice were vaccinated three times at fortnightly intervals with 3.0 nmol (14 μg) 
308 in PBS, or Pam2CysSKKKK in PBS as an adjuvant-only negative control (Figure 
3.13). Vaccination was tested via 2 routes of administration: sub-cutaneous (s.c.) 
injection or intranasal (i.n.) instillation. Mucosal delivery via i.n. instillation is preferred 
for TB vaccination due to the local activation of vaccine-specific immunity at the site of 
TB infection; the lungs (Giri and Khuller 2008). Three weeks after the final vaccination, 
mice were euthanised and the lungs and spleen collected for analysis of T cell responses. 
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Briefly, single cell suspensions of the lungs and spleen were restimulated by overnight 
culture in the presence of ESAT61-20 or TB10.43-11 (10 μg/mL). Epitope-specific cells 
were detected by intra-cellular cytokine staining and flow cytometry as described 
(section 6.4.2). 
   
Figure 3.13: Experimental design for evaluation of T cell activation by Pam2Cys-ESAT6-TB10.4 vaccine 
candidate 308. 
Pam2Cys-ESAT6-TB10.4 vaccine candidate 308 induced strong ESAT6-specific CD4+ 
T cell responses in the lung and spleen following i.n. vaccination (Figure 3.14). 
ESAT6-specific cells were IL-2+IL-17+TNF+, IL-17+TNF+, or IL-17+ (data for 
co-expression not shown). Notably, there was no detectable cytokine response in the 
lungs of mice that were subcutaneously vaccinated. No significant populations producing 
cytokine in response to TB10.4 was seen in the lungs of any immunised group, although 
a small population of IFNγ and TNF-producing TB10.4-specfic cells was observed in the 
spleens of subcutaneously immunised groups. 
The striking induction of IL-17 is consistent with previous findings that TLR2 agonists 
can promote Th17 responses, characterised by high levels of IL-17 and IL-21 (Oberg et 
al. 2010; Reynolds et al. 2010). Typically, Th17 responses are observed in protective 
immune responses against intracellular pathogens such as viruses and intracellular 
bacteria, which has led to their investigation as a potent anti-tubercular immune subset 
(Khader et al. 2007; Rai et al. 2016). 
Harvest lung, spleen 
for T Cell studies 
Day 49 
Vaccine candidate 
3.0 nmol (14 μg)  
(sub-cutaneous)  
Days 0, 14, 28 
C57BL/6 
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Figure 3.14: Mucosal delivery of Pam2Cys-ESAT6-TB10.4 vaccine candidate 308 induced strong local 
TNF and IL-17 responses. Frequency of cytokine-producing CD4+ or CD8+ T cells in the lungs and spleen 
of vaccinated C57BL/6 mice was assessed at 3 weeks following final immunisation. Data are the 
mean ± SEM (n = 3 mice/group). Statistically significant differences to relevant Pam2Cys control are 
shown, as determined by ANOVA with Bonferroni post-hoc comparison (*p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001). 
3.6.2 Tuberculosis protection 
Encouraged by the observation that Pam2Cys-ESAT6-TB10.4 vaccine candidate 308 
induced strong CD4+ T cell responses in the lungs of C57BL/6 mice, we examined the 
capacity of 308 to protect from challenge by M. tuberculosis. To this end, groups of 6 
mice received 3 vaccinations of 308 (i.n. or s.c.) at fortnightly intervals as described 
above, or Pam2CysSKKKK as a negative control. As a positive control, a group of mice 
were vaccinated with BCG. Six weeks after the final vaccination, mice were challenged 
with the H37Rv strain of M. tuberculosis by low-dose aerosol infection (100 CFU). Four 
weeks later, bacterial load in the lungs and spleen were enumerated. Briefly, serial 
dilutions of tissue homogenates were cultured on 7H11 agar plates for 21 d, and colonies 
were counted manually. See the Materials and Methods (section 6.4.2) for full 
experimental details. 
Vaccination with self-adjuvanting conjugate vaccine 308 provided significant protection 
from TB challenge in the lung by both i.n. and s.c. administration (Figure 3.16). 
Consistent with immunological data, no protection was generated in the spleen. It should 
be noted that vaccination with BCG afforded a greater protection than vaccination with 
308. However, one of the BCG does not express ESAT6, and so the protective immune 
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responses must target different antigens. As such, future work will investigate whether 
any synergistic effects can be obtained by vaccination with both agents.  
 
 
 
 
 
Figure 3.15: Experimental design for evaluation of the protective efficacy of Pam2Cys-ESAT6-Ag85B 
vaccine candidate 308 against M. tuberculosis infection. 
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Figure 3.16: Protective efficacy against M. tuberculosis infection was induced by immunisation with 
Pam2Cys-ESAT6-TB10.4 vaccine candidate 308. C57BL/6 mice (n = 6 mice/group) were immunised with 
conjugate vaccine (3 nmol), or with an equivalent amount of Pam2Cys-containing adjuvant alone. Six 
weeks following final vaccination, mice were challenged with a low-dose aerosol of M. tuberculosis H37Rv 
(100 CFU). Additional mice were immunised with 5x105 CFU BCG once by subcutaneous injection 
10 weeks before challenge with M. tuberculosis H37Rv. After 28 days, mice were harvested and the 
bacterial loads in the (A) lungs and (B) spleen were enumerated following culture on Middlebrook 7H11 
media. The data are the means ± SEM. Statistical significance was determined by ANOVA with Bonferroni 
post-hoc comparison to adjuvant only control (*p<0.05, **p<0.01, ****p<0.0001). 
 
 
Self-Adjuvanting Vaccine Candidates for Tuberculosis 
 72 
 Conclusions and Future Directions 
To the best of our knowledge, the work presented in this chapter details the synthesis of 
the first self-adjuvanting vaccine candidate for tuberculosis. The vaccine consists of 
Pam2Cys as an adjuvant on the N-terminus, separated by a triethyleneglycolate spacer 
from the CD4+ T cell epitope ESAT61-20 and the CD8+ T cell epitope TB10.43-11. The 
vaccine was assembled through one-pot native chemical ligation-desulfurisation in 
acceptable yields and, importantly, on the multi-milligram scale required for 
immunological evaluation. When delivered intranasally into C57BL/6 mice, 308 induced 
ESAT6-specific cell-mediated immunity, and demonstrated protection from 
M. tuberculosis infection in the lung. TB protection experiments are lengthy, and 
experiments to ensure this finding is reproducible are underway. In future experiments, 
we will examine any synergy between vaccination with Pam2Cys-ESAT6-TB10.4 and 
other TB vaccines, including BCG. 
Synthesis of Pam2Cys-P25-TB10.4 vaccine candidate 301 was abandoned due to the 
instability of the P25-TB10.4 peptide sequence in aqueous buffer. However, each peptide 
sequence was stable in isolation. We hypothesise that swapping the order of the two 
epitopes such that the P25 epitope is on the C-terminus would circumvent the degradation 
observed above. As such, future work will involve the synthesis of a TB10.4-P25 
conjugate peptide for decomposition studies, followed by synthesis and immunological 
evaluation of a Pam2Cys-TB10.4-P25 self-adjuvanting vaccine candidate (Figure 3.17). 
 
Figure 3.17: Structure of proposed Pam2Cys-TB10.4-P25 vaccine candidate. 
The synthesis of 308 required the development of strategies for the synthesis and 
purification of fully unprotected lipopeptide fragments, and their subsequent ligation. 
This work will serve as a model for the rapid iteration of other self-adjuvanting vaccines 
on synthetically and biologically useful scales. Indeed, this methodology was applied to 
the synthesis and immunological evaluation of a novel MUC1 vaccine candidate in the 
next chapter. 
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PAM2CYS-MUC1VNTR 
SELF-ADJUVANTING CANCER 
VACCINES 
 Aims 
The MUC1VNTR-based self-adjuvanting vaccine candidates evaluated in Chapter 2 
induced strong MUC1-specific humoral immune responses, but not cell-mediated 
responses. The aims of this chapter were to: 
1. Redesign the MUC1VNTR glycopeptide epitope in order to maintain a strong 
humoral immune response while also generating tumour-specific CTLs.  
2. Incorporate the redesigned MUC1VNTR glycopeptide into a novel 
self-adjuvanting glycolipopeptide vaccine candidate using the synthetic 
methodology developed in Chapter 3. 
3. Evaluate the capacity of the novel vaccine candidate to induce MUC1-specific 
humoral and cell-mediated immune responses. 
 MUC1VNTR epitope design 
4.2.1 Glycopeptide length 
We and others have incorporated the full-length 20 amino acid glycopeptide 
MUC1VNTR into self-adjuvanting vaccine candidates (Chapter 2, Introduction section 
1.5). In MUC1 proteins, however, the VNTR sequence is repetitive. CD8+ T cell epitopes 
are typically 7-11 amino acid residues in length, and so choosing any 20 amino acid 
VNTR sequence necessarily restricts the range of potential CD8+ T cell epitopes to those 
that fall between the chosen start and end residues. As an example, the HLA-A2-binding 
epitope STAPPAHGV (Apostolopoulos, et al. 1997b; Brossart, et al. 1999) was absent 
from the glycopeptide epitopes utilised in Chapter 2 (GVTSAPDTRPAPGSTAPPAH). 
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Furthermore, it is unknown how N- or C-terminal modification of these peptide epitopes 
affects their proteasomal processing. In addition to covering a wider range of potential 
CD8+ epitopes, longer VNTR peptides are more likely to retain the residues flanking such 
epitopes, which may be important for processing by APCs. 
The repetitive nature of the MUC1VNTR also enables the choice of N- and C-terminal 
residues that are favourable for the assembly of vaccine constructs via ligation 
technologies. We envisaged that the 27 residue MUC1VNTR peptide fragment 
AHGVTSAPDTRPAPGSTAPPAHGVTSA would encompass a wider range of CD8+ T 
cell epitopes than the previous 20 residue peptides, while bearing an N-terminal Ala 
which could be readily accessed via ligation-deselenisation at selenocysteine (Figure 4.1, 
introduction section 1.3.4).  
 
Figure 4.1: Previous and revised MUC1VNTR peptide epitopes 
4.2.2 Number and position of glycans 
As discussed previously (Section 2.5), the only MUC1VNTR glycopeptide that has been 
demonstrated to bind murine MHC is SAPDT(TN)RPAP (Apostolopoulos, et al. 2003). 
Additionally, the only MUC1VNTR vaccine that has demonstrated MUC1 
glycopeptide-specific CTL induction in vivo contained SAPDT(TN)RPAP, conjugated to 
Pam3Cys and a poliovirus helper T cell epitope (Lakshminarayanan, et al. 2012). 
Combined with the finding that O-glycosylation of the SAP region can inhibit 
MUC1VNTR processing by the immunoproteasome (Ninkovic and Hanisch 2007), these 
observations led us to propose that per-glycosylation of the MUC1VNTR may have 
hindered the capacity of vaccine candidates 202-203 to induce the activation of 
MUC1-specific CTLs.  
As such, we sought to design a MUC1VNTR sequence that, when incorporated into a 
self-adjuvanting vaccine, could maintain high levels of humoral reactivity while also 
inducing MUC1-specific CTLs. Of the 7 potential sites of O-glycosylation in the 27mer 
MUC1VNTR peptide proposed above, glycosylation of both Thr in PDTR and Ser in 
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GSTA have been implicated in the generation of tumour-specific antibodies via 
stabilisation of highly immunogenic conformations of the peptide backbone (Gaidzik, et 
al. 2011; Movahedin, et al. 2016). We hypothesised that 27mer MUC1VNTR 
glycopeptide 401, glycosylated with TN at these two sites, would retain the 
H-2Kb-binding epitope SAPDT(TN)RPAP without sacrificing antibody reactivity 
(Scheme 4.1). Glycopeptide 401 was synthesised via Fmoc-SPPS from Rink amide resin 
as described in the general methods. After global deprotection and cleavage, glycan O-
acetyl groups were removed by treatment with aqueous hydrazine, and 401 was obtained 
in 41% yield over 54 steps following HPLC purification (98% yield per step). 
 
Scheme 4.1: Synthesis of MUC1VNTR glycopeptide 401. 
To test the hypothesis that 401 could induce MUC1-specific CD8+ T cell responses, 
C57BL/6 mice (n = 5 mice/group) were vaccinated with PBS or 5.0 nmol 401 admixed 
with the adjuvant saponin; a mixture of steroid glycosides isolated from Quillaja 
saponaria bark which is a potent adjuvant for cell-mediated immune responses through 
a mechanism that is still unclear (Rajput, et al. 2007; Sun, et al. 2009). One week after 
vaccination, in vivo CTL activity against the MUC1 nonaglycopeptide epitope 
SAPDT(TN)RPAP 213 was assessed as described previously (section 2.4.2; section 
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6.2.6). Briefly, C57BL/6 splenocytes labelled with 214 or the scrambled sequence 215, 
and MUC1-specific CTL activity calculated from the ratio of recovered target and control 
cells. Mice vaccinated with admixed 401 and saponin tended to display more 
MUC1-specific CTL activity than PBS-treated mice, but the difference was not 
statistically significant (p = 0.095, Figure 4.2). Indeed, even if the increase in CTL 
activity had been statistically significant, the absolute magnitude was low (~20%). We 
hypothesised that this lacklustre CTL activity was due to the poor immunogenicity of the 
MUC1VNTR, and that improved CTL responses might be induced by a self-adjuvanting 
MUC1VNTR vaccine candidate. 
 
Figure 4.2: In vivo CTL activity towards glycopeptide 213 induced by vaccination with glycopeptide 401 
and saponin. Lines represent mean (± SEM) of n = 5 mice. Results were analysed using a Mann-Whitney 
test (p = 0.095). 
 Synthesis of Pam2Cys-MUC1VNTR self-adjuvanting vaccine via 
selenoester-selenocystine ligation-deselenisation 
4.3.1 Design and retrosynthesis 
In order to determine whether a self-adjuvanting vaccine candidate containing 
MUC1VNTR glycopeptide 401 could induce strong CTL activity, we designed 
self-adjuvanting vaccine candidate 402, bearing the adjuvant Pam2CysSKKKK 
covalently attached to MUC1VNTR glycopeptide 401 via a triethyleneglycolate linker 
(Scheme 4.2). It was envisaged that 402 could be synthesised by combining the 
methodology developed in Chapter 3 for the synthesis and purification of lipopeptides 
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via native chemical ligation and the selenoester-selenocystine ligation-deselenisation 
methodology recently developed in our laboratory (Introduction section 1.3.4; Mitchell, 
et al. 2015). Retrosynthetically, we envisaged that 402 could be accessed via 
ligation-deselenisation of lipopeptide selenoester 403, bearing an N-terminal Pam2Cys, 
and glycopeptide diselenide 404, bearing an N-terminal selenocystine residue (the 
oxidised form of selenocysteine).  
 
Scheme 4.2: Retrosynthesis of Pam2Cys-MUC1VNTR vaccine candidate 402. 
4.3.2 Synthesis of Pam2Cys lipopeptide selenoester 403 
Synthesis of lipopeptide selenoester 403 was achieved via Fmoc-strategy SPPS on 2-CTC 
resin as described in the general methods. The N-terminal amine was protected with a 
Boc group by on-resin treatment with di-tert-butyl dicarbonate and pyridine in DMF, and 
the protected peptide was removed from resin by mild acidic cleavage with HFIP. The 
crude, protected lipopeptide was converted to the phenyl selenoester by treatment with 
diphenyl diselenide (DPDS, 30 eq.) and tributyl phosphine (Bu3P, 30 eq.) in DMF for 
2 h. Selenoesterification is typically carried out at 0 °C to avoid epimerisation of the 
C-terminal residue, however the selenoesterification of 403 was carried out at room 
temperature as there was no epimerisation possible at the achiral triethylene glycolate 
residue. The solvent was subsequently removed under a stream of N2 overnight, and then 
the protecting groups were removed by global cleavage with an acidic cocktail. After 
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semi-preparative HPLC using the conditions optimised in Chapter 3, lipopeptide 
selenoester 403 was obtained in 9% yield over 16 steps (86% yield per step). 
 
Scheme 4.3: Synthesis of Pam2Cys-containing lipopeptide selenoester 403. 
4.3.3 Synthesis of MUC1VNTR diselenide 404 
Synthesis of MUC1VNTR glycopeptide diselenide 404 was carried out via 
Fmoc-strategy SPPS as described for glycopeptide 401 above. A protected selenocysteine 
building block, N-Boc protected (4R)-1,3-selenazolidine-4-carboxylic acid 
(Boc-Sez-OH), was provided by Ms. Abera Sayeed, a summer student in the Payne 
laboratory. Boc-Sez-OH was coupled onto the nascent glycopeptide in the presence of 
HATU, HOAt and iPr2NEt. Global acidic cleavage and deprotection provided crude 
glycopeptide 405, bearing an N-terminal selenazolidine and two per-acetylated TN 
glycans (Scheme 4.4). Treatment of crude 405 with aqueous hydrazine effected the 
concomitant removal of the O-acetyl groups and conversion of the N-terminal 
selenazolidine to selenocysteine, which rapidly oxidised to form the desired diselenide 
404 (Scheme 4.5). The crude glycopeptide was observed as a very broad peak by 
UPLC-MS, which was attributed to the formation of asymmetric diselenides with 
impurities arising from SPPS. Approximately 10 s prior to HPLC purification, crude 404 
was treated with stoichiometric TCEP to reduce any such diselenides. It is important to 
note that prolonged exposure to TCEP would lead to deselenisation of selenocysteine to 
alanine (vide infra). However, brief treatment with TCEP and immediate purification led 
to successful isolation of 404 as a selenol, which immediately re-oxidised to provide pure 
diselenide 404 in 32% yield over 53 steps (98% yield per step). 
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Scheme 4.4: Synthesis of crude glycopeptide 405. 
4.3.4 One-pot ligation-deselenisation  
With lipopeptide selenoester 403 and MUC1VNTR glycopeptide diselenide 404 in hand, 
the assembly of Pam2Cys-MUC1VNTR vaccine candidate 402 via 
ligation-deselenisation could be investigated. Due to the insolubility of 403 in aqueous 
ligation buffer (1 M HEPES, 6 M guanidine hydrochloride, pH ~7), both NMP as an 
organic co-solvent and Tween®-20 as a non-ionic surfactant were investigated to 
solubilise the lipopeptide selenoester for ligation. 403 was soluble under both conditions, 
and ligation reactions were performed in a mixed solvent system of NMP:buffer (1:4 v/v). 
Unfortunately, the lipopeptide selenoester was not stable under these ligation conditions. 
Within 5 minutes, 403 was converted into two distinct product peaks by UPLC-MS, one 
with a mass corresponding to loss of phenyl selenol. We propose that this was due to 
aminolysis of the selenoester by any of the five primary amines (the N-terminal amine or 
the ε-amines of the four lysine residues) to form a macrolactam. See Scheme 4.6 for one 
such structure, 406. The other major product had twice the mass of this macrolactam, 
which we propose could arise from the direct aminolysis of selenoester 403 by one of the 
four primary amines of macrolactam 406. See Scheme 4.6 for one such structure, 407. 
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Scheme 4.5: Synthesis of glycopeptide diselenide 404. 
405 (ESI+) calcd: [M+2H]2+ = 1631.20, [M+3H]3+ = 1087.80; found 1631.20, 1087.95. 
404 (ESI+) calcd: [M+4H]4+ = 1498.66, [M+5H]5+ = 1199.12, [M+6H]6+ = 999.44, [M+7H] 7+ = 856.80; 
found 1499.15, 1199.35, 999.45, 856.75. 
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Scheme 4.6: Proposed formation of macrolactams 406 and 407 via aminolysis of 403. 
In order to avoid macrolactamisation of 403 prior to ligation, glycopeptide diselenide 404 
was lyophilised into a microcentrifuge tube along with 4 equivalents of lipopeptide 
selenoester 403 (2 eq. w.r.t. 404 monomer). The solid mixture was then dissolved in the 
mixed solvent ligation buffer to achieve a glycopeptide diselenide concentration of 
2.5 mM (10 mM w.r.t. 403). It was rationalised that aminolysis would proceed faster at 
higher pH, and so the pH was not adjusted after dissolution of the fragments, and the 
ligation was carried out at pH 5.2. The ligation reaction was monitored by UPLC-MS 
(Scheme 4.7, Figure 4.3, Figure 4.4). 
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Scheme 4.7: Synthesis of Pam2Cys-MUC1VNTR vaccine candidate 402 via ligation-deselenisation of 
lipopeptide selenoester 403 and glycopeptide diselenide 404. 
By the time the first UPLC-MS sample was taken (< 10 s), macrolactams 406 (♦) and 407 
(■) were present, suggesting a small amount of macrolactamisation occured during 
handling and lyophilisation. Pleasingly, however, the ligation reaction was rapid, and at 
t = 2 min, the major product was the desired diselenide ligation product 408.  
The selenoester-selenocystine ligation reaction liberates phenyl selenol, which is 
typically oxidised to DPDS, which precipitates from the aqueous ligation buffer. In the 
mixed solvent system utilised here, however, DPDS remained soluble. In solution, 
diselenides undergo dynamic exchange through an as-yet uncertain mechanism (Ji, et al. 
2014; Rasmussen, et al. 2014; Mitchell, et al. 2015). The facile exchange of DPDS with 
symmetric peptide diselenides 404 and 408 gave rise to asymmetric diselenide products, 
represented here as ο and □, respectively (Scheme 4.8). At t = 5 min, selenoester 403 
had been consumed, and so TCEP was added to reduce these asymmetric diselenides, and 
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the reaction mixture was extracted with hexane three times in order to remove the bulk 
of the phenylselenol, which would otherwise inhibit the deselenisation reaction.  
To effect deselenisation of the ligation product 408, the ligation mixture was degassed 
under a stream of argon for 5 min, then TCEP as a reductant and dithiothreitol (DTT) as 
a hydrogen atom source were added in one volume of mixed solvent ligation buffer, and 
the deselenisation reaction was allowed to proceed at pH 4.0 overnight at 37 °C. 
Following HPLC purification and lyophilisation, self-adjuvanting vaccine candidate 402 
was obtained in 62% yield over the two steps. The purity of the final product was 
confirmed by analytical HPLC (Figure 4.5). 
This method enabled the rapid synthesis of 402 in high yield on multi-milligram scale. 
However, the efficiency of the key ligation step was hampered by a requirement for 
excess equivalents of lipopeptide selenoester due to unforseen reactions leading to the 
formation of macrolactam by-products, eg. 406 and 407 in Scheme 4.6. Although the 
triethyleneglycolate selenoester moiety in 403 has not previously been tested in ligation 
reactions, the rapid rate of both direct aminolysis and ligation suggests that it is very 
reactive. Indeed, thioesters and selenoesters which have less steric bulk at the α- and 
β-positions, such as glycine or alanine, are more reactive than more sterically hindered 
esters, such as valine (Hackeng, et al. 1999; Mitchell, et al. 2015). We propose that this 
reactivity, in combination with the flexibility of the triethyleneglycolate spacer, led to 
aminolysis which was competitive with the ligation reaction. If a ligation junction were 
chosen such that the requisite selenoester were less reactive, ligation would be slower, 
but the reaction would likely be more selective for the desired vaccine candidate. 
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Figure 4.3: Monitoring of ligation-deselenisation of lipopeptide selenoester 403 and glycopeptide 
diselenide 404 via UPLC-MS (10-100% B over 8 min, λ = 214 nm). ♦ = macrolactam 406, ■ = macrolactam 
407, ο = 404 asymmetric diselenide, □ = 408 asymmetric diselenide. 
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Figure 4.4: ESI mass spectrometry of: 
403 (ESI+) calcd: [M+2H]2+ = 779.48, [M+3H]3+ = 519.98; found 779.25, 519.70. 
♦ 406 (ESI+) calcd: [M+2H]2+ = 700.50, [M+3H]3+ = 467.33; found 700.55, 467.25.  
■ 407 (ESI+) calcd: [M+3H]3+ = 933.66, [M+4H]4+ = 700.50, [M+5H]5+ = 560.60; found 933.95, 700.65, 
560.70. 
404 (ESI+) calcd: [M+4H]4+ = 1498.66, [M+5H]5+ = 1199.12, [M+6H]6+ = 999.44, [M+7H]7+ = 856.80, 
[M+8H]8+ = 749.83; found 1499.25, 1199.40, 999.55, 856.85, 749.60.  
ο 404 asymmetric diselenide (ESI+) calcd: [M+2H]2+ = 1576.63, [M+3H]3+ = 1051.42, [M+4H]4+ = 788.82; 
found 1576.40, 1051.75, 788.95. 
□ 408 asymmetric diselenide (ESI+) calcd: [M+3H]3+ = 1518.08, [M+4H]4+ = 1138.81, [M+5H]5+ = 911.25, 
[M+6H]6+ = 759.54; found 1518.15, 1139.05, 911.10, 759.40. 
408 (ESI+) calcd: [M+5H]5+ = 1758.72, [M+6H]6+ = 1465.77, [M+7H]7+ = 1256.51, [M+8H]8+ = 1099.58, 
[M+9H]9+ = 977.51; found 1759.35, 1466.70, 1257.00, 1099.95, 977.55.  
402 (ESI+) calcd: [M+3H]3+ = 1439.77, [M+4H]4+ = 1080.08, [M+5H]5+ = 864.26, [M+6H]6+ = 720.38; 
found 1439.90, 1080.35, 864.30, 720.40.  
 
 
Scheme 4.8: Dynamic diselenide exchange  
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Figure 4.5: Analytical HPLC trace of Pam2Cys-MUC1VNTR vaccine candidate 402. Rt 18.7 min 
(10-100% B over 30 min, λ = 214 nm). LRMS calcd: [M+3H]3+ = 1439.77, [M+4H]4+ = 1080.08, 
[M+5H]5+ = 864.26, [M+6H]6+ = 720.38; found (ESI+) 1439.90, 1080.35, 864.30, 720.40. 
 Immunological evaluation 
4.4.1 Experimental design 
In order to immunologically evaluate Pam2Cys-MUC1VNTR self-adjuvanting vaccine 
candidate 402, C57BL/6 mice were vaccinated with 5.0 nmol 402 in PBS, or PBS alone 
as a negative control (Figure 4.6). Mice received two vaccinations, on days 0 and 14 of 
the experiment. For enumeration of MUC1-specific antibodies, serum was collected 
weekly via sub-mandibular bleed. On day 20, in vivo MUC1-specific CTL activity was 
assessed by injection of a mixed cohort of target and control cells as described above 
(Section 4.2.2). Spleens and inguinal lymph nodes were collected for flow cytometric 
analysis on day 21. 
4.4.2 Cell-mediated immunity 
In vivo cytotoxicity towards MUC1VNTR glycopeptide 213 was assessed as described 
above (Section 4.2.2). As with the admixture of 401 and saponin, there was a trend 
towards increased MUC1-specific lysis in mice vaccinated with self-adjuvanting vaccine 
candidate 402 compared to negative controls which was not statistically significant 
(p = 0.089, Figure 4.7).  
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Figure 4.6: Vaccination schedule and experimental design for immunological evaluation of 
Pam2Cys-MUC1VNTR vaccine candidate 402. 
In order to determine whether vaccination with 402 induced CD8+ T cell activation 
despite the lack of CTL activity, the draining lymph nodes and spleens of vaccinated and 
PBS-treated mice were isolated, and single cell suspensions were cultured overnight in 
the presence of MUC1VNTR glycopeptide 401, and Brefeldin A was added for the final 
four hours to block exocytosis. Cell suspensions were then stained for expression of 
intracellular cytokines as described in the general methods (section 6.2.4). See Figure 
2.12 for an example of the gating strategy used. Significantly more CD8+ T cells from the 
spleens of vaccinated mice expressed TNF than controls, indicating that a MUC1-specific 
T cell response was induced by vaccination (Figure 4.8). However, no differences were 
observed in the other cytokines tested (IFN-γ, IL-2), and no differences were seen in the 
draining lymph nodes. This data is consistent with the induction of a weak CD8+ T cell 
response towards MUC1 by self-adjuvanting vaccine candidate 402. As discussed 
previously (Section 2.5), generation of robust CD8+ T cell responses towards 
MUC1VNTR glycopeptides may require CD4+ T cell help. Future work will involve the 
synthesis and immunological evaluation of self-adjuvanting vaccine candidates 
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containing helper T cell epitopes in order to probe the importance of T cell help in this 
system. 
 
 
Figure 4.7: in vivo CTL activity towards glycopeptide 213 induced by vaccination with self-adjuvanting 
vaccine candidate 402. Bars represent mean (± SD) of n = 10 mice from two independent experiments. 
Results were analysed using a Mann-Whitney test (p = 0.089). 
 
Figure 4.8: Frequency of CD8+ T cells isolated from the inguinal lymph nodes (LN) or spleen expressing 
IFN-γ, IL-2, and TNF. CD8+ T cells isolated from the spleens of mice immunised with PBS or vaccine 
candidates 402 on day 21 of the immunisation schedule activated in vitro with MUC1VNTR glycopeptide 
401. Bars represent median (± IQR) of n = 5 C57BL/6 mice. Results were analysed by ANOVA with a 
Sidak post hoc test. 
4.4.3 Induction of MUC1-specific antibodies 
The MUC1VNTR self-adjuvanting vaccine candidate 402 was designed to induce a 
strong CD8+ T cell response while maintaining the ability to induce strong 
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MUC1-specific antibody responses. In order to test whether 402 could induce 
MUC1-specific antibodies, serum was collected by sub-mandibular bleed weekly though 
the vaccination schedule, and stored at -30 °C. MUC1-specific antibodies were then 
enumerated by standard indirect ELISA as described in the general methods 
(section 6.2.7), using ELISA plates coated with MUC1VNTR glycopeptide 402. 
Unfortunately, vaccination with 402 induced low titres of MUC1-specific IgM, and no 
detectable IgG (Figure 4.9).  
These results are juxtaposed with the strong IgM and IgG responses induced by 
vaccination with MALP2-MUC1 vaccine candidate 202, which contains a single 20 
amino acid copy of the MUC1VNTR per-glycosylated with the TN antigen (Chapter 2). 
There were three major differences which may explain the discrepancy between the 
humoral responses in the two experiments: 
1) Unlike Pam2Cys, MALP2 can directly activate B cells without the need for CD4+ 
T cell help (Borsutzky, et al. 2005). 
2) Reducing the number of glycans may have reduced the immunogenicity of the 
MUC1VNTR epitope. This seems unlikely, however, because 
MUC1VNTR-specific antibody induction is typically inversely correlated with 
the degree of glycosylation (Chapter 2; Gaidzik, et al. 2011, Wilkinson et al. 2011, 
Wilkinson et al. 2012) 
3) The MALP2-MUC1 conjugate vaccine 202 was injected four times at weekly 
intervals, a dose schedule which has been shown to induce strong antibody 
responses but not CTL responses (Ingale, et al. 2009). To avoid CD8+ T cell 
overstimulation and subsequent anergy, the Pam2Cys-MUC1VNTR vaccine 
candidate 402 was injected twice, 14 days apart. It is possible that increased 
antibody titres would be observed upon further boosting. It should be noted, 
however, that higher titres of MUC1-specific IgM were induced following a 
single vaccination with 202 than two vaccinations with 402, suggesting that 
number of injections was not wholly responsible for the differences observed. 
Taken together, these observations suggest that choice of adjuvant was likely responsible 
for the disparate antibody outcomes between vaccination with MALP2-containing 
vaccine candidate 202 and Pam2CysSKKKK-containing vaccine candidate 402. Future 
work will test this hypothesis directly (vide infra). It should be noted that the differences 
in immune responses to 202 and 402 might not be due to the differential activities of 
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MALP2 and Pam2CysSer, but could arise instead due to pharmacodynamic 
considerations such as in vivo stability and ability to be taken up or presented by relevant 
APCs. 
 
Figure 4.9: MUC1-specific titres of IgM and IgG over time in sera collected from mice treated with PBS 
or vaccinated with 402. Plotted points represent median (±IQR) endpoint titres of n = 5 mice/group. 
 
 Conclusions and Future Directions 
The work presented here details the iterative design, synthesis and immunological 
evaluation of a novel Pam2Cys-MUC1VNTR self-adjuvanting vaccine candidate, 402. 
The length and degree of glycosylation of the MUC1VNTR epitope incorporated into 
MALP2-MUC1 vaccines 201-203 was revised with the goal of inducing MUC1-specific 
CTL responses while maintaining a strong humoral response. Combining the 
methodology developed in Chapter 3, for the synthesis and purification of long 
lipopeptides, with the recently developed selenoester-selenocystine ligation technology, 
the revised MUC1VNTR glycopeptide epitope 401 was incorporated into 
self-adjuvanting vaccine candidate 402 in good yield on multi-milligram scale. 
Unfortunately, when injected into C57BL/6 mice, 402 induced only weak humoral 
responses and weak or absent cell-mediated immune responses.  
The synthesis of 402 constitutes the first synthesis of a glycolipopeptide assembled via 
selenocystine-selenoester ligation-deselenisation. The key ligation step was very rapid, 
and deselenisation was achieved without intermediate purification in good yield. This 
work will serve as a general technology platform for the rapid synthesis of 
self-adjuvanting vaccines in the future, to accelerate the improvement of such vaccines 
through iterative design, synthesis and evaluation. 
We propose that the difference in immunological outcomes between the experiments 
upon vaccination with Pam2Cys-MUC1VNTR vaccine candidate 402 and 
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MALP2-MUC1 vaccine candidate 202 was due primarily to the difference in adjuvant 
activity between Pam2Cys and MALP2. Additionally, we propose that inclusion of a 
helper T cell epitope might be sufficient to induce stronger CTL responses and stronger, 
class-switched antibody responses. In order to investigate these two parameters 
independently, future work will involve the synthesis of two self-adjuvanting 
MUC1-based glycolipopeptide vaccine candidates. The first, 409, will contain the 
adjuvant Pam2CysSKKKK, separated by a triethyleneglycolate spacer from a helper T 
cell epitope from tetanus toxoid (Ttx) and the revised MUC1VNTR glycopeptide epitope 
401 (Scheme 4.9). We envisage that 409 could be synthesised via 
selenoester-selenocystine ligation between MUC1VNTR glycopeptide diselenide 404 
and lipopeptide selenoester 410. The second proposed vaccine candidate, 411, will 
contain MALP2 and 401, again separated by a triethyleneglycolate spacer. We envisage 
that 411 could be constructed via ligation between lipopeptide selenoester 412 and 
glycopeptide diselenide 413, bearing an N-terminal β-selenoaspartic acid residue recently 
described by our laboratory (Mitchell, et al. 2017). Importantly, each of these ligation 
reactions will occur at C-terminal amino acid selenoesters which we would expect to be 
much less reactive than the triethyleneglycolate described here, which will enable us to 
test the hypothesis that less-reactive selenoesters will not be subject to the aminolysis 
observed for selenoester 403. 
Finally, it may be the case that neither a stronger adjuvant nor T cell help will 
simultaneously improve the humoral and cell-mediated immune responses towards the 
MUC1VNTR. An alternative approach will be to optimise the structure of the 
MUC1VNTR epitope to induce high titres of class-switched MUC1-specific antibodies, 
augmented by a CTL response to a related but separate T cell epitope. Reports of CTL 
induction towards the signal peptide of MUC1 led us to investigate the efficacy of 
vaccination with peptide fragments from both the VNTR and signal peptide of MUC1 
(Chapter 5). 
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Scheme 4.9: Structure and retrosynthesis of proposed Pam2Cys-Ttx-MUC1VNTR and 
MALP2-MUC1VNTR self-adjuvanting vaccine candidates 409 and 411. 
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 MUC1 SIGNAL 
PEPTIDE 
 Introduction 
5.1.1 Biology of the MUC1 Signal Peptide 
Most cell-surface proteins, including MUC1, contain a 15-40 residue “signal peptide” on 
the N-terminus that targets the protein for transport to the cell surface. During transport 
from the ER to the Golgi, these peptides are cleaved from the nascent protein by 
proteolytic enzymes such as signal peptidase (Vonheijne 1985).  
The MUC1 signal peptide (henceforth MUC1SP) 501 is a 21-amino acid peptide which, 
along with most eukaryotic signal peptides, consists of a hydrophobic central region with 
a more polar N-terminus. Although functions have been identified for several signal 
peptides following cleavage from their proteins (See Kapp, et al. 2009), little is known 
about the fate of the MUC1SP. 
5.1.2 MUC1SP as a cancer antigen 
The majority of MUC1 vaccination strategies focus on the use of the MUC1VNTR. 
However, a 10-mer peptide from the C-terminus of MUC1SP (LLLLTVLTVV) was 
identified as an HLA-A*0201-binding peptide using in silico prediction and confirmed 
using in vitro binding assays (Brossart, et al. 1999).  The authors proceeded to generate 
CD8+ CTL clones recognising this peptide, which were able to lyse human tumour cells 
lines in an HLA-A2- and MUC1-specific manner. Independently and at the same time, 
Carmon and co-workers obtained similar results (Carmon, et al. 2000). These studies 
represent the first descriptions of MUC1SP as a potential cancer antigen. 
To date, the only research group to use the MUC1SP in vaccines is Vaxil Biotherapeutics 
(henceforth VaxilBio), led by Lior Carmon. VaxilBio made use of a murine model in 
which BALB/c mice carrying a transgene coding for HLA-A*0201 were inoculated with 
human MUC1+ murine mammary tumour cells. Vaccination with admixed MUC1SP and 
 
501 
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granulocyte-macrophage colony-stimulating factor (GM-CSF) prior to tumour 
inoculation, or 7 days after inoculation, led to significant reduction in tumour burden at 
17 weeks. This protection was associated with the production of αMUC1SP antibodies 
and CTLs.  
VaxilBio also identified significantly higher titres of αMUC1SP antibodies in the serum 
of multiple myeloma patients than healthy donors (Kovjazin, et al. 2012). The biological 
relevance of these antibodies was unclear, however, given that the authors could not 
detect levels of soluble MUC1SP in patient sera. Future studies subsequently identified 
cell-surface expression of MUC1SP on tumour cells, but not healthy MUC1+ cells such 
as leukocytes and epithelial cells (Kovjazin, et al. 2014). Furthermore, it was 
demonstrated that polyclonal antibodies produced against synthetic MUC1SP peptides 
were capable of eliciting antibody-dependent cellular cytotoxicity (ADCC) against those 
cancer cells expressing MUC1SP at the cell surface. Taken together, these findings 
indicate that cell-surface MUC1SP is a potential diagnostic marker for cancer as well as 
a promising target for anti-tumour vaccine development. 
Translating these findings into the clinic, VaxilBio carried out a Phase I/II clinical trial 
of MUC1SP admixed with GM-CSF in a small cohort of multiple myeloma patients with 
stable or progressive disease (Carmon, et al. 2015). Although the primary goal of this 
study was to ascertain safety, all vaccinated patients exhibited increased levels of IFNγ 
in response to MUC1SP, and 10/15 patients exhibited increased levels of serum 
αMUC1SP antibodies.  
5.1.3 MUC1 in immune suppression 
MUC1 is an oncogene; overexpression of human MUC1 in mice causes the development 
of pancreatic tumours (Tinder, et al. 2008a). This oncogenicity has previously been 
attributed to the immunosuppressive and biophysical properties of the MUC1VNTR. The 
C-terminal cytoplasmic tail of MUC1, MUC1-CT, has also been implicated in tumour 
progression. In human pancreatic cancer cells, it was shown that MUC1-CT is transported 
to the lysosome after interaction with HSP70. This relocation inhibits lysosomal 
permeabilisation and promotes tumour cell survival (Banerjee, et al. 2012). 
However, possibly the best-described role for MUC1 in oncogenesis is as an 
immunosuppressant. The MUC1 VNTR can interact with intercellular adhesion molecule 
1 (ICAM-1) to enhance cell motility and promote metastasis (Hayashi, et al. 2001; Rahn, 
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et al. 2005). It has also been suggested that the upregulation of soluble MUC1 in the 
serum of cancer patients acts to suppress the immune system by occupying ICAM-1 on 
the surface of T cells in circulation, preventing them from reaching the tumour site 
(Longenecker, et al. 1998 US Patent Application PCT/US1997/015928).  
Additionally, tumour-associated MUC1VNTR glycopeptides have been shown to be 
chemotactic for immature DCs (Carlos, et al. 2005). In this study, Finn and co-workers 
demonstrated that this recruitment of immature DCs led to maturation and the production 
of IL-6 and TNF, but not IFN-γ and, as such, did not support a type-I immune response, 
but rather contributed to a pro-tumour inflammatory microenvironment. Others have 
demonstrated that recombinant MUC1 glycopeptides bearing the sialyl-T antigen 
actually impair the maturation of DCs and lead to secretion of immunoregulatory IL-10 
and reduced expression of the co-stimulatory molecules CD80/86 (Rughetti, et al. 2005).  
The interactions of tumour-associated MUC1 with T cells are controversial. Some reports 
claim that MUC1 isolated from human tumour samples inhibits the proliferation of T 
cells (Agrawal, et al. 1998a; Agrawal, et al. 1998b), while others assert that tumour-
associated MUC1 associates with an unknown molecule that is responsible for these 
effects (Paul, et al. 1999).  
Despite these roles of the MUC1VNTR and MUC1c in regulating the immune system to 
promote tumour growth, to date no studies have identified a similar role for the MUC1SP. 
 Aims 
Previous research identified the signal peptide of MUC1 as an attractive target antigen 
for the development of cancer vaccines due to its overexpression in many forms of cancer 
and its high density of T cell epitopes. Furthermore, MUC1SP was found on the surface 
of cancer cells but not their healthy counterparts (Kovjazin, et al. 2014), indicating that 
αMUC1SP antibodies may prove therapeutically valuable. The MUC1VNTR-based 
conjugate vaccines developed in our laboratory (Chapter 2) induced strong, 
MUC1-specific, class-switched antibody responses in murine studies, but lacked 
detectable T cell responses. We envisaged the combination of these two MUC1-derived 
antigens into multi-epitope vaccines which could generate humoral AND T cell immunity 
towards tumour-associated MUC1. With this goal in mind, we first sought to synthesise 
the MUC1SP via Fmoc-strategy SPPS. 
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 Synthesis of MUC1SP 
5.3.1 Prior attempts to synthesise MUC1SP 
In order to assess MUC1SP as a tumour vaccine antigen in our pre-clinical animal 
models, we first required a source of MUC1SP. Initial attempts to synthesise the peptide 
via standard Fmoc-strategy SPPS proved unsuccessful. This was likely due to the 
abundance of hydrophobic residues in the MUC1SP sequence, particularly the FFLLLLL 
motif in the centre of the peptide. Such hydrophobic sequences are difficult to synthesise 
using standard SPPS conditions because the peptide chain aggregates on-resin, reducing 
the availability of the N-terminus for elongation (Coin, et al. 2007). Figure 5.1 shows an 
LCMS trace of a MUC1SP peptide that was ordered from a commercial supplier of 
custom peptides. Similar to prior attempts in our laboratory, the crude cleavage mixture 
of this peptide contained many truncated sequences indicative of incomplete peptide 
coupling. In addition, the crude mixture contained sequences which matched the mass of 
amino acid deletions, indicating that either the capping or Fmoc removal steps of SPPS 
were not proceeding to completion. Finally, three of the peaks in the UV trace were 
associated with the mass of the desired product. There are two possible explanations for 
this: 1) these peaks contained isomers (likely epimers) of the target compound, or 2) the 
full-length MUC1SP was prone to aggregation on the reverse-phase column, causing it 
to elute at more than one retention time.  
 
Figure 5.1: HPLC-MS trace of commercial MUC1SP 501. (0 to 100% B over 30 min, λ=214 nm). Peaks 
containing product are labelled with *. (ESI+) calcd: [M+2H]2+ = 1145.65, [M+3H]3+ = 764.1; found 
1145.90, 764.10.  
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5.3.2 Microwave-assisted SPPS 
Based on the above experiment, the synthesis of MUC1SP clearly required significant 
optimisation of SPPS conditions. The most successful conditions employed Rink 
amide-ChemMatrix® resin, which is based on a polyethylene glycol (PEG) scaffold, as 
opposed to the more commonly used polystyrene. PEG-based resins have much better 
swelling properties than polystyrene, meaning that they have a higher degree of solvation 
in DCM and DMF; the solvents most commonly used in SPPS. Couplings were carried 
out using the Biotage Alstra Initiator+ microwave peptide synthesiser using higher 
temperatures, more equivalents of coupling reagents, and longer reaction times than are 
typically used by our laboratory or suggested by the manufacturer. Additionally, 
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) was included in the Fmoc removal step to 
ensure complete removal of the Fmoc protection at each step and avoid deletions. The 
optimised conditions are outlined in Table 5.1. Finally, an Fmoc-protected pseudoproline 
residue (Fmoc-L-Leu-L-Thr[ψMe,MePro]-OH) was incorporated at each of the two LT 
junctions within the MUC1SP sequence to improve the yield by restricting the available 
conformations of the growing peptide chain (Wohr and Mutter 1995; Wohr, et al. 1996). 
Table 5.1: microwave-assisted SPPS conditions for the synthesis of the MUC1SP 
 Standard SPPS MUC1SP synthesis 
Resin 2-chlorotrityl chloride 
on polystyrene resin 
Rink amide on PEG resin 
Coupling temp (°C) 50 75 
Coupling time (min) 12 20 
Washing temp (°C) rt 50 
Eq. of AA residues 4 10 
Fmoc deprotection  20% piperidine in DMF 1% DBU, 10% piperidine in DMF 
 
(Fmoc-L-Leu-L-Thr[ψMe,MePro]-OH) 
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The MUC1SP was synthesised using these conditions and, the LCMS peaks containing 
compounds with the mass of the desired product were the most abundant. However, 
similar to the commercial material obtained using standard SPPS conditions, there were 
three peaks in the LCMS with the mass of the product. As mentioned above, we proposed 
that this was due to unexpected epimerisation or the aggregation of a single product 
during purification. In order to probe this, fractions were collected from the two most 
abundant peaks on preparative HPLC. Upon UPLC-MS analysis, each of these samples 
contained multiple peaks all with the same mass, consistent with a single product eluting 
at multiple retention times. To overcome this issue, HPLC purification was performed at 
60 ℃ with a solvent system containing iPrOH in both eluents A and B (see section 6.1.4). 
Under these conditions, the three product-related peaks coalesced into a single peak 
(Figure 5.2), and MUC1SP was purified in 12% yield (calculated from initial resin 
loading, 94% yield per step). Importantly, the forcing SPPS conditions developed here 
represent a general approach to the synthesis and purification of hydrophobic peptides 
that are limited by aggregation on-resin.  
 
Figure 5.2: Analytical UPLC traces of purified MUC1SP 501 at 30 °C and 60°C (0-100% B over 8 min, 
λ = 214 nm) 
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5.3.3 A soluble MUC1SP analog 
Although these optimised conditions led to the production of pure MUC1SP, the peptide 
had very poor solubility in water and PBS as a consequence of its hydrophobicity. 
Reasoning that a more soluble MUC1SP peptide might be more amenable to synthesis, 
purification, and handling, we designed 502, a MUC1SP peptide bearing four lysine 
residues on the N-terminus, spaced by an aminotriethylene glycolate residue. Throughout 
this chapter, this peptide will be referred to as both 502 and K4-MUC1SP. The pKa of the 
ε amines of lysine side-chains is ~10.5 (See Hass and Mulder 2015) and, therefore, the 
N-terminus of K4-MUC1SP will carry multiple positive charges at physiological pH, 
compared to a single positive charge at the N-terminus of the native MUC1SP. We 
reasoned that this extra charge, in addition to the polarity of the PEG linker, would make 
K4-MUC1SP more soluble and less aggregation-prone than the MUC1SP. 
 
502 
Synthesis of 502 was carried out in a similar manner to native MUC1SP 501, using an 
automated microwave peptide synthesiser with forcing coupling and deprotection 
conditions. The crude HPLC trace of 502 (Figure 5.3) showed the desired product as the 
major peak (*), contaminated with a considerable amount of a compound with a mass 
16 amu higher than the desired product (†). This was likely due to the oxidation of the 
thioether side-chain of methionine to methionine sulfoxide (Scheme 5.1). 
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Figure 5.3: Crude HPLC trace of K4-MUC1SP 502 (0% B for 10 min then 0 to 100% B over 30 min). 
†Denotes K4-MUC1SP bearing an oxidised Met residue (Rt= 28.5 min). *Denotes the desired K4-MUC1SP 
product (Rt= 28.8 min) 
502 (ESI+) calcd: [M+2H]2+ = 1474.89, [M+3H]3+ = 983.59, [M+4H]4+ = 737.95, [M+5H]5+ = 590.56; 
found 1175.45, 984.00, 738.15, 590.70. 
Oxidised 502 (ESI+) calcd: [M+2H]2+ = 1482.89, [M+3H]3+ = 988.93, [M+4H]4+ = 741.95, 
[M+5H]5+ = 593.76; found 1483.20, 989.25, 742.10, 593.80. 
 
Scheme 5.1: Oxidation of methionine to methionine sulfoxide. 
Oxidation of methionine is readily reversible, and can be prevented by the addition of a 
suitable thioether as a sacrificial reductant in the acidic cleavage and deprotection step 
(Tam, et al. 1982). Indeed, addition of thioanisole (2.5 vol%) into the acidic cleavage 
cocktail led to a marked improvement in the purity of the crude peptide as measured by 
LCMS (Figure 5.4). Using this protocol, K4-MUC1SP was synthesised in 26% yield 
calculated from initial resin loading. Pleasingly, K4-MUC1SP was readily soluble in PBS 
at concentrations up to 10 mg/mL. 
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Figure 5.4: Crude HPLC-MS trace of K4-MUC1SP 502 with thioanisole in the cleavage cocktail (0% B 
for 10 min then 0 to 100% B over 30 min, Rt = 28.5 min). (ESI+) calcd: [M+2H]2+ = 1474.89, 
[M+3H]3+ = 983.59, [M+4H]4+ = 737.95, [M+5H]5+ = 590.56; found 1175.10, 983.75, 738.05, 590.55. 
 
 MUC1SP vaccination in a mouse model of UV-induced skin 
cancer 
5.4.1 UV13-1 tumours are MUC1+ 
We sought to find a tumour model in which we could quickly assess the anti-tumour 
efficacy of our MUC1-based vaccine constructs. The model most commonly used in the 
literature is the B16-MUC1 melanoma model (Rowse, et al. 1998). This model involves 
orthotopic transplantation of B16 melanoma cells that have been transduced with the 
human MUC1 gene. This is required because the B16 melanoma line, like most 
melanomas, do not express MUC1. Nonetheless, skin tumours such as melanoma are 
attractive as tumour models, because they enable simple measurement of tumour size 
using calipers throughout the time-course of the experiments. We reasoned that an 
orthotopic, transplantable skin tumour model in which the tumour over-expressed MUC1 
endogenously would be a superior model. The UV13-1 cell line was derived from a UV 
radiation-induced squamous-cell carcinoma (SCC) in a C3H/HeN mouse. Flow 
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cytometry was used to demonstrate that UV13-1 cells express MUC1, albeit at a lower 
level than the human breast cancer cell line MCF-7 (Figure 5.5). 
 
Figure 5.5: UV13-1 cells express MUC1. Histograms depict staining of cultured MCF-7 or UV13-1 cells 
with a biotin-conjugated αMUC1 (red) or isotype control (black), and a FITC-streptavidin conjugate as a 
secondary stain. Cells stained with αMUC1 but no secondary stain are shown in grey. 
5.4.2 Tumour Growth  
With a MUC1+ murine tumour model and the synthetic MUC1SP and K4-MUC1SP 
peptides in hand, we sought to confirm the findings that MUC1SP could treat MUC1+ 
murine cancers. We envisaged construction of conjugate vaccines bearing an adjuvant, 
MUC1SP, and a MUC1VNTR glycoform. With several adjuvants and MUC1VNTR 
glycoform candidates, the full range of possible combinations was too large to feasibly 
synthesise in a reasonable timeframe. In order to identify a lead combination, we carried 
out vaccinations of C3H/HeN mice with admixtures of MUC1SP, the TN or STN 
glycoforms of the MUC1VNTR glycopeptide 401, and and either 
trehalose-6,6’-dibehenate (TDB), α-galactosylceramide (αGalCer) or 
Pam2CysSerKKKK as an adjuvant. Since these glycolipid and lipopeptide adjuvants are 
insoluble in water, they were first lyophilised from a preparation of sucrose, Tween-20 
and L-histidine. Negative controls were injected with either PBS or the lyophilised 
mixture without any adjuvant or MUC1 peptides. Mice received 2 vaccinations 14 days 
apart, and were inoculated with UV13-1 tumour cells 7 days later. Little difference in 
tumour growth was observed between mice treated with different adjuvants and different 
Re
l. 
Ab
un
da
nc
e 
MUC1 
MCF-7 UV13-1 
MUC1 Signal Peptide 
 103 
MUC1VNTR glycoforms. Surprisingly, however, those mice that were treated with 
K4-MUC1SP exhibited markedly faster tumour growth than control mice (Figure 5.6). 
Mice with a tumour >100 mm2 were euthanised as the ethical endpoint of the experiment, 
and so this increased growth corresponded to a significant reduction in survival, from 38 
days in the control group to 26 days in the K4-MUC1SP group. 
 
Figure 5.6: Accelerated UV13-1 Tumour growth and decreased survival of C3H/HeN mice treated with 
K4-MUC1SP. Mice received intramuscular injections of mixtures containing 5 nmol K4-MUC1SP (red), 
PBS or liposome controls (black) 21 and 7 days prior to transfer of UV13-1 cells. Difference in survival 
was analysed using a log-rank test. 
5.4.3 Flow cytometry of tumour-infiltrating leukocytes 
Previously, progression of UV-induced SCCs has been associated with the presence of 
intratumoural CD11b+ tumour-associated macrophages (TAMs), while clearance has 
been associated with the intratumoural recruitment of CD11c+ DCs (Byrne and Halliday 
2003). Indeed, flow cytometry revealed that the UV13-1 tumours in mice treated with 
PBS were characterised by a large number of CD11b+ cells, and a near lack of CD11b-
CD11c+ cells (Figure 5.7). Surprisingly, tumours in mice treated with K4-MUC1SP 
displayed a 100-fold increase in CD11b-CD11c+ cells and a concomitant 3-fold decrease 
in CD11b+CD11c- cells despite having much faster tumour growth. It should be noted 
that both percentages and numbers of total live cells and CD45+ cells were similar 
between the two groups, such that changes in the percentages of each of these cell types 
were indicative of changes in intratumoural cell numbers.  
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Figure 5.7: Intramuscular treatment with K4-MUC1SP is associated with an increase in intratumoural 
CD11C+ cells and a decrease in CD11b+ cells. 
Perplexed that our findings conflicted with previous reports demonstrating that increases 
in CD11c+ cells were associated with regression, we carried out preliminary examinations 
of the phenotype of these intratumoural CD11c+ cells in mice treated with K4-MUC1SP 
(Figure 5.8). As expected, the CD11b+CD11c- TAMs and CD11b+CD11c- cells (which 
mainly consist of inflammatory myeloid-derived DCs) (Byrne, et al. 2008) exhibited high 
levels of class II MHC on their surface, and had relatively high forward and side scatter 
(FSC and SSC, respectively). The CD11c+ cells were very large and granular, indicated 
by their high forward- and side-scatter, and were CD8-GR-1-CD4-CD19-CD3-. However, 
these cells exhibited very low class II MHC staining, if any. DCs are characterised by 
their ability to act as professional APCs through their expression of class II MHC, and so 
it is unclear from these data whether these cells are indeed DCs. Future work will focus 
on elucidating the nature of these cells. 
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Figure 5.8: Phenotype of intratumoural cells from mice treated with intramuscular K4-MUC1SP. 
Populations were previously gated on forward and side scatter, and were LIVE/DEAD-CD45+. Histograms 
represent CD11b+ cells (black), CD11c+ cells (red), and CD11b+CD11c+ cells (blue). 
 MUC1SP is immunosuppressive 
It has been documented that the VNTR of MUC1 can be immunosuppressive as well as 
acting as a cancer antigen (vide supra). The finding that K4-MUC1SP could exacerbate 
transplanted skin tumours led us to consider whether it might also cause immune 
suppression. To test this hypothesis, we carried out contact hypersensitivity (CHS) 
assays: a mouse model of contact dermatitis. C57BL/6 mice were injected with MUC1SP, 
K4-MUC1SP, K4-MUC1SP+TDB or PBS alone, using the same dose schedule as the 
UV13-1 tumour experiments (two subcutaneous injections 14 days apart). 7 days after 
the second injection, mice were topically sensitised to 1-fluoro-2,4-dinitrobenzene 
(DNFB) on the abdomen. DNFB is a contact sensitiser: initial exposure primes a T 
cell-dependent immune response, which leads to hypersensitivity and severe 
inflammation upon subsequent exposure. 5 days after sensitisation, mice were challenged 
with DNFB applied topically to the ears, and ear thickness was measured daily starting 
immediately prior to the challenge. In addition to acting as a contact sensitiser, DNFB is 
an irritant. To account for non-specific irritation, the change in ear thickness of mice that 
received the DNFB challenge without being sensitised was subtracted from the change 
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in ear thickness of each treated mouse to provide the specific change in ear thickness. As 
expected, the specific change in ear thickness of PBS-treated mice was 50-70 μm over 
the first 48 hours after challenge (Figure 5.9). Mice treated with MUC1SP, K4-MUC1SP 
or K4-MUC1SP admixed with TDB, however, exhibited significantly less ear swelling. 
This result indicates that MUC1SP acts as an immunosuppressant in BL/6 mice, even in 
the presence of an external adjuvant. 
The injection regimen used in the experiments above was chosen to align with previous 
vaccination studies using the MUC1VNTR. Next, we sought to investigate the effect of 
different MUC1SP injection regimens on the suppression of CHS: reducing the number 
of injections from 2 to 1 and altering the dose. The specific change in ear swelling was 
similar in mice that received one or two injections of K4-MUC1SP (Figure 5.10), and so 
further experiments were carried out using just a single injection. A clear dose-response 
was observed between 2-10 nmol (6-30 μg) of K4-MUC1SP.  
With any peptide-based drug, it is important to distinguish between the sequence-specific 
effects such as protein-protein interaction from other, sequence-independent effects that 
peptides may possess, such as acid-base interactions. MUC1SP is a particularly 
hydrophobic, aggregation-prone peptide, so it was important to determine whether the 
immune suppression it afforded was sequence-dependent. To do this, mice were injected 
with PBS, 501 (MUC1SP), or 503: a peptide containing the same amino acids as the 
MUC1SP but in a scrambled order.  
Mice injected with either MUC1SP or K4-MUC1SP displayed significantly less ear 
swelling than mice treated with either PBS or the scrambled peptide, while no significant 
difference was observed between mice treated with PBS or the scrambled peptide (Figure 
5.11). This indicates that the mechanism through which MUC1SP is immunosuppressive 
relies on its structure, rather than simply the combination of functional groups it contains. 
 
 501 (MUC1SP) 
 503 (Scramble) 
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Figure 5.9: MUC1SP and K4-MUC1SP are immunosuppressive in a CHS assay. Mice received 5 nmol s.c. 
injections of the treatment specified 21 and 7 days prior to sensitisation. Plotted points are mean ± SEM of 
n = 6 mice from 2 independent experiments. Results were analysed using a mixed ANOVA. Simple effects 
between groups at different timepoints shown here (*p<0.05, **p<0.01, ***p<0.001). 
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Figure 5.10: Effect of number and dose of K4-MUC1SP injections on suppression of CHS. 7 days prior to 
sensitisation, mice in the “# of injections” experiment received either one or two s.c. injections of 5 nmol 
K4-MUC1SP, and mice in the “dose” experiment received a single injection at the dose specified. Plotted 
points are mean ± SEM of n = 6 mice from 2 independent experiments. Results were analysed using a 
mixed ANOVA. 
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Tukey's multiple comparisons test Summary Adjusted P Value 
PBS vs. Scramble ns 0.9759 
PBS vs. MUC1SP **** <0.0001 
PBS vs. K4-MUC1SP **** <0.0001 
Scramble vs. MUC1SP **** <0.0001 
Scramble vs. K4-MUC1SP **** <0.0001 
MUC1SP vs. K4-MUC1SP ns 0.9994 
Figure 5.11: Sequence specificity of MUC1SP immunosuppression. Mice received 10 nmol s.c. injections 
of the specified treatment 7 days prior to sensitisation. Plotted points are mean ± SEM of n = 6 mice from 
2 independent experiments. Results were analysed using a mixed ANOVA with Tukey’s correction for 
multiple comparisons. P-values for main effects between each group provided here. 
 GM-CSF and MUC1SP-induced immune suppression  
Our investigations into the MUC1 signal peptide stemmed from its use by VaxilBio as a 
cancer antigen in human vaccine trials (Carmon, et al. 2015), however our experiments 
indicate that the MUC1SP causes immune suppression in both C3H/HeN and C57BL/6 
mice. To reconcile these seemingly disparate results, we examined the differences in the 
experimental designs of our experiments and the murine pre-clinical experiments 
reported by VaxilBio in Vaccine (Kovjazin, et al. 2011). In that study, BALB/c mice 
carrying a transgene coding for human leukocyte antigen (HLA) A*0201 (a common 
class I MHC allele in the Caucasian population) were injected with a vaccine cocktail 
containing MUC1SP and GM-CSF. GM-CSF is a cytokine which causes activation and 
maturation of macrophages and DCs. Given that we had observed CD11c+MHCII- cells 
in the tumours of mice treated with K4-MUC1SP, we reasoned that the inclusion of 
GM-CSF may interfere with MUC1SP-induced immunosuppression. Although mice 
treated with either GM-CSF alone or admixed K4-MUC1SP and GM-CSF displayed 
reduced ear swelling compared to PBS-treated controls, these differences were not 
statistically significant (p=0.43 and p=0.096, respectively). Further repetition of these 
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experiments is required to determine whether these differences were due to normal 
experimental errors or a real difference in ear swelling. Most importantly, however, mice 
injected with GM-CSF alone (p=0.005) or K4-MUC1SP+ GM-CSF (p=0.047) displayed 
significantly more ear swelling than mice injected with K4-MUC1SP alone (Figure 5.12). 
These data may suggest that GM-CSF is capable of blocking some or all of the immune 
suppressive activity of the MUC1SP. 
 
Tukey's multiple comparisons test Summary Adjusted P Value 
PBS vs. K4-MUC1SP **** <0.0001 
PBS vs. GM-CSF ns 0.4333 
PBS vs. MUC1SP+GM-CSF ns 0.0958 
K4-MUC1SP vs. GM-CSF ** 0.0051 
K4-MUC1SP vs. MUC1SP+GM-CSF * 0.0466 
GM-CSF vs. MUC1SP+GM-CSF ns 0.8194 
Figure 5.12: GM-CSF partially abrogates MUC1SP-induced immune suppression. Mice received 10 nmol 
s.c. injections of the specified treatment 7 days prior to sensitisation. Plotted points are mean ± SEM of n = 
6 mice from 2 independent experiments. Results were analysed using a mixed ANOVA with Tukey’s 
correction for multiple comparisons. P-values for main effects between each group provided here. 
 Discussion 
5.7.1 Implications for the role of MUC1 in oncogenesis 
As discussed in the introduction to this chapter (Section 5.1.3), MUC1 is an 
immunosuppressive oncogene. To date, all descriptions of the role of MUC1 in 
promoting tumour transformation and survival have identified functions of the MUC1 
VNTR or cytoplasmic tail. The discovery that the signal peptide of MUC1 is 
immunosuppressive independent of the MUC1VNTR or MUC1c suggests a novel 
pathway through which MUC1 may cause immune suppression to promote tumour 
growth. Furthermore, αMUC1SP antibodies have been shown to bind the surfaces of 
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tumour cells but not MUC1+ healthy primary leukocytes or epithelial cells (Kovjazin, et 
al. 2014). It is tempting to speculate, therefore, that the relocation of MUC1SP from the 
cytoplasm to the cell surface might be a contributing factor in tumour-associated immune 
suppression and the establishment of a pro-tumour microenvironment. 
5.7.2 Immunosuppressive mechanism 
These results outlined here do not provide a clear mechanism through which the 
MUC1SP induces immunosuppression in mice. However, the two models utilised here 
provide some indications for possible target cell types. In the UV13-1 tumours of 
K4-MUC1SP-treated mice, a population of CD11c+MHCII- cells was observed, 
indicating that the mechanism of action may involve CD11c+ cells. Furthermore, in the 
contact hypersensitivity assay, CD11c+ Langerhans cells take up the hapten DNFB and 
present it to T cells in the draining lymph node, which subsequently mediate the 
inflammation at the site of re-challenge. For K4-MUC1SP to interfere with the CHS 
response, therefore, it must interfere with cell-mediated immunity in some manner, 
whether through antigen presentation or T cell priming or effector functions. Taken 
together, these findings point towards a role for K4-MUC1SP in the suppression of 
antigen presentation. 
5.7.3 Potential for the use of MUC1SP as a therapeutic immunosuppressant 
The experiments outlined in this chapter demonstrate that MUC1SP is a prophylactic 
immunosuppressant in mice. The global market for immunosuppressive treatments, 
including small-molecule drugs and biotherapeutic agents such as antibodies, is generally 
divided into two categories: 
• Autoimmune diseases (primiarly rheumatoid arthritis, Crohn’s disease, psoriasis 
and multiple sclerosis): USD 61.5 Billion in 2015 (GBI Research 2015) 
• Organ transplant: USD 5.14 Billion in 2014 (Transparency Market Research 
2015) 
The finding that MUC1SP is immunosuppressive opens the door to future investigation 
of MUC1SP and its analogs as potential immunosuppressive therapies for these 
conditions. 
5.7.4 MUC1SP as a target for cancer vaccination 
The results presented here demonstrate that MUC1SP acts as an immunosuppressant. 
Even when admixed with an external adjuvant, the presence of MUC1SP induced 
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acceleration of skin tumour growth and reduced survival in C3H/HeN mice. However, 
VaxilBio reported that MUC1SP admixed with GM-CSF caused reduction of tumour 
burden in murine models (Kovjazin, et al. 2011). A clinical trial of the same treatment in 
human multiple myeoloma patients reported no major adverse events, and development 
of humoral and cell-mediated immunity directed against MUC1SP in all except 1 patient 
(Carmon, et al. 2015). Although these results appear contradictory, there are four key 
differences between the experiments detailed in those studies and the experiments 
described in this thesis which may contribute to the differing effects of MUC1SP on 
tumour growth: 
• GM-CSF: VaxilBio have not reported the effects of MUC1SP on tumour growth in 
the absence of GM-CSF. The inclusion of GM-CSF with K4-MUC1SP abrogated 
much of the immune suppression induced by K4-MUC1SP in a CHS model (Figure 
5.12). As such, it seems likely that the immunostimulatory effects of GM-CSF 
nullify or overcome the suppressive effects of MUC1SP. 
• Immunosuppression in humans: Although the results described here demonstrate 
that MUC1SP is immunosuppressive in both C57BL/6 and C3H/HeN mice, we 
have not yet demonstrated that it has a similar effect in BALB/c mice or in humans. 
As such, we cannot yet rule out the possibility that MUC1SP was not 
immunosuppressive in either the BALB/c mice or the human patients injected with 
MUC1SP.  
• HLA: The murine breast cancer experiments described by VaxilBio were carried 
out in BALB/c mice transgenic for the human HLA-A*0201 gene. The skin cancer 
experiments described here were carried out in wild-type C3H/HeN mice. The 
binding of MUC1SP epitopes to H-2Kk (the class I MHC molecule in C3H mice) 
has not been described, and so it is possible that the MUC1SP could not generate T 
cell responses in these mice. Future experiments should involve the use of 
HLA-transgenic mice to ensure that the epitopes being investigated in a pre-clinical 
setting are directly translatable to human immune responses. 
• Human and murine MUC1SP: In the murine breast cancer model described by 
VaxilBio, the tumour cells were transfected with the human MUC1 gene. The 
MUC1SP on the tumour cells was, therefore, identical to the MUC1SP used to 
vaccinate the mice. In our experiments, however, we used tumour cells that natively 
over-expressed murine MUC1. The tumour-associated changes in MUC1 
MUC1 Signal Peptide 
 113 
glycosylation are similar in mice and humans (Cascio and Finn 2016), and so it is 
reasonable to assume that vaccines containing human MUC1VNTR might give rise 
to immune responses that can cross-react to murine tumour-associated 
MUC1VNTR. However, murine MUC1SP (MTPGIRAPFFLLLLLASLKGF) and 
human MUC1SP (MTPGTQSPFFLLLLLTVLTVV) share just 13/21 amino acid 
residues, and it is difficult to predict whether any immunity to the human MUC1 
we injected would cross-react to the murine MUC1SP produced by the UV13-1 
cells.  
The inclusion or omission of GM-CSF in MUC1SP injections appears to explain the stark 
contrast between the effect of the MUC1SP on tumour growth in the experiments 
described here and those carried out by VaxilBio. Future experiments in which human 
MUC1SP (with and without GM-CSF) is injected into HLA-transgenic mice and then 
challenged with human MUC1+ tumours would provide insight into whether any of the 
other factors discussed here also contributed to the disparate tumour growth outcomes. 
 Conclusions and Future Directions 
In this work, we have developed a method for the efficient synthesis of MUC1SP and a 
soluble analog, K4-MUC1SP, via a highly optimised microwave-assisted Fmoc-strategy 
SPPS approach. Furthermore, we have identified a novel role for MUC1SP as an 
immunosuppressant. This suppression is capable of almost completely eradicating a CHS 
response in C57BL/6 mice, and markedly accelerating the growth of skin tumours in 
C3H/HeN mice. Future work will extend these findings into murine models of 
autoimmune disease such as experimental autoimmune encephalomyelitis.  
Although the mechanism through which MUC1SP causes immune suppression is 
unclear, accelerated tumour growth was associated with tumour infiltration by 
CD11c+CD11b-MHCII- cells. Furthermore, co-injection of K4-MUC1SP with GM-CSF 
prevented MUC1SP-mediated suppression of CHS. These results indicate that DCs likely 
play a role in the suppression afforded by MUC1SP. As such, future experiments will 
involve dissecting the mechanism of action by investigating the effect of MUC1SP on 
DCs and other immune subsets from the skin and draining lymph nodes in vitro. 
The immunosuppression observed upon treatment with MUC1SP inspires the hypothesis 
that MUC1SP is involved in human tumour development and progression through 
immunosuppression. However, the experiments described here only demonstrate that 
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MUC1SP is immunosuppressive in mice. Once a cellular target of MUC1SP is identified 
in mice, in vitro experiments with human PBMCs and cell lines will test whether 
MUC1SP is similarly immunosuppressive in humans. Furthermore, understanding the 
mechanism through which MUC1SP is immunosuppressive will enable us to design 
vaccines to target the tumour-associated B and T cell epitopes of MUC1SP without 
engaging its immunosuppressive effects. 
As discussed in the introduction (Section 1.5.5), the formation of higher-order structures 
by hydrophobic or amphipathic molecules in solution may contribute to their biological 
activity. The behaviour of MUC1SP and K4-MUC1SP in PBS and water will be analysed 
through dynamic light scattering and transmission electron microscopy in order to 
determine whether these molecules adopt such structures in solution. 
In addition to future investigations into the immunosuppressive roles of MUC1SP, the 
current work can serve as a model for the synthesis and immunological evaluation of the 
signal peptides of other TAAs. Within the mucin family, MUC2, MUC4, MUC5AC and 
MUC16 are all over-expressed in various cancers, and to date no reports of the synthesis 
nor study of their signal peptides have been published. Synthesis and evaluation of the 
signal peptides from these mucin proteins will therefore also be the subject of future 
work. 
In conclusion, the signal peptide of MUC1 constitutes a potent immunosuppressant and 
a promising hit for the development of a new immunosuppressive therapy. These findings 
may contribute to the understanding of MUC1 as a key protein in the development and 
progression of cancer, and help to shape the design of new therapies that can target 
MUC1SP as a cancer antigen while avoiding undesired immunosuppression. 
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 EXPERIMENTAL 
PROCEDURES 
 General synthetic procedures 
6.1.1 Fmoc solid-phase peptide synthesis (SPPS) 
General SPPS methods are presented here for the synthesis on a 0.1 mmol scale, relative 
to the initial resin loading. Throughout, all solid phase reactions on polystyrene resins 
were performed at a concentration of ~0.10 mmol nascent peptide per mL solvent, while 
reactions on Chemmatrix® resins were performed at ~0.15 mmol mL-1. Volumes 
presented in the general methods refer to reactions on polystyrene resins. Unless 
otherwise stated, reactions were performed at room temperature. All equivalents are 
given with respect to the resin-bound peptide. 
Loading of C-terminal amino acid 
Polystyrene resin bearing a 2-chlorotrityl chloride (2-CTC) linker (1.22 mmol g-1) or 
Chemmatrix® resin bearing a chlorotrityl chloride (CTC) linker (0.60 mmol g-1) was 
swollen in dry CH2Cl2 for 30 min, and the solvent filtered off. A solution of the 
C-terminal amino acid Fmoc-AA-OH (0.4 mmol, 4 eq.) and iPr2NEt (0.8 mmol, 8 eq., 
139 μL) in DMF:CH2Cl2 (1:1 v/v, 1 mL) was added, and the reaction was shaken for 16 h. 
The resin was filtered and washed with DMF (5 × 3 mL), CH2Cl2 (5 × 3 mL), and DMF 
(5 × 3 mL), and then unreacted 2-CTC or CTC functional groups were capped by 
treatment with CH2Cl2:MeOH:iPr2NEt (17:2:1 v/v/v, 2 mL)  for 1 h. The resin was 
filtered and washed with DMF (5 × 3 mL), CH2Cl2 (5 × 3 mL), and DMF (5 × 3 mL), and 
then submitted to iterative SPPS conditions as described below. 
Polystyrene resin bearing a Rink amide linker (0.44 mmol g-1) or Chemmatrix® resin 
bearing a Rink amide linker (0.42 mmol g-1) was washed with DCM (5 × 3 mL) and DMF 
(5 × 3 mL). The Fmoc-protecting group was removed by treatment with piperidine:DMF 
(1:9 v:v, 1 mL, 3 × 3 min), then washed with (5 × 3 mL), CH2Cl2 (5 × 3 mL), 
and DMF (5 × 3 mL). Meanwhile, benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP, 0.4 mmol, 4 eq., 208 mg) and N-methylmorpholine 
(NMM, 0.8 mmol, 8 eq., 88 μL) were added to a solution of the C-terminal amino acid 
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Fmoc-AA-OH (0.4 mmol, 4 eq.) in DMF (1 mL). After 5 min of pre-activation, the 
solution was added to the resin, and the reaction was shaken for 2 h. The resin was filtered 
and washed with DMF (5 × 3 mL), CH2Cl2 (5 × 3 mL), and DMF (5 × 3 mL), and then 
unreacted amines were capped by treatment with Ac2O:pyridine (1:9 v/v, 2 mL) for 5 
min. The resin was filtered and washed with DMF (5 × 3 mL), CH2Cl2 (5 × 3 mL), and 
DMF (5 × 3 mL), and then submitted to iterative SPPS conditions as described below 
Iterative peptide assembly – manual SPPS 
Washing: 
After each step, resins were filtered and then washed with DMF (5 x 3 mL), CH2Cl2 
(5 × 3 mL), and DMF (5 × 3 mL). 
Fmoc deprotection:  
Removal of the Fmoc protecting group was effected by treatment with piperidine:DMF 
(1:9 v:v, 1 mL, 3 × 3 min). 
Coupling of proteinogenic amino acids:  
PyBOP (0.4 mmol, 4 eq., 208 mg) and NMM (0.8 mmol, 8 eq., 88 μL) were added to a 
solution of Fmoc-AA-OH (0.4 mmol, 4 eq.) in DMF (1 mL). After 5 min of 
pre-activation, the solution was added to the resin, and the reaction was shaken for 
40 min. 
Coupling of non-proteinogenic amino acids:  
For the coupling of Fmoc-protected glycosylamino acids, lipoamino acids and other 
non-standard amino acids, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate (HATU, 0.15 mmol, 1.5 eq., 57 mg), 
1-Hydroxy-7-azabenzotriazole (HOAt, 0.20 mmol, 2 eq., 27 mg) and iPr2NEt 
(0.30 mmol, 3 eq., 52 μL) were added to a solution of Fmoc-AA-OH (0.15 mmol, 1.5 eq.) 
in DMF (1 mL) (or DMF:CH2Cl2 (1:1 v/v, 1 mL for Fmoc-Pam2Cys-OH). This mixture 
was pre-activated in a 37 °C waterbath for 5 min, and then added to the resin. The reaction 
was shaken for 16 h at rt. 
Capping:  
Unreacted amines were capped by treatment with Ac2O:pyridine (1:9 v/v, 2 mL) for 
5 min. 
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Iterative peptide assembly – microwave-assisted automated SPPS 
Automated SPPS was performed on a Biotage Initiator+ Alstra microwave peptide 
synthesiser equipped with an inert gas manifold. General synthetic protocols for coupling, 
Fmoc-deprotection and capping were carried out in accordance with the manufacturer’s 
specifications. 
Washing: 
After each step, resins were filtered and then washed with DMF (5 x 5 mL). 
Fmoc deprotection:  
Removal of the Fmoc protecting group was effected by treatment with piperidine:DMF 
(2:8 v:v, 4 mL, 2 × 4 min). 
Coupling of proteinogenic amino acids:  
Fmoc-AA-OH (0.4 mmol, 4 eq.), N,N’-diisopropylcarbodiimide (DIC, 0.4 mmol, 4 eq.), 
and ethyl (hydroxyimino)cyanoacetate (Oxyma, 0.4 mmol, 4 eq.) were dispensed from 
concentrated stock solutions in DMF onto the resin, and made up to a final volume of 
4 mL with DMF. The reaction was heated to 50 °C and mixed for 12 min.  
Capping:  
Unreacted amines were capped by treatment with Ac2O:pyridine (1:9 v/v, 4 mL) for 
5 min. 
Cleavage from the resin 
Unprotected peptides:  
Cleavage from resin and concomitant global removal of side-chain protecting groups was 
achieved by treatment with an acidic cocktail of TFA:iPr3SiH:H2O (90:5:5 v/v/v) for 3 h. 
The filtrate was collected and concentrated under a stream of N2 gas, and the crude 
peptide was precipitated by addition of ice-cold diethyl ether (40 mL) and then dried 
under vacuum.  
Sidechain-protected peptides:  
Cleavage of peptides from 2-CTC resin with side-chain protecting groups intact was 
effected by treatment with hexafluoroispropanol (HFIP, 30% in CH2Cl2, 3 mL, 
3 × 30 min). The filtrates were collected, combined, and reduced to dryness under 
vacuum. 
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6.1.2 Preparative high performance liquid chromatography (HPLC) 
Preparative and semi-prepartive reverse-phase HPLC was performed using a Waters 600 
Multisolvent Delivery System and Waters 500 pump with a Waters 490E Programmable 
wavelength detector operating at 214, 230, or 280 nm. 
6.1.3 Purification of (glyco)peptides 
(Glyco)peptides were purified by preparative HPLC on a Waters Sunfire C18 column 
(5 μm, 19 × 150 mm) at a flow rate of 7 mL min-1, or semi-preparative HPLC on a Waters 
Sunfire C18 column (5 μm, 10 × 250 mm) at a flow rate of 4 mL min-1. 
Solvent A: 0.1% TFA in H2O. 
Solvent B: 0.1% TFA in MeCN. 
6.1.4 Purification of lipo(glyco)peptides 
Lipo(glyco)peptides and the MUC1SP were purified by semi-preparative HPLC on a 
Phenomenex Luna C18(2) column (5 μm, 10 × 250 mm) in a column heater at 40 °C and 
a flow rate of 7 mL min-1. 
Solvent A: 0.1% TFA in H2O:MeCN:iPrOH (8:1:1 v/v/v). 
Solvent B: 0.1% TFA in MeCN:iPrOH (9:1 v/v). 
6.1.5 Analytical HPLC 
Analytical HPLC was performed on a Waters System 2695 separations module with a 
2996 photodiode array detector and an Alliance series column heater at 40 °C. 
Separations were carried out using a Waters Sunfire C18 column (5 μm, 2.1 × 150 mm) 
for (glyco)peptides or a Phenomenex Luna C18(2) column (5 μm, 2.1 × 150 mm) for  
lipo(glyco)peptides at a flow rate of 0.2 mL min-1. 
Solvent A: 0.1% TFA in H2O:MeCN:iPrOH (8:1:1 v/v/v). 
Solvent B: 0.1% TFA in MeCN:iPrOH (9:1 v/v). 
6.1.6 Low resolution mass spectrometry (LRMS) 
Analytical HPLC-LRMS was performed on a Shimadzu LC–MS 2020 instrument, 
consisting of a LC-M20A pump and a SPD-20A UV/Vis detector coupled to a Shimadzu 
2020 mass spectrometer operating in positive mode (ESI+). Separations were carried out 
using a Waters Sunfire C18 column (5 μm, 2.1 × 150 mm) for (glyco)peptides or a 
Phenomenex Luna C18(2) column (5 μm, 2.1 × 150 mm) for  lipo(glyco)peptides at a flow 
rate of 0.2 mL min-1. 
Experimental Procedures 
 119 
Analytical ultra-performance liquid chromatography UPLC-MS was performed on a 
Shimadzu Nexera UPLC-MS system equipped with a SPD-M30A diode array detector 
and a Shimadzu 2020 mass spectrometer operating in positive mode (ESI+). Separations 
were carried out using a Waters Acquity UPLC BEH C18 column (1.7 µm 2.1 x 50 mm) 
at a flow rate of 0.6 mL min-1. 
Solvent A: 0.1% formic acid in H2O:MeCN:iPrOH (8:1:1 v/v/v). 
Solvent B: 0.1% formic acid in MeCN:iPrOH (9:1 v/v). 
6.1.7 High resolution mass spectrometry (HRMS) 
Matrix-assisted laser desorption-ionisation time-of-flight (MALDI-TOF) HRMS was 
obtained on a Bruker autoflex speed LRF MALDI-TOF mass spectrometer operating in 
reflectron mode using a matrix of α-cyano-4-hydroxycinnamic acid (10 mg mL-1) in 
H2O:MeCN (7:3 v/v) containing 0.1% TFA. 
 General immunological procedures 
6.2.1 Mice 
All mouse experiments were conducted with the approval of the University of Sydney 
Animal Ethics Committee. Mice were housed at the University of Sydney under specific 
pathogen-free conditions in individually vented cages.  
C57BL/6 mice 
Female C57BL/6 mice were obtained from the Animal Resource Centre (ARC; Perth, 
Western Australia) or Australian BioResources (ABR; Moss Vale, New South Wales), 
and were 7-12 weeks of age at the start of experiments.  
C3H/HeN mice 
Female C57BL/6 mice were bred at the Gunn or Bosch animal facilities at the University 
of Sydney, and were 7-12 weeks of age at the start of experiments. 
Vaccination via sub-cutaneous injection 
Mice were coarsely shaved on the abdomen. At least 24 h later, mice were restrained by 
the scruff, and vaccine preparations in 50 μL were injected into the abdomen via 
sub-cutaneous injection with a 27-31 gauge needle. 
Vaccination via intramuscular injection 
Mice were restrained by the scruff, and vaccine preparations in 20 μL were injected into 
the caudal thigh muscle with a 27-31 gauge needle. 
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Adoptive cell transfer via intravenous injection 
Mice were restrained in a plastic mouse restrainer, such that their tails were exposed. 
Single cell suspensions were resuspended in the appropriate volume of RPMI + 2 % FCS. 
Cell suspensions (≤ 300 μL) were transferred via injection into the tail with a 25 gauge 
needle. 
Collection of serum via sub-mandibular bleeding 
Mice were restrained by the scruff, and blood (100 μL) was collected by sub-mandibular 
bleed using a 4.5 mm lancet. The blood was allowed to clot for 45 min, and then 
centrifuged (12,000 rcf) for 15 min. The clear serum was collected and stored at -30 °C 
until needed for analysis. 
Euthanasia 
Mice were euthanised via cervical dislocation in accordance with the Animal Ethics 
Committee guidelines. 
6.2.2 Media and buffers 
Phosphate-buffered saline (PBS) 
PBS (pH 7.4) was obtained as a 10x stock solution from POCD Healthcare, and was 
diluted 10x with milliQ water prior to use. 
Foetal Calf Serum (FCS) 
Sterile FCS was obtained from Sigma Aldrich, and was heat-inactivated prior to use. 
FACS buffer 
FACS buffer consists of PBS + bovine serum albumin (BSA, 1% w/v) + ethylenediamine 
tetraacetic acid (EDTA, 5mM) at pH 7.4. 
RPMI 
RPMI1640 supplemented with phenol red and Glutamax™ was obtained from Gibco.  
DMEM 
Pyruvate-free dulbecco’s modified Eagle medium (DMEM), supplemented with glucose 
(4.5 g L-1) and L-glutamine (4.5 g L-1) was obtained from Gibco. 
Tryp-LE 
Tryp-LE™ Express is a recombinant cell dissociation enzyme and trypsin replacement. 
Tryp-LE, supplemented with phenol red, was obtained from Gibco. 
Experimental Procedures 
 121 
6.2.3 Preparation of single-cell suspensions 
Single cell suspensions from the spleen and lymph nodes were generated by pressing the 
tissue through a 70 μm nylon cell strainer (Miltenyi biotec) in RPMI + 2% FCS, then 
centrifuged at 500 rcf for 5 min. Cells were washed twice with RPMI + 2% FCS, counted 
and resuspended in RPMI + 10 % FCS for culture or FACS buffer for staining. 
6.2.4 Flow Cytometry 
Flow cytometry was performed on a BD LSR-II 5 laser flow cytometer. Flow cytometry 
data was analysed using FlowJo software (TreeStar Inc.) version 10 for Windows. 
Staining of cell-surface markers 
Single-cell suspensions were stained for flow cytometry in 96-well, round-bottom 
microtitre plates (Becton Dickinson, Corning). 1-2 x 106 leukocytes suspended in PBS 
were added to each well. Cells were resuspended in 40 μL FACS buffer containing 10% 
normal mouse serum and fluorophore-conjugated primary antibodies specific for 
cell-surface markers (Table 6.1), then incubated for 30 min at 4 °C. Cells were washed 
twice with PBS and then with PBS containing Live/Dead UV (Becton Dickinson). Cells 
were washed twice and analysed by flow cytometry or stained for intracellular cytokines. 
Intracellular cytokine staining 
Cells were then fixed for 30 min in fixation and permeabilisation buffer (eBioscience) at 
4 °C. Cells were washed twice with permeabilisation buffer then resuspended in 40 μL 
staining buffer (eBioscience) containing fluorophore-conjugated antibodies specific for 
intracellular targets (Table 6.1) and incubated at 4 °C for a further 20 min. After two final 
washes in permeabilisation buffer, cells were resuspended in staining buffer, filtered 
through 70 μm nylon mesh and analysed by flow cytometry. 
6.2.5 T cell restimulation in vitro. 
5 x 106 splenocytes from mice immunised with PBS or vaccine candidates were incubated 
in RPMI + 10% FCS containing phorbol-12-myrsitate-13-acetate (PMA) and ionomycin 
or relevant peptide epitopes at 37 °C overnight in 24-well plates (Corning), and then 
Brefeldin A (Sigma Aldrich) was added to prevent cytokines from being transported 
outside of the cell. After 4 h, cells were stained for expression of cytokines as described 
above. 
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Table 6.1: Fluorescent anti-mouse antibodies used in this thesis 
Antigen Clone Conjugate Source 
Cell-surface markers 
CD11b M1/70 BV605 BioLegend 
CD11c N18 PerCP-Cy5.5 eBioScience 
CD19 6D5 PE-Cy5 BioLegend 
CD25 PC61.5 APC-eFluor780 eBioScience 
CD3 145-2C11 PE-CF594 BD Horizon 
CD4 GK1.5 AF700 BioLegend 
CD45 30-F11 PE-Cy7 BioLegend 
CD8a 53-6.7 BV711 BD Horizon 
I-A/I-E (MHC-II)  M5/114.15.2 V500 BD Horizon 
NK1.1 PK136 PerCP-Cy5.5 BD Pharmingen 
Cytokines 
IL-17a TC11-18H10 BV650 BD Horizon 
IL2 JES6-5H4 PE BD Pharmingen 
INFγ XMG1.2 FITC eBioScience 
TNF MP6-XT22 APC BioLegend 
NB: Cytokines used for the evaluation of tuberculosis vaccine candidate 308 are listed in Table 6.4 
6.2.6 In vivo CTL assay 
CFSE and CTO labelling 
5-carboxyfluorescein di-acetate succinimidyl ester (CFSE) and cell tracker orange (CTO) 
labelling was performed as described previously (Lyons and Parish 1994). Briefly, single 
cell suspensions were resuspended in RPMI (serum free) containing 1 μM or 10μM CFSE 
or CTO (Life Technologies). Cells were incubated at 37 °C for 10 min in the dark with 
occasional shaking, before staining was quenched with the addition of an equal volume 
of RPMI + 2% FCS. Cells were then washed, resuspended in RPMI + 10 % FCS and 
incubated at 37 °C for a further 30 min.  Cells were washed twice with RPMI + 2 % FCS 
and then counted and resuspended in the appropriate medium for adoptive transfer or 
further staining. 
In vivo CTL assay 
Single cell suspensions of naïve C57BL/6 splenocytes were resuspended in RPMI + 10 
% FCS. Target cells were incubated for 45 min at 37 °C with 2 μg/mL MUC1 
(glyco)peptide epitopes 212-214 and control cells were incubated with peptide with a 
scrambled sequence (PSAPRPDTA). Cells were then washed twice with RPMI + 2 % 
FCS and then stained with CFSE or CTO as described above. Target cells were stained 
with 10 μM CFSE (212), 10 μmol CTO (213) or 1 μmol CTO (213), while control cells 
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were stained with 1 μM CFSE. Equal numbers of target and control cells were adoptively 
transferred into recipient mice, and spleens were harvested 16 h later. Splenocytes were 
prepared for flow cytometry (vide supra), and CFSE/CTO intensity used to discriminate 
recovered target and control cells. Percentage specific lysis was calculated as follows: 
�1 − 𝑟𝑟𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛
𝑟𝑟𝑠𝑠𝑛𝑛𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛
� ∗ 100, where 𝑟𝑟 =  # 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑟𝑟𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠# 𝑐𝑐𝑡𝑡𝑟𝑟𝑡𝑡𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠  
6.2.7 Enzyme-linked immunosorbent assay (ELISA) for MUC1-specific antibodies 
MUC1-specific serum antibody titres were elucidated by standard indirect ELISA. 
Briefly, 96-well ELISA plates (Corning Falcon) were coated with MUC1 VNTR 
(glyco)peptides (1 μg/mL) diluted in carbonate/bicarbonate coating buffer (0.05 M, 
pH 9.6) for 2 h at 37 °C, or overnight at 4 °C. After washing 4 times with PBS + 0.05 % 
(v/v) Tween-20 (PBST), plates were blocked with PBS containing BSA (1 % w/v) for 1 h 
at 37 °C and washed 4 times with PBST. Serum samples diluted in blocking buffer were 
added to each well and plates were incubated for 1 h at 37 °C and washed 4 times with 
PBST. Unless otherwise stated, sera were incubated with the immobilised MUC1 
(glyco)peptides against which they were raised, and sera from PBS-treated mice were 
incubated with unglycosylated MUC1 peptides. Horseradish peroxidase-conjugated 
affinity-purified polyclonal secondary antibodies (Table 6.2), diluted in blocking buffer 
according to the supplier’s instructions, were added and plates were incubated for 30 min 
at 37 °C. Plates were then soaked in PBST and washed 4 times. Tetramethylbenzidine 
(TMB) substrate (Life Technologies) was added, and after 20 min, an equal volume of 
aqueous HCl (2 M) was added to stop the colourimetric reaction. Absorbance was read 
at 450 nm on an ELISA plate reader, and endpoints were determined as A450 < 0.100. 
Table 6.2: HRP-conjugated antibodies used in this thesis. 
Antigen Species Cat # Source 
Mouse IgM Goat 62-6820 Invitrogen 
Mouse IgG Goat A16090 Life Technologies 
Mouse IgG1 Goat 115-035-205 Jackson ImmunoResearch 
Mouse IgG2b Goat 115-035-207 Jackson ImmunoResearch 
Mouse IgG2c Goat 115-035-208 Jackson ImmunoResearch 
Mouse IgG3 Goat 115-035-209 Jackson ImmunoResearch 
Mouse IgA Goat 62-6720 Invitrogen 
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6.2.8 Data presentation and statistical analysis 
All immunological data were analysed with Graphpad Prism software (version 7 for 
Windows). All data were analysed by non-parametric tests. For comparisons between 
two groups, a Mann-Whitney test was performed. For comparisons between multiple 
groups, an ANOVA was performed with a Sidak post hoc test. Differences in survival 
were analysed using a log-rank (Mantel-Cox) test with Gehan Breslow-Wilcoxon post 
hoc tests. Differences in ear thickness over time were analysed using a mixed ANOVA 
(repeated measures in time, but not between treatment groups) with Tukey’s multiple 
comparisons post hoc test. 
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 Chapter 2 experimental 
6.3.1 Synthesis and characterisation of novel compounds 
MUC1 nonamer 212. H-SAPDTRPAP-OH 
 
Peptide 212 was synthesised by manual SPPS on 2-CTC resin on a 50 μmol scale, and 
25 μmol was cleaved from resin with TFA:iPr3SiH:H2O (90:5:5 v/v/v) as described in the 
general methods to provide crude 212. Preparative HPLC purification (0-25% B over 
40 min, 7 mL min-1) followed by lyophilisation afforded pure 212 as a white solid 
(16.2 mg, 71% yield). Analytical HPLC: Rt 14.8 min (0-20% B over 30 min, 
0.2 mL min-1, 0.1% formic acid, λ = 214 nm). LRMS calcd: [M+H]+ = 911.45, 
[M+2H]2+ = 456.23; found (ESI+): 911.85, 456.65. 
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MUC1TN nonamer 213. H-SAPDT(TN)RPAP-OH 
 
Glycopeptide 213 was synthesised by manual SPPS on 2-CTC resin on a 25 μmol scale. 
Fmoc-Thr(Ac3Tn)-OH was coupled overnight in the presence of HATU, HOAt and 
iPr2NEt as described in the general methods. The glycopeptide was cleaved from resin 
with TFA:iPr3SiH:H2O (90:5:5 v/v/v), and after 3 h the filtrate was reduced under a 
stream of N2 gas, and the peptide was precipitated by addition of ice-cold Et2O. The 
precipitate was dried in vacuo, then reconstituted in aqueous hydrazine (10% w/v, 3 mL). 
After 30 min, this reaction mixture was subjected to preparative HPLC purification 
(0-25% B over 40 min, 7 mL min-1) followed by lyophilisation to afford pure 213 as a 
white solid (14.8 mg, 53% yield). Analytical UPLC: Rt 3.55 min (0-20% B over 8 min, 
0.6 mL min-1, 0.1% formic acid, λ = 214 nm). LRMS calcd: [M+H]+ = 1115.53, 
[M+2H]2+ = 558.27; found (ESI+): 1115.15, 558.10. 
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MUC1T nonamer 214. H-SAPDT(T)RPAP-OH 
 
Glycopeptide 214 was synthesised by manual SPPS on 2-CTC resin on a 25 μmol scale. 
Fmoc-Thr(Ac6T)-OH was coupled overnight in the presence of HATU, HOAt and 
iPr2NEt as described in the general methods. The glycopeptide was cleaved from resin 
with TFA:iPr3SiH:H2O (90:5:5 v/v/v), and after 3 h the filtrate was reduced under a 
stream of N2 gas, and the peptide was precipitated by addition of ice-cold Et2O. The 
precipitate was dried in vacuo, then reconstituted in aqueous hydrazine (10% w/v, 3 mL). 
After 30 min, this reaction mixture was subjected to preparative HPLC purification (0-
25% B over 40 min, 7 mL min-1) followed by lyophilisation to afford pure 214 as a white 
solid (19.4 mg, 61% yield). Analytical UPLC: Rt 3.53 min (0-20% B over 8 min, 
0.6 mL min-1, 0.1% formic acid, λ = 214 nm). LRMS calcd: [M+H]+ = 1276.58, 
[M+2H]2+ = 638.79; found (ESI+): 1277.25, 639.15. 
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 Chapter 3 experimental 
6.4.1 Synthesis and characterisation of novel compounds 
Lipopeptide Thioester 305. Fmoc-(Pam2Cys)SKKKK(PEG)FQ-SR 
 
Lipopeptide 305 was synthesised by manual SPPS on 2-CTC resin on a 25 μmol scale. 
Fmoc-Pam2Cys-OH was coupled overnight in the presence of HATU, HOAt and iPr2NEt 
as described in the general methods. The resultant lipopeptide was cleaved from resin 
with side-chain protecting groups intact by treatment with HFIP:CH2Cl2 (3:7 v/v), and 
then dried in vacuo. Ethyl 3-mercaptopropionate (750 μmol, 30 eq., 94 μL), PyBOP 
(125 μmol, 5 eq., 65 mg), and DMF (2 mL) were added, and the reaction mixture was 
cooled to -20 °C. iPr2NEt (125 μmol, 5 eq., 16 μL) was added, and the thioesterification 
reaction proceeded at -20 °C for 3 h. Solvent was removed under a stream of nitrogen 
overnight, and the side-chain protecting groups were removed by treatment with 
TFA:iPr3SiH:H2O (90:5:5, v/v/v) for 3 h. Crude lipopeptide thioester 305 was afforded 
by precipitation from ice-cold Et2O. Semi-preparative HPLC purification (50-100% B 
over 40 min, 7 mL min-1, 40 °C) followed by lyophilisation afforded pure 305 as a white 
solid (2.5 mg, 5% yield). Analytical HPLC: Rt 22.0 min (20-100% B over 30 min, 
0.2 mL min-1, 0.1% formic acid, λ = 214 nm). LRMS calcd: [M+2H]2+ = 1016.12, 
[M+3H]3+ = 677.74, [M+4H]4+ = 508.56; found (ESI+): 1016.30, 677.80, 508.50. 
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Peptide bearing N-terminal β-mercaptoaspartic acid 306. 
H-(β-SH)DAYNAAGGHNAVFQIMYNYPAM-OH 
 
Peptide 306 was synthesised by manual SPPS on 2-CTC resin on a 12.5 μmol scale. 
Boc-protected β-mercaptoaspartic acid building block 304 was coupled overnight in the 
presence of HATU, HOAt and iPr2NEt as described in the general methods. The nascent 
peptide was cleaved from resin with TFA:iPr3SiH:H2O (90:5:5 v/v/v) to provide crude 
306. TCEP was added 10 s prior to purification to reduce any disulfide bonds, followed 
by preparative HPLC purification (0-60% B over 40 min, 7 mL min-1) and lyophilisation 
to afford 306 as a white solid (4.0 mg, 13% yield). Analytical HPLC: Rt 15.9 min 
(0-60% B over 30 min, 0.2 mL min-1, 0.1% formic acid, λ = 214 nm). LRMS calcd: 
[M+2H]2+ = 1226.02, [M+3H]3+ = 817.68; found (ESI+): 1226.45, 817.95. 
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Unsuccessful ligation between 305 and 306 
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Lipopeptide thioester 305 (1.0 mg, 0.49 μmol) and peptide 306 (2 eq., 2.4 mg, 0.98 μmol) 
were dissolved in NMP (40 μL), and aqueous HEPES buffer (1.0 M, pH 7.4 160 μL) 
containing guanidine hydrochloride (6 M), tris(2-carboxyethyl)phosphine (TCEP, 
50 mM) and Tween-20 (0.5% v/v) was added. The pH was adjusted with NaOH to pH 7.4. 
Trifluoroethane thiol (TFET, 2% v/v) was added, and the reaction was incubated at 37 °C 
for 24 h. The reaction was followed by LC-MS.  
P25-TB10.4 fusion peptide 307. H-FQDAYNAAGGHNAVFQIMYNYPAM-OH 
 
Peptide 307 was synthesised by manual SPPS on 2-CTC resin on a 25 μmol scale. The 
peptide was cleaved from resin with TFA:iPr3SiH:H2O (90:5:5 v/v/v) to provide crude 
307. Preparative HPLC purification (0-60% B over 40 min, 7 mL min-1) followed by 
lyophilisation afforded pure 307 as a white solid (7.3 mg, 11% yield). Analytical HPLC: 
Rt 20.0 min (0-50% B over 30 min, 0.2 mL min-1, 0.1% formic acid, λ = 214 nm). LRMS 
calcd: [M+2H]2+ = 1347.60, [M+3H]3+ = 898.73, [M+4H]4+ = 674.30; found (ESI+): 
1347.70, 898.95, 674.50. 
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Lipopeptide thioester 309. H-[Pam2Cys]SKKKK[PEG]MTEQQWNF-SR 
 
Lipopeptide 309 was synthesised by manual SPPS on 2-CTC resin on a 25 μmol scale. 
Fmoc-Pam2Cys-OH was coupled overnight in the presence of HATU, HOAt and iPr2NEt 
as described in the general methods. The lipopeptide was cleaved from resin with side-
chain protecting groups intact by treatment with HFIP:CH2Cl2 (3:7 v/v), and then dried 
in vacuo. Ethyl 3-mercaptopropionate (750 μmol, 30 eq., 94 μL), PyBOP (125 μmol, 
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5 eq., 65 mg), and DMF (2 mL) were added, and the reaction mixture was cooled to -20 
°C. iPr2NEt (125 μmol, 5 eq., 16 μL) was added, and the thioesterification reaction was 
agitated at -20 °C for 3 h. The solvent was subsequently removed under a stream of 
nitrogen overnight and the side-chain protecting groups were then removed by treatment 
with TFA:iPr3SiH:H2O (90:5:5, v/v/v) for 3 h. Crude lipopeptide thioester 309 was 
afforded by precipitation from ice-cold Et2O. Semi-preparative HPLC purification (50-
100% B over 40 min, 7 mL min-1, 40 °C) followed by lyophilisation afforded pure 309 
as a white solid (5.8 mg, 9% yield). Analytical HPLC: Rt 16.0 min (50-100% B over 30 
min, 0.2 mL min-1, 0.1% TFA, λ = 214 nm). LRMS calcd: [M+2H]2+ = 1300.24, 
[M+3H]3+ = 867.17, [M+4H]4+ = 650.62; found (ESI+): 1300.80, 867.45, 650.75. 
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Peptide bearing N-terminal cysteine 310. H-CGIEAAASAIQGQIMYNYPAM-OH 
 
Peptide 310 was synthesised by manual SPPS on 2-CTC resin on a 50 μmol scale. The 
peptide was cleaved from resin with TFA:iPr3SiH:thioanisole:H2O (85:5:5:5 v/v/v/v) to 
provide crude 310. TCEP was added 10 s prior to purification to reduce any disulfide 
bonds. Preparative HPLC purification (0-60% B over 40 min, 7 mL min-1) followed by 
lyophilisation afforded pure 310 as a white solid (14.6 mg, 13% yield). Analytical 
HPLC: Rt 13.1 min (0-100% B over 30 min, 0.2 mL min-1, 0.1% TFA, λ = 214 nm). 
LRMS calcd: [M+2H]2+ = 1102.50, [M+3H]3+ = 735.33; found (ESI+): 1102.60, 734.45.  
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Pam2Cys-ESAT6-TB10.4 vaccine candidate 308. 
H-[Pam2Cys]SKKKK[PEG]MTEQQWNFAGIEAAASAIQGQIMYNYPAM-OH 
 
Lipopeptide thioester 309 (2.5 mg, 0.96 μmol) and peptide 310 (2 eq., 4.2 mg, 1.92 μmol) 
were dissolved in aqueous phosphate buffer (0.1 M, pH = 7.4, 192 μL, 5 mM 
w.r.t. thioester) containing guanidine hydrochloride (6 M), TCEP (50 mM) and Tween-
20 (0.5% v/v). The pH of the reaction mixture was adjusted with NaOH to pH 7.2. TFET 
(2% v/v) was added, and the reaction was incubated at 37 °C for 24 h. The reaction was 
followed by UPLC-MS.  
After consumption of the thioester as measured by LCMS (~24 h), the reaction was 
degassed under a stream of argon, and one volume of degassed aqueous phosphate buffer 
containing guanidine hydrochloride (6 M), TCEP (500 mM), reduced glutathione (GSH, 
80 mM), and the radical initiator VA-044 (40 mM) was added. The reaction was allowed 
to proceed at 37 °C for 8 h. Preparative HPLC purification (0-60% B over 40 min, 
7 mL min-1, 40 °C) followed by lyophilisation afforded pure vaccine candidate 308 as a 
white solid (1.5 mg, 34% yield). Analytical HPLC: Rt 15.1 min (25-100% B over 30 
min, 0.2 mL min-1, 0.1% formic acid, λ = 214 nm). LRMS calcd: [M+3H]3+ = 1545.48, 
[M+4H]4+ = 1159.36, [M+5H]5+ = 927.69; found (ESI+): 1545.95, 1159.65, 927.85. 
HRMS calcd for C214H348N47O58S4: [M+H]+ = 4634.466; found (MALDI-TOF): 
4634.462. 
Experimental Procedures 
 136 
 
 
6.4.2 Immunological evaluation of TB vaccine candidate 
Immunological evaluation of tuberculosis vaccine candidate 308 was carried out by Mrs 
Anneliese Ashhurst in Prof. Warwick Britton’s laboratory at the Centenary Institute, 
NSW.  
Bacterial strains 
Table 6.3: Bacterial strains utilised in this study.  
Strain Description/Use 
M. bovis BCG Pasteur 1173P2 Vaccination of mice 
M. tuberculosis H37Rv (BEI Resources, 
NIAID, NIH, NR-13648) 
Aerosol challenge for murine TB model  
 
Bacterial growth conditions 
M. tuberculosis H37Rv and M. bovis BCG Pasteur 1173P2 (kindly provided by the 
laboratory of A/Prof Jamie Triccas, University of Sydney; originally provided by B. 
Gicquel, Institut Pasteur, Paris, France) were cultured in Middlebrook 7H9 (Difco) broth 
supplemented with albumin-dextrose-catalase (ADC; 10% v/v), glycerol (0.2% v/v) and 
Tween-80 (0.05% v/v) at 37 oC. To enumerate M. tuberculosis and M. bovis, cultures 
were plated onto Middlebrook 7H10 or 7H11 (Difco) agar, supplemented with oleic-acid-
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albumin-dextrose catalase (OADC; 10% v/v) and glycerol (0.5% v/v), and incubated at 
37 oC for 21 d. 
Mice 
C57BL/6 mice were obtained from Animal BioResources (Moss Vale, NSW, Australia). 
All murine experiments were conducted with the approval of the Sydney Local Health 
District Animal Welfare Committee (protocol number 2013/054) and were housed under 
SPF conditions in the Centenary Institute animal facility. 
Immunisation of mice 
Subcutaneous 
Mice were anaesthetised with gaseous isofluorane (4%) and injected at the base of tail 
with 200 µL vaccine solution. 
Intra-nasal 
Mice were anaesthetized by intra-peritoneal (i.p) injection with 200 µl ketamine/xylazine 
solution (50 mg/6.25 mg/kg). 50 µL vaccine in isotonic solution was applied to the nares, 
and mice allowed to inhale the solution.  
Collection and processing of murine organs 
Mice were sacrificed via CO2 asphyxiation and the relevant tissues removed utilising 
aseptic technique before storage on ice. Leukocytes isolated from mice were enumerated 
using a haemocytometer or by an automated cell counter (Countess; Invitrogen). Viability 
was determined by Trypan Blue (0.04%) exclusion. 
Lungs 
Prior to collection of the lung lobes circulating blood was removed by injection of cold 
PBS and heparin (20 U/mL; Sigma) into the right atrium of the heart to inflate and perfuse 
the lungs. For isolation of leukocytes from the lungs, lobes were collected into complete 
RPMI media. Diced lung tissue was digested with collagenase type 4197 (50 U/mL; 
Freehold NJ) and DNAse I (13 µg/mL; Sigma) at 37 oC for 45 min prior to 
homogenisation and multiple filtration steps. Erythrocytes were removed using ACK 
lysis buffer. 
Experimental Procedures 
 138 
Lymph nodes and spleen 
Lymph nodes and spleens were homogenised by passing through a 70 µm sieve in 
complete RPMI and the leukocytes pelleted by centrifugation (5 min, 1500 rpm).  
Erythrocytes were removed by ACK lysis buffer.  
Flow cytometry 
Single-cell suspensions were prepared and up to 4x106 cells aliquoted for 
immunostaining and flow cytometry analysis. After washing cells with FACS wash (PBS 
with 2% FCS), Fc receptors were blocked with anti-mouse CD16/CD32 (2.4G2, 1:100, 
20 min, 4 oC; BD Biosciences). Cells were incubated (20 min, 4 oC) with appropriate 
antibody mix in FACS wash to label surface markers then washed thoroughly.   
Antigen-specific cytokine production by murine T-lymphocytes was enumerated by 
intra-cellular immunostaining and flow cytometry. Up to 4x106 lymphocytes were 
stimulated for 1-4 hr (37 oC, 5% CO2) with appropriate peptide (Genscript) recall antigen 
(5 µg/mL), or with anti-mouse CD3 (1452C11, 5 μg/mL; produced and kindly provided 
by the laboratory of Dr Bernadette Saunders, Centenary Institute) and anti-mouse CD28 
(37.51, 5 μg/mL; BD Pharmingen) or media alone as controls. This was followed by 
addition of Brefeldin A (10 µg/ml; Sigma) and further incubation (3-16 h, 37 oC, 5% 
CO2) to allow intracellular accumulation of cytokine. Surface cell markers were 
immunostained as above, then the cells were fixed using BD Cytofix/perm (20 min, 4 oC) 
followed by thorough washing with BD Perm/Wash. Cells were incubated (20 min, 4 oC) 
with appropriate antibody mix prepared in BD Perm/Wash buffer, then washed with the 
same buffer.  
Compensation controls were prepared by immunostaining BD CompBeads with the same 
antibody utilised in the experimental panel, except for live dead staining, or where the 
antibody utilised would not bind to compensation beads, in which case murine leukocytes 
were labelled with the appropriate marker in the same manner as experimental samples.   
All immunostained cells/beads were fixed in 10% neutral buffered formalin prior to 
acquisition of the data using an LSRFortessa or LSRII 5L flow analyser (BD Biosciences) 
and analysis using FlowJo (Tree Star Inc.).  
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Table 6.4: Antibodies used in Chapter 4 
Antibody specificity 
(anti-mouse) 
Fluorochrome Clone Supplier 
CD8 APCCy7 53-6.7 BD Pharmingen 
CD4 PECy7 RM4-5 BD Pharmingen 
CD3 PerCPCy5.5 17A2 BioLegend 
IFNγ FITC XMG1.2 BD Pharmingen 
IL-17A PB TC11-18H10.1 BioLegend 
TNFα PE/APC MP6-XT22 BioLegend 
IL-2 APC/PE JES6-5H4 BioLegend 
 
Live/dead fixable 
blue dead cell stain 
 Invitrogen 
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Figure 6.1: Gating strategy used for assessing intra-cellular cytokine release by T-lymphocytes. A time 
gate was applied to verify consistent fluorescence signal during sample collection. After excluding debris 
by FSC and SSC, dead cells were excluded by live/dead UV stain. The CD4+ and CD8+  populations were 
gated. Expression of IFNγ, IL-2 and TNFα was gated for both T-lymphocyte populations, and also IL-17A 
expression for CD4+ cells. To quantitate cells producing multiple cytokines, a Boolean analysis was 
applied. 
Experimental M. tuberculosis infection 
Mice were challenged with M. tuberculosis H37Rv by low-dose aerosol infection 
(100 CFU) in an inhalation exposure system (Glas-Col, Terre Haute, IN). Bacterial loads 
in the lungs and spleen were determined by plating serial dilutions of the tissue 
homogenate onto 7H10 or 7H11 plates, incubated at 37 oC for approximately 21 d. 
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Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6 or 7 software (GraphPad 
Software, La Jolla, CA), as detailed in figure legends. Differences between groups were 
determined by ANOVA with Bonferroni post-hoc comparison, and were considered 
significant when the P values were ≤0.05 (*p<0.05, **p<0.01, ***p<0.001, 
***p<0.0001). 
 Chapter 4 experimental 
6.5.1 Synthesis and characterisation of novel compounds 
MUC1 glycopeptide 401. H-AHGVTSAPDT(TN)RPAPGS(TN)TAPPAHGVTSA-NH2 
 
Glycopeptide 401 was synthesised by automated SPPS on Rink amide resin on a 200 
μmol scale. Fmoc-Thr(Ac3Tn)-OH was manually coupled overnight in the presence of 
HATU, HOAt and iPr2NEt as described in the general methods. The resin was split into 
2 batches prior to coupling the N-terminal residue to allow for the divergent synthesis of 
403. The glycopeptide (12.5 μmol) was cleaved from resin with TFA:iPr3SiH:H2O 
(90:5:5 v/v/v), and after 3 h the filtrate was reduced under a stream of N2 gas, and the 
peptide was precipitated by addition of ice-cold Et2O. The precipitate was dried in vacuo, 
then reconstituted in aqueous hydrazine (10% w/v, 3 mL). After 30 min, this reaction 
mixture was subjected to preparative HPLC purification (0-25% B over 40 min, 7 mL 
min-1) followed by lyophilisation to afford pure 401 as a white solid (11.6 mg, 32% yield). 
Analytical HPLC: Rt 21.3 min (0-20% B over 30 min, 0.2 mL min-1, 0.1% TFA, λ = 214 
nm). LRMS calcd: [M+2H]2+ = 1459.20, [M+3H]3+ = 973.13, [M+4H]4+ = 730.10; found 
(ESI+): 1460.00, 973.45, 730.15. 
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Lipopeptide selenoester 403. H-[Pam2Cys]SKKKK[PEG]-SePh 
 
Lipopeptide 403 was synthesised by automated SPPS on 2-CTC resin on a 25 μmol scale. 
Fmoc-Pam2Cys-OH was coupled overnight in the presence of HATU, HOAt and iPr2NEt 
as described in the general methods. The lipopeptide was cleaved from resin with the 
side-chain protecting groups intact by treatment with HFIP:CH2Cl2 (3:7 v/v), and then 
dried in vacuo. Diphenyl diselenide (DPDS, 375 μmol, 15 eq., 117 mg), DMF (2 mL), 
and Bu3P (375 μmol, 15 eq., 93 μL) were added, and the selenoesterification reaction 
proceeded at rt for 3 h. The solvent was removed under a stream of nitrogen overnight, 
and then the side-chain protecting groups were removed by treatment with 
TFA:iPr3SiH:H2O (90:5:5, v/v/v) for 3 h. Crude lipopeptide selenoester 403 was afforded 
by precipitation from ice-cold Et2O. Semi-preparative HPLC purification (50-100% B 
over 40 min, 7 mL min-1, 40 °C) followed by lyophilisation afforded pure 403 as a white 
solid (8.4 mg, 22% yield). Analytical UPLC: Rt 4.73 min (20-100% B over 8 min, 
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0.6 mL min-1, 0.1% formic acid, λ = 214 nm). LRMS calcd: [M+2H]2+ = 778.98, 
[M+3H]3+ = 519.65; found (ESI+): 779.45, 519.75. 
 
 
MUC1 glycopeptide diselenide 404. 
(UHGVTSAPDT(TN)RPAPGS(TN)TAPPAHGVTSA-NH2)2 
 
Glycopeptide diselenide 404 was synthesised as described for glycopeptide 401 above. 
Boc-protected selenazolidine-4-carboxylic acid was manually coupled overnight in the 
presence of HATU, HOAt and iPr2NEt as described in the general methods. The 
glycopeptide (on a 25 μmol scale) was cleaved from resin with TFA:iPr3SiH:H2O (90:5:5 
v/v/v), and after 3 h the filtrate was reduced under a stream of N2 gas, and the peptide 
was precipitated by addition of ice-cold Et2O. The precipitate was dried in vacuo, and 
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concomitant removal of the carbohydrate O-acetyl groups and the ring-opening of the 
selenazolidine was effected by addition of aqueous hydrazine (10% w/v, 3 mL). After 30 
min, TCEP (2 mg) was added to reduce any diselenides, and 10 s later the reaction 
mixture was subjected to preparative HPLC purification (0-25% B over 40 min, 7 mL 
min-1) followed by lyophilisation to afford pure 404 as a white solid (11.8 mg, 32% yield). 
Analytical UPLC: Rt 5.07 min (0-20% B over 8 min, 0.6 mL min-1, 0.1% TFA, 
λ = 214 nm). LRMS calcd: [M+4H]4+ = 1498.65, [M+5H]5+ = 1199.12, 
[M+6H]6+ = 999.43, [M+7H]7+ = 856.80, [M+8H]8+ = 749.83; found (ESI+): 1499.05, 
1199.35, 999.50, 856.75 749.70. 
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Pam2Cys-MUC1VNTR vaccine candidate 402. 
H-[Pam2Cys]SKKKK[PEG]AHGVTSAPDT(TN)RPAPGS(TN)TAPPAHGVTSA-NH2 
 
Ligation: 
Glycopeptide diselenide 402 (2.9 mg, 0.48 μmol) and lipopeptide selenoester 403 
(3.0 mg, 1.93 μmol, 2 eq. w.r.t. 402 monomer) were lyophilised together into a 
microcentrifuge tube and then NMP:ligation buffer (1:4 v/v, 193 μL, 5mM w.r.t. 402 
monomer). The ligation buffer consisted of aqueous HEPES buffer (1.0 M, pH 7.4) 
containing guanidine hydrochloride (6 M). After addition of the ligation mixture, the pH 
was 5.2. After 2 min, the ligation reaction was complete as measured by LCMS.  
Deselenisation: 
TCEP (12 mg, 48 μmol, 50 eq.) and dithiothreitol (DTT, 0.7 mg, 4.8 μmol, 5 eq.) were 
added in 1 volume of buffer (final pH = 4.0). This solution was extracted with hexane 
(3 × 1 mL). An emulsion formed at the interface, which was retained with the aq. layer. 
The reaction mixture was then heated to 37 °C. After 3 h, the emulsion had resolved, and 
deselenisation was complete as measured by LCMS.  
Semi-preparative HPLC purification (50-100% B over 40 min, 7 mL min-1, 40 °C) 
followed by lyophilisation afforded pure 403 as a white solid (2.6 mg, 62% yield). 
Analytical HPLC: Rt 18.7 min (10-100% B over 30 min, 0.2 mL min-1, 0.1% TFA, 
λ = 214 nm). LRMS calcd: [M+3H]3+ = 1439.77, [M+4H]4+ = 1080.08, 
[M+5H]5+ = 864.26, [M+6H]6+ = 720.38; found (ESI+) 1439.90, 1080.35, 864.30, 720.40. 
HRMS calcd for C193H330N48O60S: [M+H]+ = 4313.397; found (MALDI-TOF) 4313.363. 
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 Chapter 5 experimental 
6.6.1 Modified Iterative peptide assembly – microwave-assisted automated SPPS 
For the synthesis of MUC1SP peptides, the general method for microwave-assisted 
automated SPPS was modified as follows (conditions are provided for synthesis on a 
0.1 mmol scale): 
Washing: 
After each step, resins were filtered and then washed with DMF (5 x 5 mL) at 50 °C. 
Fmoc deprotection:  
Fmoc removal was effected by treatment with 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU):piperidine:DMF (1:9:90 v/v/v, 4 mL, 2 × 4 min). 
Coupling of proteinogenic amino acids:  
Fmoc-AA-OH (1.0 mmol, 10 eq.), N,N’-diisopropylcarbodiimide (DIC, 1.0 mmol, 10 
eq.), and ethyl (hydroxyimino)cyanoacetate (Oxyma, 1.0 mmol, 10 eq.) were dispensed 
from concentrated stock solutions in DMF onto the resin, and made up to a final volume 
of 4 mL with DMF. The reaction was heated to 75 °C and mixed for 20 min.  
Capping:  
Unreacted amines were capped by treatment with Ac2O:pyridine (1:9 v/v, 4 mL) for 5 min 
at rt. 
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6.6.2 Synthesis and characterisation of novel compounds 
MUC1SP 501. H-MTPGTQSPFFLLLLLTVLTVV-OH 
 
Peptide 501 was synthesised by automated SPPS on Chemmatrix® Rink amide resin on 
a 12.5 μmol scale using the modified method outlined above. At both Leu-Thr junctions, 
a pseudoproline dipeptide Fmoc-L-Leu-L-Thr[ψMe,MePro]-OH was incorporated. The 
peptide was cleaved from resin with TFA:iPr3SiH:thioanisole:H2O (90:2.5:2.5:5 v/v/v/v). 
Preparative HPLC purification (0-80% B over 40 min, 7 mL min-1, 60 °C) followed by 
lyophilisation afforded 501 as a white solid (3.5 mg, 12% yield). Analytical UPLC: Rt 
4.10 min (0-100% B over 30 min, 0.6 mL min-1, 0.1% formic acid, λ = 214 nm). LRMS 
calcd: [M+2H]2+ = 1145.65, [M+3H]3+ = 764.1; found (ESI+) 1145.90, 764.10. HRMS 
calcd for C110H180N22O28S: [M+Na]+ = 2311.312; found (MALDI-TOF): 2311.312. 
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K4-MUC1SP 502. H-KKKK[PEG]MTPGTQSPFFLLLLLTVLTVV-OH 
 
Peptide 501 was synthesised by automated SPPS on Chemmatrix® CTC resin on a 
12.5 μmol scale using the modified method outlined above, except that coupling reactions 
were performed at 50 °C. At both Leu-Thr junctions, a pseudoproline dipeptide 
Fmoc-L-Leu-L-Thr[ψMe,MePro]-OH was incorporated. The peptide was cleaved from resin 
with TFA:iPr3SiH:thioanisole:H2O (90:2.5:2.5:5 v/v/v/v). Preparative HPLC purification 
(0-80% B over 40 min, 7 mL min-1, 60 °C) followed by lyophilisation afforded pure 501 
as a white solid (9.6 mg, 26% yield). Analytical UPLC: Rt 3.91 min (0-100% B over 30 
min, 0.6 mL min-1, 0.1% formic acid, λ = 214 nm). LRMS calcd: [M+2H]2+ = 1475.38, 
[M+3H]3+ = 983.92, [M+3H]3+ = 738.19; found (ESI+) 1145.90, 764.10. HRMS calcd 
for C140H239N31O35S: [M+H]+ = 2946.760; found (MALDI-TOF): 2946.758. 
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6.6.3 Formulation of glycolipids for intramuscular injection 
For the tumour described in Section 5.4.2, MUC1SP, MUC1VNTR glycopeptide and 
glyocolipid adjuvants were delivered via intramuscular injection. Glycolipids such as 
αGalCer and TDB are poorly soluble in de-ionised water and PBS, and were therefore 
formulated for injection as previously described (Anderson, et al. 2014). Briefly, 
glycolipid (1.2 μmol, 1.0 mg for αGalCer or 1.2 mg for TDB), sucrose (280 mg), L-
histidine, and Tween-20 (5 mg) were dissolved in water (1 mL) and heated to 60 °C with 
stirring until fully dissolved. This solution was lyophilised to provide a fluffy white solid, 
which was reconstituted with PBS immediately before use. 
6.6.4 UV13-1 skin tumours 
Tissue culture of UV13-1 cells 
Frozen UV13-1 cells were stored in liquid nitrogen. Frozen cells were rapidly thawed in 
a 37 °C water bath. Once completely thawed (approx. 1 min), they were added to excess 
pre-warmed media (20 mL DMEM containing 10 mM glutamate and 10% FBS) and 
centrifuged (120 rcf, 5 min, rt). Cells were then resuspended in warm media and ~1x106 
were added to a 75 cm2 flask containing warm media (20 mL). When 80% confluent by 
eye (typically 3-4 days later), cells were split 1:8 by removal of media, washed gently 
with PBS (10 mL, Ca2+- and Mg2+-free) and treated with tryp-LE (2-3 mL, 37 °C, 2-3 min 
or until cells fully detached). Trypsinised cells were washed into a centrifuge flask with 
excess media (20 mL) and centrifuged and re-plated as above. 
Tumour inoculation and monitoring 
Female C57Bl/6 mice (6-8 weeks, ~20 g) had their back and flanks coarsely shaved. One 
day later, trypsinised UV13-1 tumour cells were resuspended in serum-free media 
(4x107 cells/mL) and injected into the shaved flank (50 μL, 2x106 cells) at two sites. 
Injection sites were monitored closely for infection in the following days. After 5-7 days, 
when tumours were palpable, daily measurement of tumour size began. The length and 
width of the tumours were measured using digital calipers, and area was reported as: 
Area = Length × Width. 
Harvest of UV13-1 tumours and preparation of single-cell suspensions 
At the ethical endpoint of the experiment (>10 tumours or any tumour >100 mm2), mice 
were euthanised by cervical dislocation. Tumours were carefully removed from the back 
using surgical scissors, maintaining the skin around the tumour for histology. Tumours 
Experimental Procedures 
 150 
were cut in half and the two halves were weighed. One half of each tumour was frozen 
for histological analysis, while single-cell suspensions were prepared from the other 
halves for in vitro experiments and flow cytometry. Briefly, the tumour mass was cut 
away from the surrounding skin and chopped finely with a scalpel. The tumour was then 
digested enzymatically by treatment with collagenase IV (2 mg mL-1) in RPMI for 45 
min at 37 °C with constant agitation. The digested cells were filtered through a cell 
strainer (miltenyi biotec, 0.70 μm), and centrifuged (500 rcf, 5 min, rt). Cells were 
resuspended in FACS buffer for staining as described in the general methods.  
6.6.5 Contact hypersensitivity (CHS) assay 
MUC1SP was delivered via sub-cutaneous injection into the abdomen as described in the 
general methods. Seven days later, mice were topically sensitised to 
1-fluoro-2,4-dinitrobenzene (DNFB, 0.5 vol%) in olive oil/acetone (1:4, v/v, 30 μL) via 
application to the shaved abdomen. Five days after sensitisation, mice were challenged 
on the ear with topical DNFB (0.25 vol%) in olive oil/acetone (1:4, v/v, 15 μL). Ear 
thickness was measured daily from immediately before challenge using manual digital 
calipers. Positive controls for ear swelling consisted of mice that were treated with PBS 
instead of MUC1SP. Negative or irritant controls consisted of a group of mice that 
received the DNFB challenge, but not the sensitisation. The average of the change in ear 
thickness from this control group was subtracted from the change in ear thickness of other 
samples to account for non-specific irritation due to the application of DNFB, olive oil 
and acetone. Thus, the values reported here are the “Specific change in ear thickness” 
calculated as follows: 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝛥𝛥𝛥𝛥𝛥𝛥𝑟𝑟 𝑇𝑇ℎ𝑆𝑆𝑆𝑆𝑘𝑘𝑘𝑘𝑆𝑆𝑘𝑘𝑘𝑘 = ∆𝛥𝛥𝛥𝛥𝑟𝑟 𝑇𝑇ℎ𝑆𝑆𝑆𝑆𝑘𝑘𝑘𝑘𝑆𝑆𝑘𝑘𝑘𝑘𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐 − 𝑀𝑀𝑆𝑆𝛥𝛥𝑘𝑘 ∆𝛥𝛥𝛥𝛥𝑟𝑟 𝑇𝑇ℎ𝑆𝑆𝑆𝑆𝑘𝑘𝑘𝑘𝑆𝑆𝑘𝑘𝑘𝑘𝐼𝐼𝑟𝑟𝑟𝑟𝐼𝐼𝑐𝑐𝑡𝑡𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑟𝑟𝑐𝑐𝑐𝑐𝑠𝑠 
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